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Abstract
Introduction: The Alzheimer’s Disease Neuroimaging Initiative (ADNI) has continued 
development and standardization of methodologies for biomarkers and has provided an increased 
depth and breadth of data available to qualified researchers. This review summarizes the over 400 
publications using ADNI data during 2014 and 2015.
Methods: We used standard searches to find publications using ADNI data.
Results: (1) Structural and functional changes, including subtle changes to hippocampal shape 
and texture, atrophy in areas outside of hippocampus, and disruption to functional networks, are 
detectable in presymptomatic subjects before hippocampal atrophy; (2) In subjects with abnormal 
b-amyloid deposition (Aβ+), biomarkers become abnormal in the order predicted by the amyloid 
cascade hypothesis; (3) Cognitive decline is more closely linked to tau than Aβ deposition; (4) 
Cerebrovascular risk factors may interact with Aβ to increase white-matter (WM) abnormalities 
which may accelerate Alzheimer’s disease (AD) progression in conjunction with tau 
abnormalities; (5) Different patterns of atrophy are associated with impairment of memory and 
executive function and may underlie psychiatric symptoms; (6) Structural, functional, and 
metabolic network connectivities are disrupted as AD progresses. Models of prion-like spreading 
of Aβ pathology along WM tracts predict known patterns of cortical Aβ deposition and declines in 
glucose metabolism; (7) New AD risk and protective gene loci have been identified using 
biologically informed approaches; (8) Cognitively normal and mild cognitive impairment (MCI) 
subjects are heterogeneous and include groups typified not only by “classic” AD pathology but 
also by normal biomarkers, accelerated decline, and suspected non-Alzheimer’s pathology; (9) 
Selection of subjects at risk of imminent decline on the basis of one or more pathologies improves 
the power of clinical trials; (10) Sensitivity of cognitive outcome measures to early changes in 
cognition has been improved and surrogate outcome measures using longitudinal structural 
magnetic resonance imaging may further reduce clinical trial cost and duration; (11) Advances in 
machine learning techniques such as neural networks have improved diagnostic and prognostic 
accuracy especially in challenges involving MCI subjects; and (12) Network connectivity 
measures and genetic variants show promise in multimodal classification and some classifiers 
using single modalities are rivaling multimodal classifiers.
Discussion: Taken together, these studies fundamentally deepen our understanding of AD 
progression and its underlying genetic basis, which in turn informs and improves clinical trial 
design.
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1. Introduction
The Alzheimer’s Disease Neuroimaging Initiative (ADNI) began in 2005 as a naturalistic 
longitudinal study to develop and validate biomarkers for subject selection and as surrogate 
outcome measures in clinical trials of Alzheimer’s disease (AD)-modifying therapies. The 
initial 5-year study, known as ADNI-1, enrolled 800 participants from 56 study sites in the 
United States and Canada, in the three groups: normal cognitive aging (CN), mild cognitive 
impairment (MCI), and early Alzheimer’s disease (AD) [1]. This was extended by a Grand 
Opportunities grant (ADNI-GO) in 2009, and a competitive renewal of ADNI-1 (ADNI-2) in 
2011 [1] with each successive grant enrolling earlier stage patients and incorporating newly 
developed techniques. A further competitive renewal, ADNI-3, extends the study for another 
5 years from 2016 to 2021 [2].
ADNI is structured as a public-private partnership overseen by the Private Partner Scientific 
Board comprising representatives of private, for-profit entities, and nonprofit organizations 
which facilitates precompetitive collaboration [3]. ADNI has been described as an exemplar 
of how these partnerships can impact both clinical and basic science research [4]. First, it 
has systematically optimized biomarkers for clinical trials through validation, and 
reproducibility studies, statistical analysis, and the avoidance of bias [5]. Second, ADNI has 
been an unmitigated success from the standpoint of generating new knowledge about the 
underlying physiopathology and genetic contributions to AD [6]. These advances have been 
largely predicated on the development of standardized protocols for use in multiple centers, 
the emphasis of the initiative on studying multiple modalities, and a policy of open data 
sharing [7]. ADNI’s approach has proved so successful that its framework has provided 
inspiration for similar consortia around the world. These include worldwide studies modeled 
on ADNI [8], as well as initiatives focused on biomarker discovery for diseases such as 
multiple sclerosis and Parkinson’s disease [1], and Down’s syndrome [9].
The impact of ADNI’s policy of open data sharing cannot be overemphasized [10]. All data 
generated by the eight ADNI cores [1] are deposited in the Laboratory of Neuro Imaging 
(LONI) at the University of Southern California, an informatics infrastructure which, after 
quality-control procedures, disseminates ADNI data to a continually growing number of 
investigators in the wider scientific community [11]. LONI has received nearly 1800 
applications for data from scientists from multiple disciplines ranging from neuroscience to 
radiology to genetics to computer science. These investigators have downloaded over 7 
million neuroimages and clinical data sets from the ADNI repository [11] resulting in the 
burgeoning number of scientific studies published using ADNI data over the past decade 
(Fig. 1).
The purpose of this review was to provide a comprehensive overview of the advances in the 
field of dementia from all studies published (to the best of our knowledge) in 2014 and 2015 
using ADNI data (approximately 400). We hope that this will allow investigators to 
Weiner et al. Page 3
Alzheimers Dement. Author manuscript; available in PMC 2019 October 29.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
determine what analyses have already been done on ADNI data to help prevent duplication 
and to identify which questions remain to be answered. Previous successive reviews 
compiled summaries of publications using ADNI data until the end of 2011 [12], mid-2012 
[13], and the end of 2013 [1]. The complete list of ADNI studies may be found at http://
adni-info.org/Scientists/ADNIScientistsHome/ADNIPublications.html.
The review is structured in a thematic manner in three parts to reflect evolving views of AD 
progression. The first part outlines primarily technical advances made by the ADNI Clinical, 
Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Biomarker, 
and Genetics cores that do not pertain directly to disease progression or the improvement of 
clinical trials. The second part takes a holistic approach to the discussion of disease 
progression, incorporating advances from many ADNI cores. This section addresses in 
particular (1) the extension of the disease continuum to include the preclinical stage; (2) the 
importance of Aβ positivity at even preclinical stages; (3) the concept of the disease 
disrupting structural, functional, and metabolic connectivity in the brain; and (4) the role of 
white-matter (WM) disease in alternative pathways to dementia. The final part of the study 
discusses the application of these advances in our knowledge of disease progression to the 
improvement of clinical trials for AD preventive or modifying therapies, the ultimate goal of 
ADNI.
2. Cognitive and clinical aspects of Alzheimer’s disease
As cognition lies at the heart of AD, so too does cognitive characterization of the ADNI 
cohort. This is central to the development of all other biomarkers and to the improvement of 
clinical trial efficiency. With the focus of disease intervention shifting to the presymptomatic 
phase, there has been substantial effort in adapting cognitive tests to improve their sensitivity 
at early disease stages. Recognition that CN and MCI groups selected on the basis of 
cognition in fact represent a heterogeneous mix of pathologies has spurred studies to identify 
the basis of that heterogeneity and ultimately increase the power of clinical trials by 
selecting cohorts with defined pathology. Other studies have identified cognitive measures 
capable of predicting future decline. Beyond improving clinical trial efficiency, studies have 
investigated the associations between neuropsychiatric symptoms, or clinical risk factors in 
AD, and imaging and fluid biomarkers.
During ADNI-2, ADNI’s Clinical Core, led by Dr. Paul Aisen, focused on characterizing the 
trajectory of subjects in the early stages of disease. This required the development of 
cognitive and functional measures able to detect the first of subtle cognitive changes [14]. A 
subjective memory concern (SMC) group with self-reported memory problems was enrolled 
in ADNI-2 to facilitate investigation of the very earliest cognitive changes. This group was 
selected using a quantitative approach based on 12 episodic memory items from the self-
rating form of the 20 item Cognitive Change Index [15–17]. The Clinical Core then used the 
self and informant versions of the Everyday Cognition instrument to study the relationship 
to AD biomarker measures [18]. Across all groups, a total of 1182 subjects were enrolled 
and followed during ADNI-2 (Table 1), many of whom will be followed in the next phase of 
the study which will incorporate computerized cognitive assessments.
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2.1. Psychometric analysis of cognitive tests
Psychometric analysis was applied to cognitive tests to improve their reliability, to allow the 
comparison of different cognitive tests, and to increase understanding of the cognitive 
processes underlying each test. The comparison of studies of cognitive decline is often 
hampered by the use of multiple cognitive tests. Gross et al. [19] derived summary factors 
based on the strength of association between cognitive change on a particular test and 
changes in cortical thickness and hippocampal volume biomarkers. These represented the 
average rate of cognitive decline and allowed the direct comparison of longitudinal decline 
on different cognitive tests. Trzepacz et al. provided a conversion table permitting translation 
of scores between the Montréal Cognitive Assessment and Mini–Mental State Examination 
(MMSE) [20]. Balsis et al. [21] determined the correspondence between scores on the 
Alzheimer’s Disease Assessment Scale–cognitive (ADAS-cog), MMSE, and Clinical 
Dementia Rating–Sum of Boxes (CDR-SB) measures in the entire ADNI cohort (Fig. 2). 
Their analysis suggested that ADAS-cog and CDR-SB were more precise than MMSE at 
measuring the severity of cognitive dysfunction. The reliability of ADAS-cog scores for 
measuring change in more cognitively intact subjects between baseline and 1 year was 
improved by reweighting the scale subtests for AD subjects, but not MCI subjects, although 
overall reliability remained low (0.39–0.61 for MCI subjects and 0.53–0.64 for AD subjects) 
[22].
Application of a psychometric model to the free recall task of ADAS-cog suggested that 
impaired patients have deficits in both long-term memory encoding, and short-term memory 
retrieval, in addition to poorer transfer into long-term memory of items successfully 
retrieved from short-term memory, and poorer retention of items encoded into long-term 
memory after long delays [23]. Their immediate recall of encoded words and long-term 
memory were unaffected. Using a psychometric dual retrieval model, Brainerd et al. [24] 
found that differences in reconstructive retrieval, rather than recollective retrieval in the 
delayed recall component of the Rey Auditory Verbal Learning Test (RAVLT) distinguished 
MCI from AD subjects, and predicted conversion of MCI to AD more accurately than APOE 
ε4 status, supporting the idea that declines in nonrecollective processes characterize memory 
loss in AD. A comparison of methods for quantifying how quickly a list of words is learned 
in a verbal learning test concluded that simple slope calculations, while less highly 
correlated with structural brain changes, offered ease of calculation advantages over 
regression-based methods [25]. Finally, psychometric analysis showed that the RALVT 30-
minute delayed recall score was the best predictor of Aβ pathology with an accuracy equal 
to the best imaging biomarker, regional [18F]-fluorodeoxyglucose (FDG) PET measures 
(area under receiver operating curve [AUC] = 0.67 for both) [26] and that the addition of 
imaging biomarkers did not significantly improve either predictor. Overall, cognitive tests 
were more predictive of Aβ status in APOE4 ‒ subjects.
2.2. Associations between cognitive measures and AD biomarkers
Several studies investigated the underlying neural correlates of cognitive measures. In early-
stage risk groups (CN to early MCI [EMCI]), Aβ was highly associated with APOE 
genotype, whereas EMCI subjects characterized by subtle memory performance changes 
were associated with decreases on structural MRI and metabolism on PET [16]. Episodic 
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memory decline in MCI patients was associated with hippocampal atrophy and basal 
forebrain degeneration in Aβ+ subjects [27], and the association was mediated by 
hypometabolism in domain-specific cortical networks. Cognitive impairment in MCI 
subjects in the absence of hippocampal volume loss was accounted for by changes in 
hippocampal texture [28]. In Aβ− MCI subjects, episodic memory decline was correlated 
with hypometabolism in multiple regions outside the temporoparietal areas associated with 
memory deficits in Aβ+ MCI subjects [29]. Attentional control was associated with basal 
forebrain degeneration in MCI subjects [27]. Impairment of daily function was associated 
with greater hypometabolism in middle frontal and orbitofrontal regions [30] and temporal 
atrophy [31]. Worsening impairment of instrumental activities of daily living was associated 
with baseline middle frontal and posterior cingulate hypometabolism [30] and predicted by 
baseline parietal and temporal atrophy [31].
2.3. Associations between neuropsychiatric symptoms and AD biomarkers
Most patients with dementia suffer from neuropsychiatric symptoms (NPSs) such as anxiety, 
depression, apathy, and psychosis. MCI subjects differed in their trajectories of NPSs, with 
one group characterized by an initial low NPS burden that remained stable, a second group 
by an initial moderate NPS burden that worsened, and a final group with an initial high NPS 
burden that decreased over 2 years [32]. The group with worsening symptoms had the most 
rapid declines in cognition and function and had a 1.74 fold chance of being diagnosed with 
AD than the stable group.
Anxiety and irritability are common NPSs endorsed by cognitively impaired subjects. 
Anxiety was correlated with greater Aβ deposition [33]. Anxiety severity was correlated 
with increased rate of progression from MCI to AD above and beyond the effects of 
depression, memory loss, or atrophy and predicted greater rate of entorhinal cortex atrophy 
[34]. Therefore, anxiety may accelerate cognitive decline by affecting the entorhinal cortex 
and influencing Aβ deposition. Irritability was correlated with Aβ deposition in parietal 
regions in AD subjects [33].
Approximately 40% of AD subjects suffer from depressive symptoms. Depression may 
either be a risk factor for developing dementia, a symptom of dementia, or an early reaction 
to cognitive loss. MCI converters (MCIc) with depressive symptoms had earlier ages of 
progression [35] and those with chronic depressive symptoms had a 60% shorter progression 
time to AD than subjects without this history of depression [36]. These symptoms may exert 
their effect via modulation of Aβ load, tau pathology, brain structure, and/or metabolism. 
Amnestic MCI patients with a lifetime history of major depression had higher Aβ deposition 
in the frontal cortex than controls [37]. Current depressive symptoms in Aβ+ MCI subjects 
were associated with a higher Aβ load in the frontal, temporal, and insular cortices and with 
hypometabolism in the frontal cortices compared with nondepressed controls [38]. 
Depressed AD subjects had a greater correlation between levels of total tau (t-tau) and 
cortical thickness in the precuneus and parahippocampal cortex [39]. MCI subjects with 
depressive symptoms who converted to AD within 2 years had greater left hippocampal 
volume loss compared with converters without depressive symptoms [35]. Chronic 
depressive symptomatology was associated with accelerated cortical atrophy in the frontal 
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lobe and anterior cingulate [36], and AD subjects with depressive symptoms had greater 
cortical thinning in the left parietal and temporal regions [39]. Finally, CN, but not MCI or 
AD, subjects with subsyndromal depression had greater frontal WM lesion volume and 
smaller orbitofrontal cortical volumes than controls [40].
Psychosis in the form of symptoms, such as delusions, physical aggression, and 
hallucinations, has long been recognized in AD and is now known to be an independent 
predictor of more rapid cognitive decline. Substantial evidence suggests that AD with 
psychosis is a distinct variant of AD with neuropathological specificity and localization [41]. 
Current psychosis in AD subjects was associated with reduced orbitofrontal brain 
metabolism, and functional decline, and decline on the MMSE [42], and the onset of 
psychosis in MCI or AD subjects was most significantly associated with increased atrophy 
in the lateral frontal lobe [43]. Delusional MCI and AD subjects had greater atrophy in the 
right frontotemporal regions compared with those without delusions [44]. Hallucinations and 
apathy also appear to be associated with both changes in brain structure and in metabolism. 
MCI patients with apathy had decreased metabolism in the posterior cingulate cortex, a 
landmark region for hypometabolism in AD, compared to subjects without apathy [45]. 
Greater temporal and parietal atrophy at baseline in CN, MCI, and AD subjects was 
associated with worsening apathy and hallucinations over 3 years [46]. These studies support 
the idea that psychosis predominantly affects frontal brain regions, with concomitant 
reductions in regional glucose metabolism, resulting in an acceleration of cognitive decline.
2.4. Other clinical risk or protective factors
A variety of other clinical factors have been associated with accelerated cognitive decline or 
in the preservation of cognition. Sleep breathing abnormalities such as snoring or complete 
airway obstruction have a high prevalence in the elderly and may be associated with 
cognitive impairment. Subjects with sleep-disordered breathing had an earlier age of 
progression from both CN to MCI, and MCI to AD than subjects without sleep-disordered 
breathing, but treatment with continuous positive airway pressure almost completely offset 
this effect and delayed MCI onset [47]. Epidemiological studies have suggested a link 
between dietary supplementation with fish oil, cancer history, and educational attainment, 
among other factors, and preservation of cognition. The use of fish oil supplements, 
containing omega-3 polyunsaturated fatty acids, in CN APOE4− subjects, was associated 
with preserved cognition, lower cortical gray-matter (GM) and hippocampal atrophy, and 
lower ventricular expansion, suggesting that fish oil supplementation may influence 
cognition by inhibiting brain morphology changes [48]. A history of cancer was associated 
with a later onset age of AD. Across the ADNI cohort, the number of previous cancer 
incidences incrementally increased the age of AD onset, from 81.7 to 84.3 to 85.7 years for 
subjects with zero, one, and two previous cancer incidences, respectively, and patients with a 
history of cancer showed regional atrophy in the frontal gyrus compared to patients with no 
cancer history [49]. These results suggest that alternative mechanisms to the metabolic 
survival theory (positing the metabolic survival of GM in these patients due to the presence 
of cancer cells that do not undergo apoptosis) may account for the delay in the onset of 
dementia in cancer survivors. The protective effect of educational attainment on cognition 
has led to the concept of cognitive reserve although the mechanisms underlying cognitive 
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reserve remain uncertain. Higher education and larger hippocampal volume were 
significantly associated in AD but not CN or MCI subjects [50]. However, large intracranial 
volume, a measure of brain reserve, increased the risk of progression to AD and increased 
the rate of cognitive decline and brain atrophy in male MCI APOE4 noncarriers [51].
Falls are common in cognitively impaired elderly and can have serious consequences—
around 13% of falls on the ADNI cohort are reported to be either serious or severe adverse 
events [52]. Alzheimer’s medication use was associated with hazard of fall after adjusting 
for age and Beers list medications use, suggesting that clinicians need to be aware of this 
additional risk when managing medications for AD patients [52]. In addition, the use of 
medications with high anticholinergic activity in CN subjects was associated with decreases 
on structural MRI and metabolism on FDG PET, in addition to the known risk of these drugs 
for cognitive decline [53].
2.5. Conclusions
Recent publications of predominantly clinical and cognitive analyses have steadily expanded 
our knowledge in numerous areas. Psychometric analyses have resulted in methods of 
correlating cognitive tests, characterized the nature of memory loss in AD, and even shown 
that cognitive measures can predict Aβ pathology. Neuropsychiatric symptoms in MCI 
subjects were associated with more rapid decline and generally found to accelerate atrophy, 
increase Aβ burden, and decrease metabolism. Psychosis symptoms appeared to mainly 
affect frontal brain regions. The neuroprotective effects of education, cancer history, and fish 
oil suggested by epidemiological approaches were supported by studies investigating their 
association with brain morphology and APOE4 status. Finally, changes on neuroimaging 
biomarkers in CN subjects were used to demonstrate the adverse effects of anti-cholinergic 
medications.
3. Magnetic resonance imaging
The ADNI MRI Core has played a central role in the development of biomarkers for clinical 
trials. Jack et al. [54] reviewed the contributions of the MRI Core over the course of 
ADNI-1, ADNI-GO, and ADNI-2. Major accomplishments of this Core include the 
development of standardized protocols for use across different scanner platforms, quality-
control methodologies, and algorithms to measure longitudinal change for use as potential 
outcome measures in clinical trials. The MRI Core has been instrumental in standardizing 
imaging approaches for clinical trials in addition to structural MRI that reflect both 
technological development and evolving views of disease progression. These include 
sequences to image cerebrovascular disease (Fluid Attenuation Inversion Recovery 
[FLAIR]) and cerebral microbleeds (T2* gradient echo), and functional measures such as 
perfusion MRI (arterial spin labeling), diffusion MRI (diffusion tensor imaging [DTI]), and 
task-free functional MRI (TF-MRI, resting-state fMRI). Functional measures were 
introduced primarily because of their potential to detect early disease-related changes 
occurring before the atrophic changes detected by structural MRI. Jack et al. [54] present an 
excellent review of studies pertaining to the MRI Core over the course of ADNI-2.
Weiner et al. Page 8
Alzheimers Dement. Author manuscript; available in PMC 2019 October 29.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
In 2008, ADNI entered into collaboration with the European Alzheimer’s Disease 
Consortium to develop a harmonized protocol for manual hippocampal segmentation. The 
goal of this international endeavor was to create a standard definition for hippocampal 
boundaries and standard data sets to facilitate use of hippocampal volumetry in clinical 
trials. This project had many phases and succeeded through the concerted effort of many 
scientists. A summary of how the harmonized segmentation protocol (HarP) was established 
is presented in Fig. 3.
In the preliminary phase, the most reliable standard orientation for hippocampal volumetry 
was determined to be perpendicular to the anterior-posterior commissure [56]. Landmark 
variability across 12 manual segmentation protocols was reduced to four discrete and 
measurable segmentation units: the alveus/fimbria, whole hippocampal tail, and medial 
border of the body [57]. An international Delphi panel agreed on the inclusion of these 
segmentation units, finding that this definition captured 100% of hippocampal tissue and all 
of AD-related atrophy, and had good intrarater and interrater reliability estimates [58]. Two 
steps in the implementation of the HarP were the provision of benchmark labels which 
produced high intraclass and interclass correlation coefficients and could be used for training 
human tracers [59], and the development of a platform for training and qualifying new 
tracers to perform manual segmentation using the HarP [60]. Further validation for the 
protocol came from comparison of hippocampi segmented by tracers following local 
protocols and then segmented following the HarP [55]. Local protocols were in low 
agreement compared to the high measurement stability and good reproducibility within and 
among human tracers using the HarP. Pathological validation revealed that hippocampal 
volume was significantly correlated to Braak and Braak staging, tau, Aβ burden, and 
neuronal count and that hippocampal subfields were associated with Aβ, tau, and neuronal 
count [61]. A set of reference hippocampal labels in the HarP is publicly available on the 
Web for training and qualification of human tracers and automated algorithms [55,62].
Although manual segmentation is currently considered the gold standard approach to 
determining hippocampal morphology, the method is time consuming and dependent on the 
experience of tracers. Therefore, there is much interest in developing automated methods 
that can successfully segment this highly variable structure in clinical settings as well as for 
large brain imaging initiatives such as the Enhancing Neuro Imaging Genetics through Meta 
Analysis (ENIGMA) consortium. The subregion segmentation module in the FreeSurfer 
software package had high test-retest reliability and trans-platform reliability in 11 of the 12 
human hippocampal subregions [63]. FreeSurfer had superior reproducibility of 
hippocampal volume change over 1 year to manual segmentation after removal of initially 
visible incorrect automated segmentation [64]. A large number of novel methods for robust 
and fully automated hippocampal segmentation have been developed and tested on ADNI 
data. These are summarized in Table 2.
The ADNI set of MRI images has been instrumental in the development of new 
methodologies for improving imaging at multiple stages and in the assessment of existing 
methodologies. These run the gamut from image acquisition at different field strengths [81–
85] to brain extraction strategies [86,87] to improvements in registration and segmentation 
[88–96] to approaches for measuring longitudinal change [97–107] to cortical thickness 
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estimation [108,109] to better morphometry techniques [110–117]. Many of these studies 
have been detailed by Jack et al. [54] and are summarized in Table 3.
Finally, the ADNI MRI data set has been used in investigations of other neurological 
conditions. The ADNI control set was used in the comparison of NeuroQuant, an automated 
measure of brain volume in patients with traumatic brain injury, with manual interpretation 
of scans [119], and in the investigation of systematic differences in corpus callosum for 
morphology and periventricular nodular heterotopia [120].
4. Positron emission tomography
The ADNI PET Core, under the leadership of Dr. William J. Jagust, has collected 
longitudinal data on glucose metabolism, reflecting changes in neuronal metabolism, from 
FDG PET and on Aβ deposition from the uptake of radiotracers, 11C-Pittsburgh compound 
(PiB) tracer in ADNI-1, and subsequently the 18F-labeled florbetapir [121].
4.1. FDG PET
The ADNI PET Core has been responsible for the development of standardized procedures 
for FDG PET [121]. The importance of standardized procedures for FDG PET was 
underscored by a Cochrane systematic review of studies, including three from ADNI, that 
used baseline FDG PET measures to predict future MCI to AD progression [122]. The meta-
analysis found considerable variability in specificity values, thought to be due to the lack of 
standardization and a lack of a threshold value for abnormality, and the review concluded 
that these obstacles precluded the use of FDG PET as a diagnostic modality in clinical 
practice. The PET Core has addressed these issues by developing image registration 
strategies to improve the consistency of qualitative values extracted from the scans, 
improving the quality-control process, and producing standardized sets of preprocessed 
images available for download from LONI. The PET Core discontinued conducting FDG 
PET scans on ADNI participants in 2014, having amassed a considerable library of 
longitudinal scans for future analysis [121].
4.2. Amyloid PET
The importance of Aβ status is underscored by its inclusion in the revised diagnostic criteria 
for AD [123] and by its use in the selection of asymptomatic subjects likely to progress for 
therapeutic clinical trials. The ADNI PET Core has worked on methodological quality 
assurance and control, as well as the standardization of Aβ PET images [121]. Collection of 
longitudinal data has enabled the examination of rates of Aβ accumulation and its effect on 
cognitive decline [121]. Longitudinal changes in cortical florbetapir standardized uptake 
value ratios (SUVRs) were more accurately measured by the use of subcortical WM 
reference regions compared with the cerebellum or pons [124]. These reference regions also 
increased the power to detect longitudinal increases in fibrillar Aβ and significant 
associations between Aβ increases and clinical decline over 24 months and improved the 
evaluation of Aβ-modifying treatment effects in Aβ+ subjects and CN APOE4 carriers 
[125].
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Are the different Aβ ligands themselves equivalent in terms of detecting Aβ? Chiotis et al. 
[126] compared 11C PiB and florbetapir PET imaging and found similar mean regional 
uptake patterns and strong correlations between regions of interest across patient groups. 
Landau et al. [127] found that cortical retention between three radiotracers, 11C PiB, 
florbetapir, and 18F-flutemetamol were highly correlated. Although flutemetamol had higher 
WM retention and florbetapir had lower WM retention compared with PiB, the threshold 
values for Aβ positivity were consistent when the values were converted using PiB values as 
an intermediary. Thus, comparison of results obtained using different radiotracers appears to 
be valid, a conclusion supported by the comparable results using all three measures obtained 
by Nosheny et al. [128] in their investigation of the effect of Aβ positivity on hippocampal 
atrophy. A focus of the next phase of ADNI will be the development of the Centiloid scale 
for the direct comparison of amyloid tracers [2].
4.3. Tau PET imaging
The accumulation of Aβ plaques is only minimally associated with cognitive decline, which 
appears to be more closely associated with neurofibrillary tangles (NFTs) formed by tau 
amyloid fibrils [129]. Insoluble fibrillar species of tau assemble into intraneuronal inclusions 
known as NFTs as well as neuropil threads in neuronal processes, which represent >80% of 
tau pathology in AD compared with NFTs [130]. Notably, NFTs and neuropil threads in AD 
brains display all the features of amyloids [131]. Soluble tau detected in cerebrospinal fluid 
(CSF) is a putative indicator of neuronal damage as indicated by increases in CSF tau after 
traumatic brain injury [132]. New developments in tracer technology have led to the 
development of PET ligands that track tau fibrillary amyloid accumulation. The inclusion of 
this imaging in ADNI-3 [2] will likely help to unfold the contribution of this pathological 
event to the disease process [133].
5. CSF and blood biomarkers
The study of CSF and blood biomarkers in ADNI is led by the Penn Biomarker Core and 
overseen by Drs. Leslie M. Shaw and John Q. Trojanowski. A detailed account of progress 
throughout ADNI-2 and future plans is given by Kang et al. [129]. The primary goals of the 
Biomarker Core have been to develop CSF and plasma biomarkers signatures to identify AD 
subjects, CN to MCI progressors, and MCI to AD progressors, and to establish the 
longitudinal trajectories of CSF and plasma biomarkers. Multimodal data analyses in 
collaboration with other ADNI Cores have established the temporal order of changes in 
clinical measures, imaging data, and CSF biomarkers and allowed a greater understanding of 
AD pathophysiology. A secondary goal has been to develop biomarkers to detect common 
copathologies such as Lewy bodies, vascular disease, TDP-43 inclusions, and hippocampal 
sclerosis. Potential novel biomarkers have been identified from genome-wide association 
studies (GWAS) in collaboration with the Genetics Core and using proteomics approaches. 
These biomarkers may be able to not only detect AD pathology but also indicate the 
presence of mixed pathology. Through January 2016, the Biomarker Core received and 
processed a total of 10,279 biofluids (CSF, plasma, and serum) and prepared and stored 
161,301 aliquots for use by qualified investigators. They provided a total of 2635 plasma, 
1051 serum, and 3622 CSF blinded aliquot samples to 15 investigators whose request for 
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samples was reviewed and approved during ADNI-2 by the Resource Allocation Review 
Committee. To track the longitudinal progression of all biomarkers, 265 ADNI subjects have 
provided series of three or more CSF samples over as much as 8 years. A total of 1248 
subjects have provided at least three longitudinal samples of serum and plasma. These have 
proven invaluable for the study of CSF Aβ42, t-tau, and p-tau181 trajectories in individual 
subjects [129] and will help establish the trajectories of new biomarkers such as YKL-40, 
Vilip-1, total and phosphorylated α-SYN (Ser129-α-SYN), as well as neurogranin.
5.1. Established CSF biomarkers
5.1.1. Methodological improvements—The Biomarker Core has improved standard 
methodologies that allow the accurate comparison of CSF biomarker results across multiple 
centers. They have developed fully automated analyses of Aβ42, t-tau, and p-tau181 using the 
accuracy- and precision-based Roche Elecsys immunoassay platform, which improves on 
the AlzBio3 immunoassay platform. To circumvent difficulties associated with standardizing 
immunoassays across multiple centers (differences in antibodies, matrix problems, the lack 
of a CSF-based standard reference material), they have validated a mass spectrometry (MS) 
assay for Aβ42, Aβ40, and Aβ38 using a 2D-UPLC/MS-MS platform [129,134], calibrated 
with a surrogate calibrator matrix prepared from artificial CSF plus 4 mg/mL bovine serum 
albumin. This assay had equivalent diagnostic utility to the AlzBio3 immunoassay in 
quantifying CSF Aβ42 differences between controls and AD subjects (sensitivity = 92.7%, 
specificity = 84.5%) [134]. This reference method was developed as part of an international 
effort to develop reference methodology for Aβ42 [135]. It is expected that this will strongly 
support ongoing efforts to obtain harmonization across methods and platforms used 
worldwide for this essential CSF AD biomarker [136].
Another methodological improvement was described by Vidoni et al. [137] who 
demonstrated that the use of 24 bore atraumatic needles reduced the incidence of postlumbar 
puncture headache.
5.1.2. Comparison of CSF and PET measures of Aβ—CSF Aβ42 and amyloid 
PET measures are often assumed to be equivalent, but this may not be a valid assumption 
because the structure and biophysical properties of Aβ fibrils (measured by amyloid PET) 
and soluble Aβ (measured by CSF Aβ42) differ [138]. Some CN and stable MCI subjects 
have abnormally low CSF Aβ measures but no evidence of Aβ amyloid deposits by PET 
measures, suggesting that low CSF Aβ42 may not always be indicative of the accumulation 
of PET-detectable fibrillary Aβ deposits or alternatively that CSF Aβ42 becomes abnormal 
before amyloid PET [139]. However, pathologically low CSF levels of Aβ42 were strongly 
associated with AD diagnosis and cortical Aβ accumulation independent of APOE 
genotype, suggesting that abnormally low CSF levels of Aβ42 reflect cortical Aβ deposition 
and not the APOE genotype [140].
However, the two measures appeared comparable in the classification of MCI converters or 
AD subjects [139] compared to CN subjects, although florbetapir PET had a greater 
specificity than CSF Aβ42 for the latter classification. These measures provided partly 
different and independent information according to a further study by the same group [141]. 
Weiner et al. Page 12
Alzheimers Dement. Author manuscript; available in PMC 2019 October 29.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
CSF Aβ42 was more strongly related to APOE4 genotype, whereas PET Aβ was more 
strongly associated with levels of CSF tau and ADAS-cog scores. Furthermore, discordance 
between the two measures was most common in CN and SMC subjects (Fig. 4) and 
concordance between the two was more common in late-stage AD. The results suggest that 
CSF Aβ42 is a more sensitive marker of very early emergence of Aβ pathologies and that 
PET Aβ may better reflect later stage AD progression.
5.1.3. Amyloid pathway—Aβ is generated by the sequential action of b-site amyloid 
precursor protein (APP) cleaving enzyme 1 (BACE1), the target of γ-secretase inhibitors, 
and β-secretase on the trans-membrane Aβ precursor protein. This process also generates a 
soluble N-terminal fragment, s-APPβ, reported to be correlated with BACE-1 activity [142]. 
Independent studies found no differences in either activity of BACE1 [142–144] or 
concentrations of s-APPβ [142,143] in CSF across all patient groups. Although these 
measures cannot be used to differentiate between healthy elderly and AD individuals, the 
results suggest that CSF levels of s-APPβ may be used as a surrogate for BACE-1 activity in 
clinical trials of β-secretase inhibitors.
5.2. Other CSF and blood analytes
Beyond established CSF biomarkers, Aβ, and p-tau181, there has been much interest in 
alternative CSF and blood analytes that are in some way associated with the disease process. 
Some have been already identified as AD risk factors or as being linked to common 
copathologies. Other novel analytes have been identified using Rules Based Medicine 
immunoassay technology and may have diagnostic or prognostic utility.
5.2.1. Associations between known AD risk factors in CSF and blood and AD 
pathology—Abnormally high blood homocysteine is a major cardiovascular risk factor as 
well as a risk factor for AD and was previously shown to be associated with lower regional 
WM and GM volumes in ADNI [145]. High levels of plasma homocysteine were associated 
with a cortical signature of reduced GM thicknesses, volumes, and surface areas in memory 
networks and the default mode network (DMN) [146], both of which are susceptible to Aβ 
deposition, metabolic disruption, and atrophy, and consistently implicated in AD. As 
elevated homocysteine is easily treatable, this cortical biomarker signature may have utility 
in assessing interventions for lowering homocysteine.
Low plasma levels of the obesity-related hormone leptin have been linked to AD 
pathogenesis. Conversely, high levels of leptin may function in a protective manner by 
regulating levels of Aβ in neurons through the inhibition of β-secretase activity and by 
modulating tau kinases to reduce tau phosphorylation [147]. Johnston et al. [148] reported 
that leptin levels in plasma reflected those in CSF, and that women had two-fold higher 
plasma levels of leptin than men in all groups. In women but not men, leptin levels were 
associated with body mass index. Seventy percent of MCI subjects, of whom half were 
APOE ε4 allele carriers, had lower plasma leptin than CN subjects. Given that reduced 
plasma leptin levels have been established in MCI and AD subjects, Maioli et al. [147] 
examined brain leptin levels across AD progression, including cellular localization of leptin 
and leptin receptors in the hippocampus and frontal cortex. Although they found no 
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differences in CSF leptin levels across all diagnostic groups, they found that leptin 
localization in the brain was altered. In AD subjects, distribution shifted to the hippocampus 
where leptin translocated to become more abundant in reactive astrocytes and less so in 
neurons. A similar translocation was observed in Aβ+ and APOE ε4+ mice, suggesting an 
impairment of leptin signaling in AD in the presence of constant levels of the hormone. 
Animal models of Aβ accumulation indicated that changes in leptin signaling occurred 
before a downregulation of leptin receptors. The authors suggest a mechanism in which 
APOE ε4 allele, in conjunction with Aβ accumulation, transiently enhances leptin signaling 
leading to a leptinresistant state over time and subsequent decrease in cognition. Changes in 
leptin signaling are likely behind the observation that increased body mass index in the 
middle age is a risk factor for AD [149].
How do the gene products of major AD risk alleles exert their effect on the brain? Several 
groups have used multi-modal ADNI data to gain insight into this critical question, bridging 
the gap between genetics and pathophysiology. Three isoforms of the APOE gene product, 
apolipoprotein E (ApoE), corresponding to the ε2, ε3, and ε4 alleles, are found in CSF and 
blood. Plasma ApoE was mildly correlated with CSF ApoE, but not with longitudinal 
changes in cognition or atrophy [150], and was associated with left hippocampal volume in 
APOE4+ MCI subjects [151]. The APOE ε4 allele may increase neurodegeneration via a 
mechanism involving brain iron levels. CSF ferritin levels, reflecting cortical iron levels, 
were strongly associated with CSF ApoE levels in AD subjects and were elevated by the 
APOE ε4 allele [152]. They were also associated with ADAS-cog scores and greater rates of 
hippocampal atrophy and ventricular expansion (Fig. 5) and predicted MCI to AD 
progression [152]. Interestingly, ferritin affected cognitive performance to a similar degree 
as ApoE and p-tau/Aβ42. However, the analytes differed in the level of their effect over time; 
the effect of ferritin was constant, whereas the effect of both ApoE and p-tau/Aβ42 increased 
with disease severity resulting in a greater decrease in cognitive performance over time. 
ApoE may raise the baseline iron load of the brain and so lower the threshold for iron-
mediated neuronal loss.
Although Apo E4 appears to underlie neurodegeneration, Apo E2 or Apo E3 may exert a 
neuroprotective effect. In carriers of the APOE ε2 and ε3 alleles but not the ε4 allele, 
increased levels of CSF ApoE were associated with higher p-tau, an indicator of neuronal 
damage, whereas decreased baseline levels of ApoE were associated with worse longitudinal 
cognitive decline, MCI progression, and atrophy rate independent of CSF p-tau/Aβ42 ratio 
[150]. Therefore, Apo E2 or Apo E3 may be increased in CSF in response to neuronal injury 
and protect against neurodegeneration by decreasing neuronal damage independent of tau 
and Aβ deposition.
CLU, the gene for clusterin, has been identified and confirmed as an AD genetic risk factor 
[153–155]. Deming et al. [156] searched for additional SNPs associated with clusterin levels 
and used gene ontology analyses to identify molecular mechanisms by which CLU may 
exert its action. They found that CSF, but not plasma, levels of clusterin were significantly 
higher in AD subjects and were correlated with both p-tau/Aβ42 ratio and CSF ApoE, 
suggesting that clusterin and ApoE may interact to influence Aβ deposition. Clusterin may 
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contribute to immune system changes observed in AD or disrupt healing after 
neurodegeneration [156].
5.2.2. Associations between novel CSF and blood analytes and AD 
pathology—Mattsson et al. [157] selected a panel of 70 CSF proteins involved in 
biological functions such as Aβ metabolism, microglia activity, and synaptic/neuronal 
function that may be altered in the early stages of AD. At baseline, several proteins in 
addition to Aβ and tau were mildly associated with atrophy over 4 years in specific regions: 
apolipoprotein D, α−1-micro-globulin, apolipoprotein CIII, apolipoprotein H, and 
interleukin 6 with the middle temporal cortex; apolipoprotein CIII, apolipoprotein D, α−1-
microglobulin, apolipoprotein H, and interleukin 16 with the inferior temporal cortex. 
Several proteins (ferritin, S100b, apolipoprotein CIII, apolipoprotein H, and hepatocyte 
growth factor) were associated with atrophy rates that interacted with Aβ, suggesting that 
they act via an Aβ-dependent mechanism, but others appear to act via an Aβ-independent 
mechanism. The proteins identified, if replicated, may represent novel prognostic 
biomarkers of AD-related atrophy in CN subjects.
Synaptic dysfunction occurs in the early stages of AD and is followed by neurodegeneration. 
Several studies have concentrated on finding novel CSF analytes as potential biomarkers for 
this process. Levels of a postsynaptic protein neurogranin appear to reflect synaptic 
degeneration. CSF neurogranin levels were significantly higher in AD subjects and MCI 
converters than in CN subjects [158]. Moreover, neurogranin levels predicted decreased 
MMSE and increased ADAS-cog scores and were correlated with longitudinal reductions in 
cortical glucose metabolism and hippocampal volume. Neurogranin levels were significantly 
increased in Aβ+ subjects, and elevated levels were detected even in non-symptomatic 
subjects, suggesting that it may be an independent novel biomarker for synaptic pathology. 
Paterson et al. [159] identified several analytes using a CSF multiplex analyte panel that 
influence the rate of neurodegeneration in Aβ+ subjects. Low trefoil factor 3 was strongly 
associated with higher rates of whole-brain atrophy, ventricular expansion, and hippocampal 
atrophy. High cystatin predicted higher whole-brain atrophy and hippocampal atrophy rates, 
and low vascular endothelial growth factor (VEGF) and chromogranin Awere associated 
with higher whole-brain atrophy rate. After adjustment for baseline volume, p-tau, age, sex, 
APOE4 status, and diagnosis, trefoil factor 3 was still associated with increased 
hippocampal atrophy rate and may be a valuable biomarker for decline in AD.
AD is characterized by degradation of WM tracts which progressively disconnect cortical 
and subcortical regions. Neurofilaments (NFs) are structural components of the neural 
cytoskeleton and are abundant in large caliber myelinated axons of the WM tracts. 
Zetterberg et al. [160] investigated the associations of its low molecular weight subunit, 
NFL, in CSF with diagnostic status, cognitive decline, and WM change. CSF NFL was 
elevated in AD subjects compared to stable MCI and CN subjects, and correlated with 
accelerated cognitive decline (MMSE and ADAS-cog), WM change, and increased whole-
brain atrophy, ventricular expansion, and hippocampal atrophy in MCI subjects. These 
results suggest that NFL may be a useful biomarker for tracking axonal degeneration, where 
NFs are most abundant, and this is associated with the degradation of WM tracts in cognitive 
decline.
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VEGF has been implicated as a neuroprotective factor in AD, possibly neutralizing the 
damaging effects of the AD pathological cascade through improvements in vascular survival. 
Hohman et al. [161] found that higher levels of VEGF were associated with larger baseline 
hippocampal volume, lower hippocampal atrophy over time, lower episodic memory decline, 
and lower executive function decline over time. The neuroprotective effect of VEGF, which 
was greatest in MCI subjects, appeared to be enhanced in the presence of AD CSF 
biomarkers. In Aβ+ subjects, higher VEGF levels were associated with better memory 
performance, and in tau1 subjects, higher VEGF levels were associated with lower 
hippocampal atrophy, and decline in memory and executive function. These results suggest 
that angiogenic factors may be important in individuals with biomarker abnormalities 
consistent with early AD. The mechanism by which VEGF reduces risk of 
neurodegeneration is unknown. Leung et al. [162] searched for CSF analytes associated with 
Aβ positivity and also identified fatty acid binding protein and VEGF, along with less 
strongly associated analytes including resistin, CD40 antigen, prolactin, lipoprotein A, and 
hepatocyte growth factor. These analytes are involved in different aspects of AD 
pathophysiology, including inflammatory response, lipid metabolism, atherosclerosis, and 
insulin resistance, and are potential biomarkers that require future validation in independent 
cohorts.
Another factor reported to be protective against AD, possibly through its modulation of Aβ 
accumulation, is brain-derived neurotrophic factor (BDNF), a widely distributed 
neurotrophin with multiple functions including neuronal differentiation, regulation of 
synaptic function, and modulation of hippocampal long-term potentiation, learning, and 
memory formation. Hwang et al. [163] found a significant negative association between 
BDNF protein levels in plasma and brain Aβ burden, measured by PiB PET, in the lateral 
temporal, inferior parietal, and inferior frontal, anterior and posterior cingulate, and orbital 
frontal regions. In a separate study [164], the Val66Met polymorphism which is associated 
with lower BDNF secretion in vitro was not associated with hippocampal volume or 
memory. Therefore, plasma BDNF levels may act as a biomarker of Aβ pathology but not of 
volumetric or cognitive changes in the brain. Analytes identified in these studies are 
summarized in Table 4.
5.2.3. CSF and plasma analytes for the detection of copathologies—There is a 
growing awareness that copathologies such as Lewy bodies, vascular disease, TDP43 
inclusions, and hippocampal sclerosis are common and may explain the variability in AD 
progression [169]. The development of biomarkers to predict coincident pathologies that are 
frequently observed in clinically diagnosed AD patients would be of great clinical utility and 
may improve the diagnostic and prognostic abilities of established CSF biomarkers alone 
[129]. One of the most common comorbidities in AD, present in 10%–40% of AD patients, 
is the presence of Lewy bodies, composed of α-synuclein (α-syn). Symptoms of dementia 
with Lewy bodies include hallucinations, visual spatial impairment, and executive 
dysfunction but it is not known how reduced CSF α-syn relates to AD symptoms. Mackin et 
al. [170] reported that 20% of AD, 13% of MCI, and 8% of CN subjects reported 
hallucinations and that CSF α-syn was reduced in these AD subjects. Lower CSF α-syn was 
associated with decreases in memory and language, as well as executive function, suggesting 
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that Lewy bodies may be related to overall cognitive decline in addition to the characteristic 
hallucinations of dementia with Lewy bodies.
A non-AD pathway to dementia was outlined by Alcolea et al. [144]. They reported that 
preclinical subjects as well as subjects with suspected non-Alzheimer’s pathology (SNAP) 
had higher levels of YKL40, a marker of neuroinflammation, than Aβ+ subjects early in 
disease progression. This suggests that neuroinflammation can emerge through a non–Aβ-
related pathway and that it is also detectable in CSF in preclinical stages in non-Aβ 
degenerative disorders. The correlation between YLK40 levels and age regardless of APOE 
status suggests that low-grade inflammatory processes are present in the brain even in the 
absence of Aβ. These findings suggested that CSF YKL40 levels increase with aging, 
preclinical AD, and SNAP and correlate closely with markers of neurodegeneration.
5.3. Conclusions
Considerable progress has been made in 2014 and 2015 by the ADNI Biomarker Core in 
improving methodologies for measuring established CSF biomarkers and establishing 
relationships between different measures of Aβ. The ADNI Biomarker Core has also 
emphasized the need to detect copathologies, such as α-syn amyloid deposits in Lewy 
bodies which were associated with symptoms specific to AD in addition to those 
characterizing dementia with Lewy bodies. SNAP may be associated with YLK40, a marker 
of neuroinflammation. Cerebrovascular risk factors homocysteine and body mass index, as 
reflected in CSF leptin levels, have been linked to aspects of AD pathology. A number of 
studies have addressed the mechanism of action of the APOE ε4 allele via its CSF and blood 
ApoE protein. ApoE may modulate iron levels leading to oxidative damage–induced 
neurodegeneration or act in conjunction with Aβ to enhance leptin signaling. Confirmed AD 
genetic risk factor, CLU, may exert its effect via immune response. Another focus has been 
the use of proteomic approaches to identify primarily CSF analytes associated with atrophy, 
and cortical Aβ load, WM degradation, and cognitive decline that capture distinct 
information from those identified by traditional CSF biomarkers. These include fatty acid 
binding protein, apolipoproteins AII, CIII, D, and H, interleukins 6 and 16, ferritin, and 
chromogranin A. Conversely, several studies point to VEGF and BDNF as being 
neuroprotective.
6. Studies of genetic associations
Studies of ADNI genetics data have been instrumental in deepening our understanding of 
AD pathophysiology by bridging the gap between the genetic underpinnings and 
biochemical mechanisms of the disease. The Genetics Core, under the aegis of Dr. Andrew 
Saykin, has collected blood samples at every patient visit, extracted both DNA and RNA, 
and performed APOE, TOMM40, and genome-wide array genotyping, whole-exome 
sequencing, and whole-genome sequencing (the latter generously supported by the Brin-
Wojcicki Foundation and the Alzheimer’s Association [171]). The rich ADNI longitudinal 
data set contains many biomarkers that can serve as quantitative endophenotypes for genetic 
association studies, increasing the power to detect biologically meaningful associations. In 
accordance with ADNI policy, all genetics data, like other data, have been made available to 
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the wider scientific community, resulting in well over 300 publications by 2014 that 
analyzed ADNI data sets. This section describes the work of the Genetics Core and the 
approximately 80 publications arising from ADNI genetics data in 2014 and 2015.
6.1. Reviews
Saykin et al. [171] outlined the progress and plans of the ADNI Genetics Core and 
systematically reviewed 106 articles published between 2009 and 2012. These investigations 
ran the gamut from large meta-analytic case-control GWAS to GWAS of quantitative 
endophenotypes, to studies which select genes from a particular pathway thought to be 
involved in AD, to those pinpointing the effects of a particular polymorphism or gene. 
GWAS conducted by a multistudy consortia have identified and replicated approximately 20 
genes in addition to APOE that confer risk or have protective roles in AD [172]. A number 
of these (APOE, BIN1, CLU, ABCA7, CR1, PICALM, MS4A6A, CD33, MS4A4E, and 
CD2AP) have been identified or confirmed using ADNI data. In addition, many novel 
candidate risk and protective loci cut have been identified using ADNI genetics data and 
quantitative imaging, cognitive, and fluid phenotypes (Fig. 6) [172]. However, these loci 
account for only a portion of disease heritability. As AD is a multigenic disorder influenced 
by environmental factors and epistasis, the Genetics Core has emphasized a Systems 
Biology perspective in which candidate genes identified in GWAS or from likely 
mechanistic biological pathways are studied for their associations with mRNA and other 
phenotypes. It is hoped that this integrative functional genomics approach will capture the 
biological complexity at multiple levels including genomic, transcriptomic, proteomic, and 
metabolomic (Fig. 7).
ADNI genetic studies also hold promise for improving clinical trial design and identifying 
therapeutic targets. Stratification and subject selection, currently limited to APOE, could 
likely be improved by the incorporation of combinatorial sets of genes that have a 
biologically relevant underpinning such as a target pathway. In a similar way, an improved 
understanding of pathways and mechanisms of association between AD risk genes in disease 
will provide therapeutic targets [171]. In the future, the ADNI Genetics Core will collect 
samples for the production of induced pluripotent stem cells. This will allow development of 
in vitro models that can bridge the gap between animal models and clinical development and 
that can improve phenotypic characterization of disease heterogeneity.
ADNI genetics data have contributed to a number of meta-analytic studies, most notably the 
ENIGMA consortium, a global collaborative network of over 500 scientists involved in 
neuroimaging genetics [173,174]. Using neuroimaging data from nearly 13,000 subjects, 
ENIGMA is studying 12 major brain diseases including schizophrenia, bipolar illness, and 
major depression and has identified a number of genetic loci that affect brain volumes, and 
how they may act to increase the risk of these diseases.
6.2. Genetic association studies
Two fundamentally different approaches have been used to characterize associations 
between genetic loci and phenotypes using ADNI data. Genotype approaches select 
candidate SNPs, genes, or pathways from a priori knowledge of biological function and test 
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for their association with selected imaging or fluid biomarkers. Although this approach 
cannot discover new genes, it can examine the effect of interactions between loci and 
phenotypic variation. The main alternative approach is to begin with a phenotype and search 
the genome for significantly associated loci. This approach can discover new genes but is 
often hampered by problems of ultrahigh dimensionality and multiple comparisons and 
ignores spatial information in imaging data and correlations between genetic markers due to 
linkage disequilibrium and epistatic effects. A popular hybrid approach is to select candidate 
loci and then apply further biologically informed enrichment methodologies. Genetic 
association studies from 2014 and 2015 are summarized in Table 5; confirmed and novel risk 
or protective loci identified from ADNI studies during this period are detailed in Table 6.
6.2.1. Genotype
6.2.1.1. APOE: The APOE ε4 allele is the single locus that confers the greatest risk for 
sporadic late-onset AD. Carriers of this allele have greater hippocampal atrophy rates than 
noncarriers [175,176], significant morphological deformation of the left hippocampus [177], 
accelerated rates of atrophy in limbic and cortical areas, particularly the amygdala [176], 
faster ventricular expansion, and regional patterns of ventricle morphology [178]. Although 
a family history of AD was associated with greater regional longitudinal atrophy rates in 
MCI participants, these were accounted for by APOE4 genotype [232]. These studies 
suggest that there is a genotype-specific network of brain regions associated with the APOE 
ε4 allele that undergoes faster atrophy and morphological changes. The effect of this allele is 
stronger in women than in men. Sampedro et al. [179] found that female APOE4 carriers 
had widespread brain hypometabolism and cortical thinning in several regional clusters 
compared to female noncarriers, whereas male APOE4 carriers differed only slightly from 
male noncarriers (Fig. 8). However, male APOE4 carriers had a higher risk of cerebral 
cortex microbleeds then the male noncarriers, suggesting that there is a differential sex bias 
of the APOE4 allele on diverse aspects of disease pathology.
6.2.1.2. Candidate SNPs and genes
6.2.1.2.1. SNPs in confirmed risk alleles: Candidate SNPs for association studies are 
chosen because of their location in confirmed AD risk alleles or in genes of suspected 
importance on the basis of biological function. SNPs in BIN1 (rs744373), CD2AP 
(rs9349407), and CR1 (rs3818361) (AD risk variants implicated in Aβ deposition) 
modulated the association between plasma ApoE levels and cortical Aβ load in different 
directions (Fig. 9), independent of APOE4 carrier status, suggesting that these genes interact 
with APOE to modulate Aβ accumulation and clearance [181]. Genetic variants in the 
recently confirmed AD risk factor, UNC5C, were associated with the atrophy rate of the left 
hippocampus and right precuneus [182]. The protective A allele of rs11771145 in EPHA1 
prevented hippocampal atrophy in MCI subjects and was associated with lower atrophy and 
greater metabolism in the temporal gyri in AD subjects [183]. Whole-exome sequencing 
identified a coding missense variant, p.S144G, in TREML2 responsible for the previously 
noted protective effect against AD [184]. This functional variant was associated with a 
reduced risk of AD, whereas a missense variant in TREM2, p.R47H had the opposite effect, 
independent of p.S144G. Cell-based analyses implicated the involvement of these variants in 
the modulation of microglial activation, possibly influencing Aβ clearance. Minor allele G 
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carriers of rs2718058 in a recently confirmed preventive locus adjacent to NME8 had higher 
CDR-SB scores, lower occipital gyrus atrophy, greater metabolic rate and ventricular 
expansion, and a lower rate of hippocampal atrophy than carriers of the major A allele, 
suggesting that the minor allele may confer its protective effect by inhibiting 
neurodegeneration [185]. The G allele in rs2070045 within SORL1 was associated with 
increased CSF tau and hippocampal atrophy, and a haplotype in this region was associated 
with higher tau and p-tau181, suggesting that SORL1 may increase AD risk by increasing 
neurodegeneration [186]. Finally, top risk allele, CFH, but not risk alleles CR1, CD33, CLU, 
and TREML2, were strongly associated with AD in a Chinese cohort [187], suggesting that 
the genetics of AD may differ among diverse populations.
The gene-gene interaction between CLU and MS4A4E was associated with APOE4− status 
and may have a possible dominant effect [188]. Lack of these risk alleles was estimated to 
decrease AD incidence by 8%. CR1 and EPHA1 interacted with cardiovascular disease risk 
factors to reduce hippocampal volume [189]. Cardiovascular risk dominated the genetic risk 
of these loci in terms of interaction effect such that at low genetic risk, high cardiovascular 
risk factors had a more detrimental effect (Fig. 10). These findings indicate that CR1 and 
EPHA1 may contribute to the etiology of late-onset neurodegeneration in the presence of 
cardiovascular disease.
6.2.1.2.2. SNPs in genes targeted for biological function: Several studies have targeted 
genes with biological functions implicated in AD. Rare variants of PLD3 are confirmed AD 
susceptibility loci; phospholipase D3 modulates APP processing. However, a common 
variant in the same gene, rs10407447, was associated with regional metabolism and lateral 
ventricular volume in CN and MCI subjects [190]. A study of SNPs found in genes 
preferentially expressed in the hippocampus identified a novel locus, NAV2 (neuron 
navigator 2), associated with episodic memory scores [191]. Neuron navigator 2 is involved 
in neurite outgrowth and cell migration.
Abnormal cholesterol levels increase the risk of AD and are influenced by several common 
genetic variants. Increased G allele dosage of rs5882 (p.I405V) in CETP (cholesterylester 
transfer protein) was associated with measures of WM integrity (lower fractional anisotropy 
and higher radial and mean diffusivities) in older individuals, suggesting that high 
cholesterol may increase AD risk through the degradation of WM integrity [192]. 3-
hydroxy-3-methylglutaryl-CoA reductase plays a central role in the production of 
cholesterol and is the target of statins which reduce the risk of sporadic AD by as much as 
70% in midlife. AD carriers of the G allele of rs3846662 in HMGCR had both a delayed age 
of onset and a reduced risk of AD [193]. The effect was greatest in women. In MCI subjects, 
the G allele reduced progression to AD over 3 years, even in APOE4+ subjects, providing 
further support for the protective role of this allele.
Altered dopamine transmission affects many aspects of brain function, including the 
formation of Aβ, and contributes to cognitive impairment. Dopamine transporter protein, 
encoded by the DAT1 gene, regulates neurotransmission by modulating dopamine receptors. 
The minor C allele of rs6347 in DAT1 was associated with poorer cognitive performance, 
greater ventricular expansion, and greater dementia risk, independent of APOE genotype 
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[194]. Although the mechanism of action of this polymorphism is unknown, dopamine 
neurotransmission may be a useful target for anti-dementia drugs. Delta opioid receptors 
promote the processing of APP and are implicated in various psychiatric and neurological 
disorders. A common variant (rs678849) in the OPRD1 gene was associated with regional 
brain volume differences in healthy elderly and may predict levels of CSF biomarkers [231].
6.2.1.3. Candidate pathways and epistatic interactions: The top 10 AD susceptibility 
genes explain only 35% of the variability in disease risk [233]. It has become apparent that 
studies of single loci are not sufficient to unravel the complex genetic etiology of the 
disease. It is thought that the “missing heritability” may come from the association of 
multiple variants in genes interacting in functional pathways. Variation in genes involved in 
oxidative phosphorylation (OXPHOS), summarized by an OXPHOS genetic risk score, is 
associated with an increased risk of stroke. Stroke increases the risk of AD, and the 
OXPHOS genetic risk score was associated with AD clinical status, CN to MCI progression, 
and volumes of hippocampus and entorhinal cortex in CN and MCI, but not AD subjects 
[196]. This suggests that the genetic structure of AD and stroke overlap and that OXPHOS 
variants exert an early influence on disease trajectory.
Epistatic interactions may also account for some of the risk variability of AD. Koran et al. 
[197] investigated genes from AD pathways, including Aβ processing, apoptosis, calcium 
homoeostasis, free radical production, and mitochondrial dysfunction, defined by the Kyoto 
Encyclopedia of Genes and Genomes database. An interaction between minor alleles in 
RYR3 (ryanodine receptor 3) and CACNA1C (αC subunit of voltage-dependent L-type 
calcium channels) was associated with a higher Aβ load and explained 6% of Aβ load 
variance. Both genes encode proteins involved in the regulation of intracellular calcium 
homoeostasis. As ryanodine receptor–driven calcium release has been associated with 
increased Aβ levels, and Aβ modulates the function of L-type calcium channels, the authors 
suggest that interaction between these two variants may increase intracellular calcium levels 
by disrupting calcium homoeostasis and lead to increased Aβ production and deposition. Aβ 
accumulation was also associated with two SNP-SNP interactions between C9 (complement 
9) and ILR6 (interleukin 6r), suggesting that neuroinflammation may exert its effect on AD 
by enhancing Aβ deposition [198].
According to the amyloid hypothesis, Aβ deposition precedes tau pathology. However, it is 
possible that the two pathologies arise independently due to upstream genetic interactions 
and that genes that confer risk for tau pathology also confer risk for Aβ pathology via 
complex epistatic relationships. Hohman et al. [199] searched for epistatic interactions 
between genes for tau kinases and genes involved in Aβ deposition associated with Aβ load. 
They found three interactions between rs334543 in GSK3β and different Aβ genes. A minor 
allele that interacted with APP was related to high levels of Aβ deposition. The combined 
interactions explained between 1.2% and 1.5% of the Aβ deposition variance, suggesting 
that Aβ burden may be increased by a combination of GSK3β and APP-related genes.
In a genome-wide search of all possible SNP-SNP interactions that affect regional brain 
volumes, one interaction between an SNP in a region encoding two transcription factors 
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(rs1345203) and an intergenic SNP (rs1213205) explained 1.9% of the variance in temporal 
lobe volume [195]. The biological relevance of this interaction has yet to be determined.
6.2.2. Phenotype—A great strength of ADNI is its wealth of quantitative phenotypes 
that can be leveraged to identify novel susceptibility loci in GWAS, and more recently, gene-
based GWAS.
6.2.2.1. Case-control studies: Complex patterns of the association may not be reflected 
solely in single SNPs. A mega meta-analysis of genome-wide data sets, including ADNI’s, 
as part of the International Genomics of Alzheimer’s Disease Consortium, identified two 
novel loci, TP53INP1 and IGHV1 [200]. The first locus encodes a proapoptotic tumor 
suppressor of interest due to the inverse association between cancer and AD, whereas the 
function of the latter locus is unknown. A similar analysis evaluated single gene associations 
in a network context, then use gene ontology and pathway enrichment methods to identify 
biologically plausible interactions [201]. Genes involved in the glutamatergic synapse, 
including GRIN2B, appeared to be overrepresented in AD subjects. Glutamate signaling 
regulates many biological processes such as learning, memory, and synaptic plasticity, and 
glutaminergic neurons located in the hippocampus and other brain areas are affected by Aβ 
plaques and tau tangles. Top genes identified by the computation of a multimarker genetic 
score associated with disease status (AEN, ADAMTS12, PSMA5, FXN, NTM, LARP1, 
WDTC1, SEMA7A, VKORC1L1, and COL5A3) were integrated into a hypothetical 
signaling network incorporating a priori protein-protein interaction data, which highlighted 
their function in cholesterol metabolism [202].
Genetic subtypes of AD may have specific molecular mechanisms of pathogenesis. A 
GWAS in APOE4 noncarriers identified three novel loci located in three haplotype blocks, 
ZNF827 (zinc finger protein 827), KDM2B (lysinespecific demethylase 2B), and NANP (N-
acetylneuraminic acid phosphatase), which were associated with CSF Aβ42, p-tau181, and 
brain atrophy, respectively [203].
Some of the missing heritability of complex diseases may be accounted for by rare variants; 
low-frequency allele variants have a higher probability of functional significance. A gene-
based analysis of alleles with frequencies lower than 3% identified one novel association 
between ZNF628 (zinc finger protein 628) and AD that reached genome-wide significance 
after adjustment for APOE4 [204]. The study also identified minor alleles in APOE, 
TOMM40, MMP1, TREM2, CBLB, and NAPRT1 that may contribute to AD heritability. 
The zinc finger proteins identified in these studies suggest that transcriptional regulation 
may play an important role in pathogenesis.
6.2.2.2. Structural imaging phenotypes: The use of structural MRI quantitative 
phenotypes in identifying genetic variants associated with AD has continued to be a 
powerful strategy. The development of machine learning approaches has facilitated 
previously challenging tasks such as the selection of imaging features with power to detect 
genetic associations. A polygenic approach using a penalized regression method to select 
109 brain wide regional measures identified a novel marker, HOMER2, associated with right 
thalamus volume and with AD clinical status [212]. Homer2 is a transcription factor which 
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may be linked to APP processing or the trafficking of APP to the cell surface. A GWAS of 
GM density data [205] jointly considered the effects of all polymorphisms, how they fit into 
biologically defined pathways, and the functional relationships of 20 genes involved in SNP-
SNP interactions. Enrichment analysis identified visual perception, DNA repair and 
replication, and olfactory pathways. A statistically significant synergistic interaction 
between two SNPs in an olfactory gene cluster suggested that this pathway may be involved 
in AD. Using a subset of imaging features able to discriminate between CN and AD subjects 
as quantitative phenotypes, genetic variation in a relatively small number of genes (ESR1, 
BIN1, LDLR, SORCS1, APP, LRAT, and TF) was found to be associated with ventricular 
enlargement, hippocampal atrophy, and cortical atrophy, suggesting that these loci could 
have potential in diagnostic classification [213]. Another study selected neuroimaging 
biomarkers associated with disease state on the basis of global shape analysis and found 
differential associations between SNPs and regional volumes at different disease stages 
[214]. Notably, in MCI subjects, SNPs in PML (promyelocytic leukemia) and STOML1 
(stomatin-like 1) were associated with shapes of the hippocampi and insular cortices.
Although most GWAS analyses focus only on baseline phenotypes, two studies used 
ADNI’s longitudinal neuroimaging data that, by capturing rates of change, have greater 
statistical power to detect genetic associations. Longitudinal structural MRI data identified a 
much larger number of SNP-phenotype associations than cross-sectional data [215]. A 
second study used longitudinal change in ventricular volume as a quantitative phenotype for 
a pathway-based gene-gene interaction analysis [216] and identified a novel interaction 
between SYNJ2 (synaptojanin 2) and PI4KA (phosphatidylinositol-4 kinase) that was 
associated with inferior lateral ventricle atrophy. Both proteins are involved the synthesis of 
phosphatidylinositol, and the authors suggest that these genes might modulate its synthesis 
leading to deficits in neuroprotective mechanisms.
A whole-exome sequencing study by Nho et al. [217] using DNA from ADNI-1 and an 
extreme phenotype approach identified a functional exonic single nucleotide variant that was 
associated with a slower rate of hippocampal atrophy in MCI subjects. The minor T allele of 
the missense variant rs3796529 in REST, a negative transcriptional regulator of adult 
hippocampal neurogenesis [206], conferred a protective effect on hippocampal loss in MCI 
and AD subjects. A subsequent study showed that carriers of this minor allele had greater 
medial temporal lobe metabolism compared to noncarriers, independent of APOE4 status 
[207] and that it was associated with reduced AD risk and did not confer susceptibility to 
AD [208]. However, a meta-analytic study using the ENIGMA cohort did not find that the 
variant conferred a significant effect on six subcortical regions including the hippocampus 
[209]. Further investigation is required to determine the relative enrichment of the variant in 
diagnostic groups and whether it protects against hippocampal atrophy in CN subjects.
Most ADNI studies are concerned with late-onset AD. However, the cohort contains a small 
number of subjects aged 55 to 65 years who have a relatively early onset form of the disease 
and who are characterized by much lower frequencies of amnestic MCI [234]. Early onset 
AD is most commonly autosomal dominant, caused by mutations in the APP, PS1, and PS2 
genes [235], but some subjects lack these risk alleles. Moon et al. [210] used the LONI 
pipeline [211] to identify 20 neuroimaging shape and atrophy changes specific to MCI 
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subjects aged 55 to 65 years, for use as GWAS quantitative phenotypes. These included not 
only hippocampal volumes but precuneus atrophy and shape changes, consistent with 
previous studies of early onset AD. A set of 15 SNPs best able to discriminate between 
early-onset MCI and early-onset AD subjects was associated with the volumetric and shape 
changes. The most significant loci, located in the genes for Janus kinase and microtubule 
interacting protein-1 and neuropilin 1, differed from those identified in the late onset form of 
the disease.
6.2.2.3. Measures of Aβ deposition: GWAS using either amyloid imaging data or fluid 
levels of Aβ have furthered our understanding of the genetic basis of Aβ deposition. Using 
florbetapir data, the minor G allele of rs509208 located upstream of butyrylcholinesterase 
(BCHE) and the APOE loci together accounted for 15% of the variance in baseline cortical 
Aβ load (Fig. 11) [218]. BCHE is a biologically plausible gene; decreased activity of 
butyrylcholinesterase, which is enriched in Aβ plaques and the target of cholinesterase 
inhibitors, increases acetylcholine levels and disrupt synaptic functioning eventually leading 
to neurodegeneration. A gene-set enrichment analysis performed on top SNPs identified in a 
GWAS of CSF levels of Aβ42, including those located in TOMM40 and near APOC1, 
revealed two clusters associated with synaptic transmission, transmission of nerve impulses, 
and trait class, and identified eight novel polymorphisms [219]. A subsequent gene-gene 
interaction network analysis identified GRIN2A as interacting with the most AD genes, 
followed by APOC1 and TOMM40 (Fig. 12). A GWAS of plasma concentrations of Aβ40 
and Aβ42 identified 18 suggestive loci, the most strongly associated of which was CTXN3 
(cortexin 3) [220]. Pathway enrichment analysis identified a variety of canonical pathways 
including some directly associated with Aβ peptide properties. Cortexin was found to 
modulate Aβ42 secretion.
Although Aβ deposition is strongly linked to APOE4 and nearby genes in linkage 
disequilibrium (TOMM40, APOC1), Aβ deposition is still observed in APOE4 noncarriers. 
A GWAS of longitudinal Aβ accumulation in these subjects [221] reported that the minor G 
allele of an intronic SNP (rs12053868) in interleukin 1 receptor accessory protein (IL1RAP) 
accounted for 7.1% of the phenotypic variance (Fig. 13). Deep sequencing of IL1RAP 
identified additional rare variants associated with the rate of change in Aβ burden. Gene- 
and pathway-based GWAS identified pathways related to cell adhesion and immune 
response, consistent with the role of IL1RAP as a proinflammatory cytokine involved in the 
activation of microglia. The minor G allele was associated with higher rates of atrophy in the 
temporal cortex, a higher rate of MCI to AD progression, and faster cognitive decline. Other 
novel loci identified in GWAS of CSFAβ42 levels in APOE4− subjects are SULG2 (GTP-
specific β-subunit, succinyl-CoA ligase), which accounted for 10.7% of the variance in Aβ42 
levels in these subjects [222], and variants in the FRA10AC1 fragile site and in the 
intergenic 15q21 locus [223]. FRA10AC1 encodes a nuclear phosphoprotein of unknown 
function.
6.2.2.4. Other CSF and blood phenotypes: A GWAS of CSF tau levels identified 
rs4728029 in protection of telomeres 1 (POT1), which modified the relationship between p-
tau181 and ventricular expansion [224]. This novel locus explained 2.6% of the variance in 
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p-tau181 and modified the relationship between p-tau181 and both ventricular dilation and 
memory performance. As this SNP was related to levels of interleukin 6 receptor, it may 
exert its effect via a neuroinflammatory mechanism. This GWAS also enriched targeted 
genes mediated by miR-33, which regulates lipid metabolism genes and disrupts cellular 
cholesterol homoeostasis.
A complementary approach to GWAS of CSF Aβ42 and tau [225] instead used CSF analytes 
involved in the processes such as endocytosis, cholesterol metabolism, and inflammatory 
and immune responses that are recognized to play important roles in AD pathogenesis 
beyond Aβ and tau pathology. This study identified five genetic associations between CSF 
proteins and angiotensin-converting enzyme, chemokine (C-C motif) ligands 2 and 4, 
interleukin 6 receptor, and matrix metalloproteinase 3. All identified proteins are involved in 
Aβ processing or proinflammatory signaling.
6.2.2.5. Neuropsychological assessments: In addition to neuroimaging and fluid 
biomarker measures, neuropsychological assessments offer another route to understanding 
AD genetics. Variants in the spondin 1 (SPON1) gene whose minor alleles were associated 
with more rapid progression were identified using longitudinal changes in ADAS-cog as a 
phenotype for a GWAS [226]. Spondin 1 inhibits cleavage of APP by BACE. Other 
significant associations were reported in genes involved in neuronal maintenance and 
neurotransmission, and calcium signaling (EXOC4, GABRG3, VAT1L), and homoeostasis 
(CAMK4, CYCS, NCS1, CACNA1G). Mukherjee et al. [236] investigated the genetic basis 
of cognitive resilience, observed in patients whose cognitive function is better than predicted 
by neuroimaging and fluid biomarkers. The top hit in their gene-based GWAS was 
RNASE13, and subsequent pathway analysis identified pathways involved in neuron loss, 
presynaptic membrane, and postsynaptic density. These included genes associated with AD 
such as PTK2B, PICALM, MS4A2, and APP.
6.2.3. Other association studies—Imaging genetic studies using ADNI data have not 
only focused on AD. Two meta-analytic GWAS identified variants influencing human 
subcortical structures [228] and cortical surface area [229]. Polymorphisms in the dopamine 
D2 receptor gene, which increases genetic risk for addictive disorders, altered regional brain 
volumes in areas implicated in addiction [230].
6.3. Methods
The biological insights that we have gained from these genetic association studies, 
particularly those using neuroimaging data, would not have been possible without a 
foundation of statistical methodologies. These have progressed from univariate analysis in 
standard GWAS to a variety of multivariate regression approaches, as well as ways to detect 
epistatic interactions or to discover associations at the gene or pathway level. Univariate 
analysis comparing single SNPs with single traits suffers from problems of high 
dimensionality and type-I errors and may not reveal significant associations without meta-
analytic approaches. ADNI studies have assessed the extent of these problems [237,238], 
improved the computational efficiency of mass univariate analyses [239–242], and 
developed methods for the selection of the most informative SNPs or quantitative features to 
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improve power to detect associations [243–247]. Two studies have developed summary 
measures representing associations between selected SNPs and traits of interest [202,248]. 
Nho et al. [249] developed specific methodologies for the analysis of whole-genome 
sequencing data, and several groups have developed methodologies for identifying and 
visualizing genetic interactions [189,205,250–253]. Finally, two groups described methods 
to select discriminative SNPs to improve diagnostic classification or prediction of future 
decline [254,255]. The studies are summarized in Table 7.
6.4. Conclusions
Much of the heritability of AD remains elusive, reflecting both the polygenic nature of the 
disease and the influence of environmental factors. The ADNI Genetics Core adopted a 
Systems Biology perspective and approaches that integrate multiple “omics” to characterize 
biological complexity on multiple levels [171]. ADNI genetics studies from 2014 and 2015 
were notable for moving beyond simple GWAS using one-SNP-simple phenotype univariate 
analyses to an expanded array of increasingly sophisticated biologically informed 
approaches, such as pathway enrichment, network analysis, and gene set enrichment, aimed 
at bridging the gap between genetic information and biochemical disease mechanisms. The 
concomitant development of a wide range of statistical methodologies supported these 
efforts (Table 7). An excellent example of the power of these integrative approaches to place 
genetic results in biologically plausible context can be seen in the hypothetical signaling 
network constructed by Wang et al. [202] from their application of a Rasch genetic 
multimarker model to ADNI case-control GWAS data (Fig. 14).
Genetic association studies begin either with a genotype, such as an SNP, gene, or a sets of 
genes in a pathway of interest, or with a phenotype (Table 5). Several GWAS notably 
capitalized on longitudinal phenotypes from ADNI’s rich data set to increase the power to 
capture significant associations [215,216,221]. Strategies for finding the “missing 
heritability” of the disease included searching for epistatic interactions, examining the 
associations of low-frequency variants, and extending analysis from a target gene to genes in 
the same biological pathway. The APOE ε4 allele was associated with atrophy and shape 
changes in the hippocampus and other regions [176–178] and was found to have differential 
effects in males and females [179]. Studies of APOE ε4 noncarriers identified loci 
responsible for disease phenotypes such as Aβ deposition in these subjects [188,222,223] 
(Table 6). Novel protective and risk loci associated with atrophy, metabolism, Aβ load, CSF 
biomarkers, and cognitive decline and with early onset AD in the absence of established 
autosomal-dominant genes were identified (Table 6). Risk genes lay in pathways involved in 
APP processing and Aβ clearance, apoptosis, cholesterol metabolism, neurotransmission, 
immune and inflammatory responses, microglial activation, and other cellular processes. 
Interestingly, stroke and AD risk genes appeared to overlap, implicating WM disease in AD 
pathology. Identified protective genes were involved in the inhibition of neurodegeneration 
and cholesterol metabolism, and cancer. Finally, ADNI genetics data have contributed to 
understanding other diseases with the inclusion of the cohort in various meta-analyses [228–
230] and in the ENIGMA consortium [173].
Weiner et al. Page 26
Alzheimers Dement. Author manuscript; available in PMC 2019 October 29.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
7. Disease progression
A better understanding of the AD pathological pathway is central to ADNI’s goal of 
developing biomarkers for the improvement of clinical trials. AD is pathologically 
characterized by amyloid plaques composed largely of fibrillar forms of Aβ, and 
neurofibrillary tangles, composed of hyperphosphorylated tau (p-tau181) that is associated 
with synapse loss and neurodegeneration. The amyloid cascade hypothesis [256] has 
dominated research over the last two decades, to the point that diagnostic criteria for AD 
now include Aβ abnormalities. The amyloid hypothesis states that incorrect processing of 
the APP to form Aβ, together with an imbalance in the clearance of Aβ accumulation, 
triggers a cascade of events: the formation of Aβ plaques, the accumulation of fibrillar tau in 
cells as NFTs and neuropil threads, neuronal death and synaptic dysfunction, disruption of 
glucose metabolism, atrophy, and eventual cognitive decline. However, although cortical 
hypometabolism is largely linked to global amyloid burden, regional amyloid plaque 
deposition has little or no association with regional hypometabolism [257]. Jack et al. [258] 
proposed a hypothetical model describing the order in which biomarkers become abnormal 
during disease progression which largely follows this cascade of events (Fig. 15). The 
Biostatistics Core has been instrumental characterizing longitudinal trajectories of 
biomarkers through their biostatistical analyses that integrate data across the breadth of 
ADNI studies [259]. Numerous studies of ADNI data have supported this model and have 
been described in a previous review [1].
However, mounting evidence suggests that AD progression is a far more complicated tale. 
At autopsy, a substantial number of subjects have copathologies such as Lewy bodies, 
hippocampal sclerosis, and transactive response DNA binding protein 43 kDa (TDP-43) 
inclusions [260] (Fig. 15). The ADNI Biostatistics Core concluded that although Aβ 
positivity accelerates the progression from MCI to AD and subsequent cognitive decline, 
there is substantial evidence for alternative pathways to this end point [259]. The purpose of 
this section, therefore, is to outline evidence for the amyloid cascade hypothesis, primarily 
gained from studies of Aβ+ subjects, and for other possible pathways to dementia.
7.1. Disease progression in Aβ-positive subjects
In an increasingly complex view of AD progression, the pathway from presymptomatic CN 
Aβ− to CN Aβ+ to predementia MCI Aβ+ to AD Aβ+ remains the backbone of the process. 
Moreover, a patient may transition from a negative to a positive Aβ status at any time (Fig. 
16). In dissecting out different pathways of disease progression, a number of studies have 
dichotomized subjects on the basis of Aβ positivity, defined either on the basis of a CSF 
Aβ42 levels, or from cortical Aβ load determined by amyloid PET. In this way, investigators 
have begun to tease out, even in those with normal cognition, the associations between Aβ 
deposition, and other factors in the disease such as metabolism, atrophy, APOE4 status, 
cerebral blood flow, and WM architecture. These studies have profound implications for our 
understanding of AD progression.
7.1.1. Aβ and the ordering of biomarkers—Aβ status clearly affects disease 
progression. A cross-sectional study [261] found that levels of CSF t-tau and p-tau181 only 
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became abnormal in Aβ+ subjects and that trajectories of the CSF biomarkers across disease 
stages were distinct in the dichotomized groups (Fig. 17). Young et al. [262] developed an 
event-based model which used distributions of biomarker values rather than predetermined 
biomarker cut points to determine the sequence in which AD biomarkers become abnormal. 
In Aβ+ or APOE4 participants, the first CSF biomarker to become abnormal was Aβ42, 
followed by t-tau and p-tau181, the order predicted by the Jack model. In Aβ+ subjects, 
several studies [261–264] reported an ordering of biomarkers consistent with the Jack 
model: levels of CSF Aβ42 becoming abnormal in the preclinical stage, tau reaching 
maximum abnormality in the MCI stage, and imaging and cognitive markers beginning to 
decline in the asymptomatic stage but accelerating with advanced clinical stage [261,264]. 
These studies favor the concept of abnormal Aβ deposition as a prequel for tauopathy in 
AD.
7.1.2. Aβ and brain atrophy—Several studies support a link between Aβ positivity and 
increased regional atrophy in the brains of CN subjects. Hippocampal atrophy, a nonspecific 
characteristic of AD, accelerates throughout the disease process but also occurs in normal 
aging. Nosheny et al. [128] found that Aβ positivity contributed to, but did not entirely 
account for, hippocampal atrophy rate in CN participants (Fig. 18). Furthermore, atrophy 
preceding that in medial temporal regions has been detected by several groups, specifically 
in the precuneus [265]; the right supramarginal/inferior parietal gyrus [261]; and the 
posterior cingulate, amygdala, putamen, precuneus, and brainstem (before the Aβ42 cut 
point of 192 ng/mL insula) [266] (Fig. 19).
Cholinergic neurons in the basal forebrain regulate the supply of acetylcholine to areas of 
the temporal cortex and to the amygdala thereby influencing memory and attention, and 
their degeneration is regarded as a key event in AD pathogenesis. Aβ burden has been 
associated with basal fore-brain degeneration independent of APOE4 status in emergent Aβ
+ asymptomatic subjects [267–269]. Moreover, basal forebrain volume classified preclinical 
patients as Aβ+ or Aβ− more accurately than hippocampal volume [269]. In MCI subjects, 
basal forebrain degeneration was more associated with impaired memory and attentional 
control, whereas hippocampal atrophy was more associated with memory deficits. This 
association was mediated by hypometabolism in domain-specific cortical networks and was 
not affected by Aβ status [27]. These studies support cholinergic basal forebrain 
neurodegeneration and the concomitant deposition of Aβ as early events in AD.
Two studies place glucose hypometabolism as an intermediary event between Aβ positivity 
and atrophy in accordance with the Jack model for the temporal ordering of biomarkers 
[258]. Kljajevic et al. [133] examined baseline FDG PET and structural MRI scans of Aβ+ 
CN, EMCI, and late MCI (LMCI) subjects compared with Aβ− CN elderly subjects. 
Glucose hypometabolism originated in the posterior parietotemporal regions before atrophy 
which originated in medial temporal regions (Fig. 20). Araque Caballero et al. [265] also 
reported that atrophy originated in the medial temporal lobe in MCI Aβ+ subjects and, 
furthermore, that this pattern of atrophy correlated with patterns of hypometabolism, 
suggesting that by the time the first cognitive symptoms arise, both these kinds of 
neurodegeneration are spatially associated. Although Kljajevic et al. [133] posit that 
abnormal Aβ deposition may affect synaptic activity leading to subsequent neuronal loss and 
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hypometabolism, the results from Dowling et al. [270] suggest that this is an earlier event in 
pathogenesis and therefore more weakly related to changes in hypometabolism and 
subsequent changes than intraneuronal neurofibrillary degeneration.
7.1.3. Aβ and cognitive deficits—The relationship between Aβ positivity and 
cognition may be more complex than the causal sequence of pathological events implied by 
the Jack model in which altered levels of CSF peptides exert a neurotoxic effect which 
impairs cell function and leads to decreased glucose metabolism, ultimately resulting in 
cognitive decline. First, Aβ positivity may affect cognition at a far earlier stage than 
previously thought. Susanto et al. [261] reported that CN Aβ+ subjects had impairments in 
executive functioning/processing speed which was accompanied by atrophy at the right 
supra marginal/inferior parietal gyrus. Mattsson et al. [271] reported that CN Aβ+ subjects 
had lower memory scores and smaller GM volumes in several regions including the 
hippocampus. Both studies reported that MCI Aβ+ subjects had widespread atrophy and 
impairments to multiple cognitive domains.
Second, Aβ positivity may exert its effect on cognition via multiple pathways. Mattsson et 
al. [271] used a mediation analysis to investigate the role of atrophy and hypometabolism in 
mediating the effect of Aβ on episodic memory in MCI patients. Hippocampal atrophy 
mediated approximately 25% of this association, and approximately 40% was mediated by a 
combination of hippocampal atrophy and hypometabolism (Fig. 21). Interestingly, the fact 
that 60% of the association between Aβ and memory was not mediated by hypometabolism 
and/or atrophy suggests that other mechanisms must exist. A study by Byun et al. [272] 
supports this idea. In subjects with significantly lower CSF Aβ42 levels compared to 
controls, they identified four subtypes of AD characterized by different patterns of regional 
brain atrophy and rates of progression: primarily hippocampal atrophy (19%), primarily 
cortical atrophy (17.7%), both hippocampal and cortical atrophy (41.1%), and neither region 
(10.4%). They found that subtypes characterized by primarily hippocampal atrophy 
exhibited more severe impairment of the memory domain (ADNI-Mem), whereas executive 
function (ADNI-EF) was more impaired in subtypes with predominantly cortical atrophy 
(Fig. 22). The finding that heterogeneous atrophy patterns exist with different rates of 
progression in the presence of Aβ neuropathology was also reported by Mattsson et al. [273] 
who found that a subset of CN participants with normal baseline levels of CSF Aβ42 that 
decreased over time, or with reduced baseline levels of CSF Aβ42, had increased frontal and 
parietal cortical atrophy but no accelerated temporal atrophy longitudinally. Byun et al. 
[272] postulated that these subtypes correlate with distribution of neurofibrillary tangles, 
suggesting a closer relationship between tau neuropathology and cognition than Aβ 
neuropathology and cognition, a hypothesis supported by two further studies. First, Fortea et 
al. [274] used correlation analysis to determine that p-tau-dependent cortical thinning was 
found only in Aβ+ subjects and not in Aβ− subjects. In the absence of abnormal p-tau, 
abnormal CSF Aβ42 was related to cortical thickening. The authors posited a two-phase 
phenomenon in which there is initial cortical thickening as Aβ levels become abnormal 
followed by cortical thinning as p-tau reaches pathological levels. Second, Dowling et al. 
[270] used a mediation analysis to examine changes in brain glucose metabolism, 
longitudinal changes in global cognition, their association over time, and the impact of 
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baseline CSF measures on these associations. Glucose hypometabolism in all AD-associated 
brain regions mediated the relationship between CSF indicators of neuronal damage (t-tau, 
p-tau181, and their ratios), and cognitive decline. In contrast, only hypometabolism in the 
middle inferior temporal gyrus mediated the effect of baseline levels of Aβ42 on cognition. 
Overall, there is general (but not universal) agreement that initial development of Aβ 
plaques accelerates development of tau tangles which leads to synapse loss and 
neurodegeneration. However, TF-fMRI activity is disrupted in CN elders who are Aβ
+ [275], suggesting that Aβ plaques alone may affect brain function before significant 
accumulation of tau tangles. Hopefully, the use of both amyloid and tau PET in future 
studies including ADNI-3 will shed more light on this matter.
Disease progression in subjects dichotomized by APOE4 status appears to be similar to that 
in subjects dichotomized by Aβ status: the two groups have the same defined sequence of 
CSF biomarkers [262] as well as faster trajectories of CSF t-tau, and p-tau [276], and faster 
hippocampal atrophy [128]. But the APOE4 allele may actually modulate disease 
progression in Aβ+ subjects. Susanto et al. [261] reported that MCI and AD carriers of this 
allele had more severe atrophy of the medial temporal lobe and worse memory impairment 
but higher executive functioning/processing speed than noncarriers, suggesting that APOE4 
modulates trajectories of both cognition and atrophy.
7.1.4. Aβ and cerebral blood flow—Mattsson et al. [277] determined the association 
of Aβ with variations in cerebral blood flow, a measurement of brain activity, across the 
cognitive spectrum. With all subjects, brain Aβ was associated with reduced cerebral blood 
flow in temporoparietal regions, but with increased cerebral flow in the posterior cingulate 
suggesting a compensatory mechanism for Aβ neurotoxicity in the latter region. 
Dichotomization of subjects by Aβ status revealed reduced cerebral blood flow is in several 
regions in Aβ+ compared to Aβ− participants. Aβ load was more associated with reduced 
cerebral blood flow than atrophy in CN subjects but the opposite was true in LMCI or AD 
patients. In keeping with the Jack model of disease progression [258], these results suggest 
Aβ is more associated with functional and synaptic loss leading to reduced cerebral blood 
flow early in disease progression and more associated with GM loss leading to atrophy later 
in disease progression.
7.2. Alternative pathways to dementia?
Beckett et al. [259] concluded that although Aβ positivity accelerates the progression from 
MCI to AD and subsequent cognitive decline, there is substantial evidence for alternative 
pathways to this end point. In their data-driven model of biomarker changes in AD, Young et 
al. [262] observed that in the pooled samples, t-tau was the first biomarker to become 
abnormal, followed by p-tau181 and Aβ42; only in Aβ+ or APOE4+ subjects was Aβ42 first 
biomarker to become abnormal, as predicted by the Jack et al. model [258]. Furthermore, 
trajectories of CSF biomarkers across disease stages in Aβ− subjects were distinct from Aβ+ 
subjects and did not feature the stereotypical decreased Aβ42 and increased p-tau181 and t-
tau [261]. These results imply that a substantial proportion of ADNI subjects have atypical 
disease progression.
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7.2.1. Heterogeneity of diagnostic groups
7.2.1.1. Subtle cognitive impairment: The appearance of subtle cognitive impairment 
(SCI), defined using 5th percentile cutoffs of composite memory and/or executive function 
scores, follows stereotypical sequential changes in Aβ and neurodegeneration biomarkers. A 
newly identified group, accounting for 5% of CN subjects, had SCI without neuronal injury 
in the presence or absence of abnormal Aβ [278]. Toledo et al. [279] reported that 27.6% of 
ADNI healthy controls had SCI and further defined three categories within this group—
memory, executive, and multidomain—that differed in biomarker profiles and in the rate of 
progression to MCI and AD. The multidomain group, characterized by having the fastest 
progression to MCI, the most abnormal levels of Aβ42, atrophy, and greatest posterior 
cingulate FDG PET hypometabolism, was most related to AD. The memory group, 
characterized by slightly abnormal Aβ42 and increased atrophy, had a slower progression to 
MCI and the executive group had the slowest progression to MCI.
7.2.1.2. MCI: Several studies identified MCI subtypes using cluster analysis of 
neuropsychological data [280–282]. An amnestic subtype characterized by isolated memory 
impairment and abnormal CSF biomarkers, representing “typical” AD, was identified in all 
studies (summarized in Table 8). However, this cluster comprised only 25.7% to 58.6% of 
MCI subjects. The remaining MCI subjects were clustered into a number of different groups, 
most commonly a dysexecutive/mixed group typically characterized by significant deficits 
predominantly in executive function, elevated p-tau181, and the fastest progression to AD 
(12.4%–33%, identified in 4/5 studies), and a normal group, comparable to CN controls 
(31.3% to 41.3%, identified in 3/5 studies). The normal group had the lowest rate of 
progression to AD (10.7% at follow-up), and a significant rate of regression to normalcy 
(9.2% at follow-up), suggesting that ADNI MCI criteria may have a high rate of false-
positive diagnostic errors leading to misclassification of subjects [280]. These criteria 
include a subjective memory concern reported by either the subject or a study partner, a 
single memory score (delayed recall of Story A from the Wechsler Logical Memory II test), 
and a global CDR score of 0.5 that may not capture variability in cognitive phenotype. 
Subjective memory impairment was overestimated by MCI subjects in the normal cluster but 
underestimated by MCI subjects in the amnestic group, suggesting that subjective memory 
concerns are not reliable in making an MCI diagnosis [282]. The false-positive diagnostic 
errors are also consistent with reports of high reversion rates of MCI subjects to cognitively 
normal [281].
The observation that MCI reverters differed little from CN subjects in levels of CSF 
biomarkers, APOE4 status, hippocampal volume, hypometabolism, and other measures but 
differed substantially from other MCI subjects supports this idea [284]. Bondi et al. [280] 
reported that MCI subjects classified using an alternative actuarial method (which diagnosed 
fewer ADNI subjects with MCI) did not contain the cluster-derived normal group. 
Interestingly, 3/5 studies identified a group with language or naming impairments (17%–
21%), and one study identified a large cluster (42%) characterized by visuospatial 
impairments and a small cluster (9%) characterized by a focal intrusions (recalled items 
which were not part of the list) [283]. The language impairment group was characterized by 
fast progression to AD and a high frequency of APOE4 [281,283]. Language deficits may 
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reflect neuronal loss in the left hemisphere. Pravata et al. [285] found greater atrophy in the 
Brodmann area 20 of the left fusiform gyrus 12 months before progression, and in the left 
hemisphere GM 12 months after progression in MCI converters with language impairment 
compared to those without.
Cluster analysis of MCI subjects on the basis of baseline MRI, CSF, and serum biomarkers 
identified four clusters with distinct biomarker patterns [286]. Like studies based on 
neuropsychological data, one group (44%) appeared to have “typical AD” characteristics 
(and a small group appeared to be pre-AD), and another was similar to normal controls 
(14%). However, the latter group also had pronounced memory deficits and smaller 
hippocampal volume, although they rarely converted to AD, and the authors suggest that the 
stable group may be undergoing a non-AD process such as hippocampal sclerosis. The final 
group (37%), characterized by severe ventricular expansion, hippocampal atrophy, and 
progression to AD but near normal levels of tau and Aβ, also appeared to be on a different 
path to dementia. Although further investigation is required to refine MCI subtypes, these 
studies imply that multiple pathological pathways underlie the substantial heterogeneity of 
this group.
7.2.1.3. Cortical atrophy: Patterns of atrophy differ in subjects stratified by Aβ status 
(Section 7.2.2) but also differ across patient groups. Ventricular expansion reflects cortical 
atrophy in regions associated with early AD. Madsen et al. [287] reported that 2-year 
ventricular expansion was associated with baseline cortical volume and thickness in 
combined patient groups and with thinning in areas of temporal, frontal, and parietal cortices 
affected by AD in MCI participants. Distinct patterns of cortical atrophy were present in 
three neuropathologically defined subtypes of AD [163]. Compared with AD subjects with a 
diffuse pattern of cortical thinning, AD subjects with a pattern of medial temporal thinning 
had more glucose hypometabolism in hippocampus and bilateral frontal cortices, and worse 
memory performance, and AD subjects with thinning in predominantly parietal regions were 
younger, had more glucose hypometabolism in parietal and occipital cortices, and showed 
Aβ accumulation in most regions [163]. No differences in CSF Aβ42 or tau levels were seen 
in any groups. Cortical atrophy patterns may reflect differing underlying pathologies.
7.2.1.4. Significant memory concerns: Current MCI diagnostic criteria include a 
significant memory concern (SMC) from either the patient, clinician, or someone close to 
the patient in addition to quantitative evidence of cognitive impairment with relative 
preservation of functional abilities [288]. ADNI-2 enrolled an additional cohort of subjects 
who were clinically evaluated as CN but who had SMCs in the interest of capturing the 
earliest cognitive decline. By most measures—cognitive performance, hippocampal volume, 
Aβ deposition, and metabolism—these subjects were indistinguishable from normal controls 
[259]. However, one study reported increased frontal atrophy in this group [279], and a 
cluster analysis of both SMC and CN subjects revealed three distinct groups (Fig. 23) [259]. 
The first cluster had normal levels of Aβ, normal metabolism, a low frequency of the APOE 
ε4 allele, but evidence of hippocampal atrophy. The second cluster appeared normal by all 
measures, and the third cluster aligned with biomarkers of “typical AD,” having abnormal 
Aβ, a high-frequency of the APOE ε4 allele, and slight hippocampal atrophy. Two studies 
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examined SMCs in MCI subjects, one reporting that these concerns were only related to 
verbal episodic learning performance and not to neuroimaging biomarkers, executive 
functioning, language, or other cognitive domains [289], and the other suggesting that these 
concerns were only weakly associated with objective functioning [282].
7.2.2. SNAP—Cluster analyses consistently identify a group characterized by signs of 
neuronal injury such as elevated p-tau181 or atrophy and accelerated progression to AD. This 
cluster is consistent with a group, comprising around a quarter of CN and MCI subjects, that 
typically has neurodegeneration in the absence of Aβ pathology and low frequencies of the 
APOE ε4 allele, recently been termed suspected non-Alzheimer’s pathology (SNAP) 
[290,291] (Fig. 24, Table 3). Over 7 years, more than half (12/19) of MCI progressors with 
SNAP developed AD; 5/19 progressed to a frontotemporal dementia, and 2 to Lewy body 
dementia [291]. It is possible that SNAP subjects who progressed to AD were misdiagnosed 
initially as being Aβ− due to limitations in the CSF Aβ42 assay or to Aβ levels being close 
to the cut point for amyloid positivity used (Amyloid positivity is defined either on the basis 
of a CSF Aβ42 level of greater than 192 pg/mL [292] or from cortical Aβ load determined 
by amyloid PET using the radiotracers Pittsburgh compound B or florbetapir [293]. Aβ+ 
subjects have levels of amyloid above either or both of these threshold values, and Aβ− 
subjects have levels of amyloid below the threshold values).
Cognitive deterioration in SNAP subjects appeared more related to neuronal damage than to 
Aβ pathology. Medial temporal tau pathology may underlie SNAP and is referred to as 
primary age-related tauopathy (PART). It is possible that SNAP represents an aging process 
separate from AD [290]. The inclusion of tau PET imaging in ADNI-3 may help to resolve 
the involvement of PART in SNAP subjects. SNAP subjects also had higher levels of 
YKL40, a marker of neuroinflammation, than Aβ+ presymptomatic subjects [144], 
supporting the idea. Although the pathophysiology of this group is not yet known, it may 
involve Aβ unrelated pathologies such as hippocampal sclerosis, argyrophilic grain disease, 
Lewy body disease, or frontotemporal degeneration, with a variety of different pathologies 
found at autopsy. Caroli et al. [291] proposed a further subdivision of SNAP subjects into a 
subgroup with severe cortical damage and no hippocampal atrophy with underlying 
frontotemporal degeneration, and a second subgroup with preserved cortical metabolism but 
hippocampal atrophy with underlying hippocampal sclerosis or argyrophilic grain disease.
7.2.3. The role of WM disease—One source of biological heterogeneity in AD may be 
small-vessel cerebrovascular disease [1,54]. WM lesions are highly prevalent in AD and 
may represent microvascular ischemic and/or demyelinating changes linked to 
cerebrovascular disease [294]. Recognition of the contribution of cerebrovascular disease to 
AD is reflected in NIA-AA criteria for AD that include a diagnosis of possible AD dementia 
in circumstances where patients have an etiologically mixed presentation including a severe 
burden of white-matter hyperintensities (WMHs), a widely accepted measure of small-vessel 
cerebrovascular disease [294]. However, as WM microstructural and cerebrovascular 
disruptions are observed in both elderly and demented subjects, the threshold separating 
WM lesion burden in these two patient groups has yet to be determined and the specific WM 
disease contribution to AD remains unclear. Is WM disease a factor that increases AD risk 
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and clinical severity independent of the prevailing pathogenic models, or does it promote 
AD neurodegenerative changes? ADNI publications over the last 2 years have begun to 
address these issues and to integrate the role of WM disease in AD into current models of 
disease progression.
Although subjects with hemispheric infarctions at baseline are excluded from ADNI, subject 
assessment includes several neuroimaging biomarkers for small-vessel pathology. T2-
weighted or FLAIR MRI sequences are used to detect WMHs, and cerebral microbleeds are 
visualized using a T2* gradient echo MRI sequence [54]. The extent of cerebrovascular 
disease in the ADNI cohort was investigated by Ramirez et al. [295] who reported that the 
ADNI-1 sample had a significantly lower WMH burden relative to other elderly and 
dementia cohort studies. Despite their conclusion that ADNI-1 sample can be considered a 
relatively pure cohort with little to no vascular burden compared with community 
populations, ADNI studies investigating the role of WM disease suggest that a low burden 
may still have a significant impact on disease progression.
7.2.3.1. Vascular disease and risk factors are associated with cognitive decline and 
worsening clinical outlook: Numerous measures reflecting vascular disease have been 
associated with worsening clinical outlook. Greater baseline WMH volume was associated 
with lower processing speed [296] and rapid cognitive decline (.6 points/year MMSE) [297]. 
A vascular index score (summarizing past or present hypertension, hyperlipidemia, diabetes, 
myocardial infarction, atrial fibrillation, smoking, and stroke) was associated with greater 
memory impairment [296], and metabolic syndrome (obesity, hyperglycemia, 
hyperlipidemia, and hypertension) increased the risk of AD and was associated with a faster 
decline in WM volume [298]. Higher homocysteine levels were associated with lower 
processing speed [296]; higher cholesterol was associated with a greater rate of increase in 
global cognition and memory impairment [296]; hyperglycemia was associated with 
cognitive decline, whole-brain volume decline, and rate of progression to AD [299]; past or 
present hypertension predicted WMH volumes in CN subjects [300]; and a history of 
cigarette smoking (associated with oxidative stress and small hippocampal volume [301]) 
was associated with lower performance on cognitive tests [302]. An alternative marker of 
cerebrovascular dysfunction, physiological fluctuations in white matter (PFWM), was 
associated with glucose metabolism and composite memory but not ventricular or 
hippocampal volume, executive function, or CSF biomarkers [303]. Peripheral insulin 
resistance was differentially associated with either hypometabolism or hypermetabolism in 
different areas depending on whether subjects progressed to AD or not, suggesting that it 
may increase AD risk by affecting glucose metabolism [304]. Vascular burden may be 
evident at very early stages of cognitive decline as several associations were found in CN as 
well as MCI subjects [296,298,300,305].
Considerable evidence suggests that cardiovascular risk factors may accelerate 
neurodegeneration and subsequent cognitive decline via Aβ independent pathways. In CN 
subjects, Aβ deposition was more associated with APOE4 positivity than with a history of 
cigarette smoking, although APOE4+ smokers had the lowest glucose metabolism and 
poorest learning and memory scores of all groups, suggesting that cerebrovascular disease 
may worsen the effects of the APOE ε4 allele (Fig. 25) [302]. Similarly, stroke risk, 
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comprising cardiovascular factors such as hypertension and cigarette smoking, was most 
related to hippocampal volume and memory performance in the absence of Aβ pathology 
(Fig. 26) [306]. Finally, the association between type-II diabetes mellitus and regional-
reduced cortical thickness was modulated by levels of p-tau181, but not by cortical Aβ load 
[307].
Vascular disease may act synergistically with neurodegeneration to accelerate cognitive 
decline. Tosto et al. [297] reported that low baseline entorhinal cortex volume, a marker of 
neurodegeneration due to AD, and high baseline WMH volume independently predicted 
rapid cognitive decline of a similar magnitude. Moreover, individuals with high entorhinal 
cortex volume and low WMH burden had a significantly lowered risk of rapid cognitive 
decline (Fig. 27).
7.2.3.2. WM disease and morphological changes in disease progression: Two distinct 
factors in AD subjects were identified in a factor analysis study of hippocampal volume, AD 
signature cortical thickness, ventricular volume, total WM volume, and volume of WM 
changes [308]. The first was associated with diffusivity, total volume of WM changes, and 
ventricular expansion. A second factor was more strongly related to MMSE and cortical 
thickness changes typical of AD and was associated with worse parahippocampal WM 
microstructure. These results imply that there are two sets of independently covarying 
degenerative changes: age-related vascular changes that are associated with ventricular 
expansion and volume of WM lesions, and WM changes in the parahippocampal gyrus that 
are associated with hippocampal atrophy and the classical patterns of AD 
neurodegeneration. WM burden may be more than a simple comorbidity due to vascular 
disease and may play a specific role in the latter pathway that is not considered in traditional 
models. Further evidence to support this comes from a study of changes in the quality of 
WM signal abnormalities. Accelerated before and after MCI progression to AD and echoed 
the acceleration of hippocampal atrophy at this time [309].
7.2.3.3. How do WM abnormalities interact with Aβ and tau deposition?: Clearly, 
cerebral WM disease influences disease trajectory. Do WMHs act independently of or 
interactively with CSF biomarkers? WM changes in the elderly have been linked to 
cognitive deficits but the relationship between the cerebral Aβ deposition and WM 
microstructure is not well understood. Wolf et al. [310] investigated the relationship between 
Aβ deposition and WM microstructure in CN subjects using DTI. They found that the 
relationship between Aβ deposition and DTI metrics of WM integrity (fractional anisotropy, 
mean diffusivity, radial diffusivity, and axial diffusivity) was not linear. In fact, at lower 
levels of Aβ burden, increasing Aβ load was associated with increases in fractional 
anisotropy and decreases in mean diffusivity and radial diffusivity, suggesting an 
improvement in WM integrity. At higher Aβ burden, increases in Aβ load were associated 
with DTI measures indicating the opposite. At low Aβ burden, compensatory mechanisms 
may act to preserve cognitive functioning, but these may be overcome by higher Aβ burden 
leading to damage to WM structure, which may, in turn, initiate cognitive decline.
In some instances, Aβ load may be correlated with WM lesions. Past or present hypertensive 
CN subjects had greater WMH volumes at a given burden of Aβ (Fig. 28) [300]. Although 
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the extracellular Aβ deposition measured by FLAIR MRI in this instance is not directly 
correlated with cerebral Aβ angiopathy, these results support the idea that Aβ accumulation 
within blood vessels could exacerbate cerebrovascular injury processes that contribute to 
WMHs. Aβ load in the medial prefrontal cortex and posterior cingulate cortex was 
correlated with WM lesion load in CN subjects in periventricular and frontal regions, 
suggesting a link between microvascular damage and Aβ pathology at the early stages of 
disease [311]. The location of cerebral microbleeds was differentially associated with CSF 
Aβ and p-tau181 levels. Lobar microbleeds at the cortico-subcortical junction, which reflect 
Aβ angiopathy, and not microbleeds in deep GM, which reflect subject hypertension, were 
associated with abnormal levels of CSF Aβ and p-tau181 [312]. Furthermore, subjects with 
cortical microbleeds were more likely to carry the APOE4 allele, suggesting that WM 
damage at this location is associated with typical AD pathology.
Do WMH levels modify the effect of tau in neurodegeneration? Subjects with low baseline t-
tau and higher frontal and parietal WMH volumes had greater entorhinal cortex atrophy than 
subjects with lower baseline t-tau and lower regional WMH volumes [313]. In addition, 
elevated WMH, particularly in the parietal lobes, predicted MCI to AD progression, and risk 
of progression increased in subjects with high levels of tau [313]. Thus, WMH burden may 
act as the “second hit” that is required, in addition to abnormal levels of CSF biomarkers, to 
produce neurodegenerative and cognitive changes associated with AD (Fig. 29).
Taken together, these studies offer an intriguing glimpse into how the effect of WM disease 
may be integrated into the traditional model for AD progression. Vascular risk factors may 
enhance cognitive decline by interacting with Aβ in the early disease stages to increase WM 
abnormalities. Regional WM abnormalities may then act as a “second hit” to augment the 
effects of tau abnormalities and neurodegeneration, thus accelerating the remaining disease 
process. The fact that these findings are from the ADNI cohort which has been characterized 
as having far lower burden of WM disease than other community samples [295] suggests 
that the contribution of WM abnormalities to dementia in the wider population may be even 
more profound.
7.3. AD as a disconnection syndrome
Several investigators have suggested that AD is a disconnection syndrome, based on the 
progressive synaptic and neural degeneration across the continuum of the disease [314,315]. 
Considerable evidence exists that specific structural and functional brain networks are 
increasingly disturbed, hypothetically due to neuronal injury caused by the abnormal 
deposition of Aβ and/or tau [275,316,317]. The different underlying biological substrates of 
these structural and functional networks, namely WM fiber tract networks, cortical thickness 
networks, and resting-state functional networks, can be mapped by applying graph 
theoretical analyses to different imaging modalities in the burgeoning field of 
“connectomics” [318]. Graph theory uses “nodes” to designate brain regions thought of as 
hubs, and “edges” to represent the connections between them to construct a topological map 
of the connectome and to generate measures (strength, weighted local efficiency, weighted 
clustering coefficient, and characteristic path length) that describe the organization of the 
network [319,320]. The inclusion of diffusion MRI for studying WM tract geometry, and 
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TF-fMRI for mapping functional networks, in the ADNI-2 protocol has produced a set of 
longitudinal data across the disease spectrum that is central to number of studies targeted at 
understanding the role of brain network disruptions in AD.
7.3.1. Structural connectivity—Diffusion MRI can be used to study WM fiber 
integrity and microstructure based on measures of local water diffusion such as fractional 
anisotropy (FA), mean diffusivity (MD), axial diffusivity (DA), and radial diffusivity (DR) 
which respectively reflect the degree of myelination, cell death and edema, axonal injury and 
demyelination, and loss of oligodendrocytes and reactive astrocytosis [321]. The trajectory 
and structural connectivity of axonal fibers can be inferred using tractography based on DTI 
data. Studies of the ADNI cohort have found both global and local changes to WM tracts 
during disease progression. Sun et al. [322] found increased global DA and increased DR in 
prodromal patients, and a further increase in these measures, along with decreased global 
FA, in demented subjects, consistent with widespread WM damage. Reduced WM fiber 
integrity may be associated with GM atrophy. Deterioration in WM integrity may decrease 
GM volume, particularly in the hippocampus. Simultaneous changes in GM volume and FA 
values were reported in AD subjects compared to CN subjects primarily in the temporal 
lobe/hippocampuscingulum, frontal/cingulate gyrus–corpus callosum, and temporal/
occipital/parietal lobe–corpus callosum/corona radiata [323]. However, there was no 
correlation between MMSE score and diffusion indices in regions known to affect memory 
[324] implying that memory loss is an event considerably downstream of network 
deterioration. Changes in WM structure have been observed in regions of the brain involved 
in known mechanisms of disease pathology—WM tracts known to be connected to areas of 
AD pathology appear most prone to deterioration. MCI subjects had increased DR and DA 
in the external capsules of the lateral cholinergic pathway, a finding consistent with the 
degeneration of cholinergic neurons of the basal forebrain as a distinct neuropathological 
feature of AD [322]. AD and MCI subjects had increased total diffusivity and DR and 
decreased FA in the optic nerves and optic tract, consistent with common visual deficits 
observed in AD despite relative lack of damage to the visual cortex, and suggesting that the 
visual pathway from eye to brain may be damaged [325]. The number of nerves fibers of 
limbic system touching the hippocampus, thalamus, and amygdala decreased from CN to 
EMCI to LMCI, and this metric was able to distinguish between EMCI and LMCI subjects 
(Fig. 30) [326]. The cingulum angular WM bundles, connected to the hippocampus, showed 
progressive deterioration in MCI and AD subjects, and their integrity was associated with 
hippocampal volume [321]. However, controlling for hippocampal volume did not remove 
all group differences, suggesting that WM damage additionally contributes to AD through an 
alternative mechanism.
AD also appears to affect the topology of the structural connectome. This is characterized by 
small-world properties such as a high mean clustering coefficient reflecting the 
concentration of highly connected brain regions (“hubs”) and low characteristic path length 
representing the WM fibers connecting them [320]. Significant group differences in these 
metrics were reported by Prescott et al. [327] indicating that the AD structural connectome 
undergoes progressive deterioration with disease progression. Another attribute of the 
structural connectome, described by the rich club coefficient, is that its hubs are more 
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interconnected than predicted by chance and play a central role in network communications 
[320]. Daianu et al. [328] used whole-brain tractography to reconstruct structural brain 
connectivity networks and to map connections between cortical regions. In MCI and AD 
subjects, there was a progressive disruption of global measures of network integrity (nodal 
degree, clustering coefficient, characteristic path length, and efficiency) but a relative 
preservation of the rich club coefficient. Thus, network disruptions were primarily in 
peripheral areas of low connectivity and left the highly connected rich club core, consisting 
of hubs in the superior frontal, insular, posterior cingulate, precuneus, and superior parietal 
region, relatively undisturbed (Fig. 31). Higher baseline characteristic path length and lower 
baseline mean clustering coefficient values were correlated with greater volumetric changes 
over 6 months in a preliminary study of MCI subjects [329]. Decreased clustering in the 
right pars opercularis, left superior parietal node, and left pericalcarine node was 
significantly associated with patterns of volumetric changes. Lower betweenness centrality 
(a measure of the number of short communication paths a node participates in) in the right 
temporal lobe was associated with greater atrophy, suggesting that this hub facilitates 
integration between anatomically unconnected regions. These studies suggest that the degree 
of integration across distributed brain regions and locally within regions decreases with 
disease progression as the small-world architecture of the brain is disturbed.
Both APOE4 and Aβ positivity appear to influence the structure of the connectome. The 
number of APOE ε4 alleles was negatively correlated with the number of WM fibers 
touching the hippocampus, thalamus, and amygdala [326]. The shortest path length was 
increased and global efficiency decreased in preclinical Aβ+ compared to Aβ− participants, 
with no concomitant differences in either hippocampal volume or metabolism [330]. These 
WM changes were specific to network structure and were not explained by changes in global 
WM integrity. The degree of Aβ burden was more strongly associated with changes in graph 
theoretical measures than with diagnostic group and affected large-scale structural networks 
more severely in CN subjects than in MCI or AD subjects [327]. The decreasing effect of 
accumulating Aβ burden with time may be because there are fewer viable connections to 
degenerate [327]. Both studies suggest that damage to the structural connectome may occur 
very early in pathophysiological development of AD, perhaps closely following Aβ 
deposition.
7.3.2. Functional connectivity—In addition to structural connectivity, the human brain 
possesses functional connectivity which reflects signaling and communication events that 
unfold within the underlying structural network [320]. Functional networks are derived from 
statistical descriptions of time series data reflecting changes in blood flow measured as a 
blood-oxygen-level dependent (BOLD) signal on TF-fMRI. They differ from structural 
networks in that they are transitory, modulated by task, and link many structurally 
unconnected node pairs. Major functional hubs with high connectivity to other regions are 
located in the ventral and dorsal precuneus, posterior and anterior cingulate gyrus, 
ventromedial frontal cortex, and inferior parietal regions, and these have significant overlap 
with the DMN, which consists of an anatomically defined set of hubs and subsystems 
located in the cingulate cortex [320]. As the DMN is implicated in the process of encoding 
new memories, and AD impairs memory function, AD pathology may specifically target this 
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functional network [331]. Increased WM lesion load was correlated with decreased 
functional connectivity of the DMN, and reduced neuronal activity in the temporal cortex 
[311].
Changes in functional connectivity appear to occur early in the disease process and can 
distinguish between EMCI and LMCI subjects. The magnitude of these changes in the 
posterior cingulate cortex, precuneus, right lingual gyrus, thalamus, and right 
parahippocampal gyrus increased across patient groups and was related to cognitive 
performance (MMSE) and the Geriatric Depression Scale [332]. Decreased functional 
connectivity in the thalamo–hippocampus, thalamo–temporal, thalamo–visual, and thalamo–
DMN networks was observed between EMCI and LMCI subjects [333], highlighting the 
importance of the thalamus, a crucial brain area believed to coordinate communication (e.g., 
memory, attention, and perception). Interestingly, there were areas of increased functional 
connectivity between the thalamus and left fusiform gyrus, right middle occipital gyrus, left 
and right precuneus, right middle temporal gyrus, and left inferior temporal gyrus in 
amnestic MCI subjects, suggesting that they may be able to use additional brain resources to 
compensate for loss of cognitive function.
APOE4 may modulate brain functional connectivity in early stages of the disease. APOE4 
noncarriers had the strongest functional connectivity, whereas EMCI subjects who were 
APOE4 carriers had the greatest dysfunction [334]. The pattern of functional connectivity 
disruptions in EMCI subjects overlapped to a large degree with that of APOE4 subjects. 
However, only the EMCI group, and not the APOE4 group, had decreased connectivity in 
the prefrontal cortex areas, suggesting a more multidimensional pathology in EMCI than is 
accounted for by the presence of an APOE ε4 allele alone [334].
Grothe et al. [335] used multimodal imaging data to assess the relationships between seven 
previously defined major functional connectivity networks (the DMN, frontoparietal-control 
network, dorsal- and ventral attention networks, limbic network, visual network, and 
somatomotor networks [Fig. 32]) and Aβ deposition, hypometabolism, and GM atrophy. Aβ 
deposition was widely distributed across the cerebral cortex, with the highest deposition in 
the DMN and frontoparietal-control network. This pattern did not change significantly 
across subject groups, consistent with Aβ deposition being an early event in AD 
progression. Atrophy occurred primarily in the anterior limbic network, followed by the 
DMN. The pattern of hypometabolism was a mixture of both Aβ- and atrophy-related 
profiles. The distribution of atrophy and hypometabolism increased with disease progression 
(Fig. 33). These results suggest that despite the high vulnerability of the DMN for changes 
in imaging abnormalities, distinct pathologic markers of AD have differential network 
specificities targeting different neuronal networks.
A study by Jones et al. [336] replicated many of the aforementioned results and offered a 
model describing how microscale proteinopathy affects macroscale brain networks to 
ultimately result in clinical symptomatology. Their multi-modal study tracked the evolution 
of connectivity changes within and between the ventral, posterior, anterior ventral, and 
anterior dorsal subsystems of the DMN (Fig. 34) across the course of the disease. They 
found both increased and decreased connectivity in different regions, consistent with a 
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previous study [332]. Connections within the posterior and ventral subsystems decreased 
linearly, whereas connections between posterior and ventral, and posterior and anterior 
dorsal subsystems, increased linearly across disease course. Decreasing posterior subsystem 
connectivity was marginally associated with elevated Aβ levels but not with hippocampal 
volume, whereas increased connectivity between the posterior and ventral DMN subsystems 
was associated with elevated Aβ levels and decreased hippocampal volume. Like McKenna 
et al. [334], they found that APOE4 positivity had specific effects on network connectivity. 
In CN Aβ− subjects, APOE4 was associated with lower posterior DMN connectivity only, 
suggesting that failure of this network may be the earliest critical event in pathophysiology, 
preceding Aβ deposition. Finally, the decrease in connectivity in the medial temporal lobe–
ventral DMN was associated with decreased memory performance.
The results support a model (Fig. 35) in which pathophysiology, possibly instigated by the 
APOE ε4 allele, originates in the posterior subsystem of the DMN. This results in a transient 
increase in connectivity between the posterior DMN networks and other systems that are 
associated with Aβ deposition and hippocampal atrophy. The increased connectivity may 
indicate high processing burden or inefficient synaptic communications and requires high 
metabolism which may trigger a cascade of downstream of molecular events associated with 
AD. The processing burden may then proliferate to downstream networks. Highly connected 
regions in the brain may be particularly vulnerable to Aβ deposition because of their 
increased synaptic activity, according to the “nodal stress” hypothesis [335,337]. Indeed, the 
authors postulated that the shifting of processing burden may lead to APP processing 
changes and Aβ deposition. Overloading of specific networks may also exacerbate 
preexisting primary age-related tauopathy in the medial temporal lobe and thereby accelerate 
tau-mediated neurodegeneration.
7.3.3. Structural covariance networks—A complementary approach to diffusion-
based and TF-fMRI studies compares patterns of structural covariance of GM volume within 
selected structural correlative networks. Aβ+ AD subjects had decreased structural 
association in the medial temporal lobe subsystem of the DMN (Fig. 35), with specific 
decreases between the entorhinal cortex and the medial prefrontal and dorsolateral prefrontal 
cortices, and in the midline core DMN subsystem [338]. The results suggest that these early 
structural disruptions between the heteromodal association cortices and the entorhinal cortex 
may isolate the hippocampus leading to memory loss. Concomitant increased connectivity 
was observed in other areas such as the salience and executive control networks [338], 
consistent with the Jones et al. model [336]. Both the salience and executive control 
networks affect frontal regions of the brain and are likely affected in AD rather than in 
earlier stages of the disease. The results support the concept of AD as a disconnection 
syndrome targeting specific large-scale brain networks.
7.3.4. Metabolic connectivity—Metabolic connectivity and the topological 
organization of metabolic brain networks can be surmised by the analysis of metabolic 
covariance between node regions, using FDG PET, which, like TF-fMRI BOLD 
measurements, reflects the brain’s metabolism. APOE4+ CN, MCI, and AD subjects had 
decreased metabolism in the parahippocampal gyrus and increased metabolism in the medial 
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frontal gyrus and inferior frontal gyrus compared to APOE4− subjects [339]. The metabolic 
networks of both groups had small-world properties, but APOE4+ subjects had lower 
clustering coefficients and significant decreases in nodal centrality, a measure of the number 
of connections maintained by each hub, in six hub brain regions. APOE4+ subjects also had 
abnormally increased local short distance and decreased long-distance interregional 
correlations. The results suggest that APOE ε4 allele carriers have a less optimal metabolic 
network than noncarriers. A second study reported that the MCI group had higher clustering 
coefficients, shorter characteristic path length, and lower betweenness centrality than control 
subjects, supporting the idea that the small-world characteristics of hub nodes are affected 
during disease progression [340]. Hub nodes targeted by AD progression were identified in 
the left anterior cingulum, right superior parietal, left fusiform, right inferior temporal gyrus, 
and right cuneus.
Hypometabolism in the posterior cingulate cortex is an early marker of AD. Teipel et al. 
[341] hypothesized that decreased metabolism in the posterior cingulate cortex is related to 
disrupted input from connected regions, such as the hippocampus, that undergo early 
atrophy. In CN and EMCI subjects, they found that posterior cingulate cortex 
hypometabolism was exclusively associated with remote hippocampal atrophy. In LMCI 
subjects, it was associated with both hippocampal atrophy and local atrophy within the 
posterior cingulate cortex, as well as with Aβ load. In AD subjects, posterior cingulate 
cortex hypometabolism was solely associated with local atrophy. These results may result 
from a diaschisis-like mechanism in which loss of function of the posterior cingulate cortex 
is caused by connection to the damaged hippocampus and are consistent with a progressive 
disconnection of the posterior cingulate cortex from subcortical brain regions.
7.3.5. Models for the spread and propagation of Aβ and tau along brain 
networks—Recent neuropathological evidence supports a “prion-like” spreading 
mechanism for AD pathology in which misfolded pathological proteins trigger the 
misfolding of adjacent same species proteins and cascade along neuronal pathways via 
trans-synaptic or trans-neuronal spread [342,343]. The initial misfolding of these proteins 
and their subsequent propagation along structural brain networks is postulated to result in 
hypometabolism, atrophy, and ultimately cognitive decline. Two ADNI studies have 
developed or tested models based on this idea. Raj et al. [344] found that their earlier model 
describing a prion-like diffusive progression along the fiber pathways defined by the brain 
connectivity network [345] accurately predicted future patterns of atrophy and 
hypometabolism based on baseline volume and metabolism. These patterns were in 
agreement with the stereotypical progression of atrophy from temporal to parietal to frontal 
regions. They also found that Aβ positivity predicted a faster rate of progression. Iturria et 
al. [346] developed a model based on similar assumptions for the spread of Aβ pathology, 
namely that the spread of Aβ as an infectious agent is constrained by the brain’s 
connectional architecture. Their stochastic epidemic spreading model also incorporated the 
brain’s clearance response to misfolded proteins and reproduced the characteristic patterns 
of Ab deposition across the disease process (Fig. 36). They found that the Aβ clearance rate 
was inversely correlated both with worsening clinical diagnosis and increasing number of 
APOE ε4 alleles and that it partially accounted for variance in CSF t-tau and p-tau181 levels, 
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supporting the idea of an interrelated pathway between Aβ pathophysiology and tauopathy. 
In addition, the model identified the posterior and anterior cingulate cortices as the most 
likely starting seed regions for the propagation process. The negative relationship between 
regional Aβ deposition patterns and effective anatomical distances from these regions 
suggested that the propagation of misfolded proteins from outbreak regions is modulated by 
the topology of the WM tracts in the brain.
7.4. Conclusions
ADNI studies in 2014 and 2015 have provided ample evidence to support not only the 
traditional view of an Aβ deposition-instigated cascade of events leading to dementia but 
also the complexity of disease progression which may involve copathologies or alternative 
pathways with as yet unidentified underlying pathology.
Cluster analysis of both MCI and CN subjects consistently identify a subtype with attributes 
of “typical” AD: abnormal levels of CSF biomarkers, hippocampal atrophy, regional 
hypometabolism, and impaired memory [279,281,283,305]. This group appears to largely 
overlap with Aβ-positive subjects, who have been identified in ADNI-2 by amyloid imaging 
and extensively characterized and who appear to follow “typical” AD progression in which 
biomarkers become abnormal in the sequence defined by Jack et al. [258]. The APOE ε4 
allele may act to modulate this trajectory [128,261,262,276]. Novel findings indicated that 
atrophy may begin in the presymptomatic phase in areas outside the hippocampus such as 
the basal forebrain [267,268], precuneus [265,266], parietal gyrus [261], and posterior 
cingulate [266]. This is an agreement with observations from connectomics experiments 
which view AD as a disconnection syndrome with the earliest disruptions to metabolic 
connectivity occurring in the posterior cingulate cortex [328,332]. The model of Jones et al. 
[336] of a cascading network failure which begins in the posterior subsystem of the DMN, 
and which propagates connectivity changes along the WM tracts of the structural 
connectome, provides a provocative framework for functionally linking the many 
observations of “typical” AD progression. The observation that the APOE ε4 allele may 
instigate the process or modulate in some way the structural and functional connectome 
[310,326,327,334,336] also is consistent with studies of Aβ+ subjects. Models of a prion-
like mechanism [344,346] by which misfolded Aβ induces further pathological misfolding 
along structural brain networks predict patterns of Aβ deposition, hypometabolism, and 
atrophy and provide a mechanistic basis for network failure. The association of WM changes 
caused by cerebrovascular disease with abnormal Aβ and with markers of neurodegeneration 
may also be viewed in the light of these models. The association of Aβ positivity with 
increased cerebral blood flow in the posterior cingulate [277], and with improvements in 
global measures of WM integrity at low Aβ burden [310], may be evidence of the initial 
compensatory changes in connectivity predicted by the model of Jones et al. [336]. Aβ 
pathology and microvascular damage may be linked at the early stages of disease [311], and 
WM changes in the parahippocampal gyrus were associated with hallmarks of AD decline 
[308]. Degradation of specific, disease-related regions of the structural connectome by 
cerebrovascular disease may exacerbate disconnection, consistent with the theory that WM 
damage causes a “second hit” in disease progression. However, WM changes do not always 
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lead to AD; the total volume of WM changes was found to be more related to age-related 
vascular changes [308].
Most MCI and CN subjects were not identified by cluster analysis as following “typical” AD 
progression. In fact, a substantial proportion were normal by most measures [280–282,286], 
suggesting that there is a high rate of false diagnostic positives in MCI subjects. Various 
other subtypes were identified, chief among them a group typified by deficits in executive 
function and abnormal tau, but having normal Aβ [280,281]. These subjects may be related 
to Aβ−, neurodegeneration positive SNAP subjects, who were found to progress to 
frontotemporal dementia and Lewy body disease in addition to AD [291]. Conversely, a 
subtype of Aβ+ patients had primarily cortical atrophy and deficits in executive function 
which correlated with the distribution of neurofibrillary tangles [157,272]. These individuals 
likely had atypical forms of AD characterized by predominantly isocortical tau pathology. 
Finally, most of the associations between Aβ and memory were mediated by neither 
hypometabolism nor atrophy, further implicating p-tau in the process. The tale of tau has yet 
to be told; the inclusion of tau PET imaging in ADNI-3 promises to shed light on this 
conundrum.
The studies have had a profound impact on how we consider the disease process, which, in 
turn, has many implications for the development of AD preventive treatments and clinical 
trial design. Many questions remain to be answered: what is the underlying pathology of the 
Aβ− subtypes? How does abnormal Aβ mechanistically prompt tau propagation? How does 
tau propagate in the absence of Aβ? How does WM damage in different regions affect 
structural, functional, and metabolic connectivity? What is a genetic contribution to these 
different pathways? The answers will undoubtedly lie in the consideration and integration of 
results from multiple approaches. The breadth and depth of ADNI positions it ideally at the 
cusp of discovery.
8. Improvement of clinical trials
The overall goal of ADNI is to validate biomarkers for AD clinical trials. A large body of 
recent ADNI publications describes improved approaches for diagnostic classification, the 
prediction of future decline and the selection of trial participants likely to decline, and 
development of outcome measures sensitive to early changes wrought by the disease. To 
some extent, progress in this area dovetails with advances in our understanding of disease 
progression; recognition of the heterogeneity and pathophysiology underlying MCI and now 
even CN participants, and of the wide variety of clinical trajectories, informs many aspects 
of clinical trial design. As trials move to presymptomatic cohorts, biomarkers will be crucial 
in identifying those with preclinical AD. Furthermore, biomarkers may provide more 
sensitive and specific markers of progression. Certainly, this is one of the major hopes for 
tau PET [347]. Knowledge of how sources of disease heterogeneity influence biomarker 
changes will enable the selection and monitoring of subjects most likely to benefit from a 
targeted therapy. These advances improve statistical power to detect a slowing of clinical 
decline in predementia populations, a major challenge which has plagued AD clinical trials 
to date.
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8.1. Diagnosis and prediction
8.1.1. Use of established modalities
8.1.1.1. Multimodal classifiers: Clinical trial design fundamentally depends on the ability 
to accurately diagnose the clinical group to which a subject belongs and to predict their 
likelihood of measurable progression within the time frame of the trial. As no single 
modality has been shown to be effective in all classification or prediction challenges, 
researchers have continued to focus on the use of multiple modalities. Optimum 
combinations of modalities differ between challenges. Although MRI and PET (FDG and 
florbetapir) were roughly equivalent in their ability to discriminate between AD and CN 
subjects and between AD and MCI subjects, changes in cortical thickness outperformed 
other measures for EMCI and CN subjects and may be an early indicator of 
neurodegeneration [348]. A systematic appraisal of the diagnostic and prognostic abilities of 
hippocampal volume and CSF biomarkers, alone and in combination, in both APOE4 
carriers and non-carriers found that their multimodal classifier outperformed either single 
modality [349]. Aβ42 levels contributed to discriminating between CN and MCI or AD 
subjects but not between MCI and AD subjects. Conversely, p-tau181, a marker of 
neurodegeneration, played a role in discriminating between AD and MCI or CN subjects but 
not between MCI and CN subjects [349].
8.1.1.2. Prediction of CN to MCI progression: Biomarkers that predict cognitive decline 
in CN subjects also reflect disease progression. Based on the hypothetical AD model [258], 
successive preclinical AD stages have been proposed comprising firstly Aβ deposition (stage 
1), followed by evidence of neuronal injury biomarkers (stage 2), and finally subtle cognitive 
impairment (stage 3) [278]. Consistent with the stages, Aβ42, but not p-tau181, predicted CN 
to MCI, but not MCI to AD progression [350]. A cut point of <220 pg/mL Aβ42, well above 
the established cut point for Aβ positivity of 192 pg/mL [292], was the best CSF predictor of 
decline on ADAS-cog in CN subjects, although t-tau and p-tau181 alone and their ratios with 
Aβ42 at modified cut points were also good predictors [350]. A combination of all CSF 
biomarkers using the modified cut points predicted progression to MCI with an accuracy of 
65% [350]. In another study, volumetric changes and t-tau/Aβ42 were associated with a 
higher risk of progression in CN subjects, and lower baseline memory measures were the 
strongest predictors of progression [278]. It is important to note that although neuronal 
injury is included as a diagnostic criterion in AD, different markers of neuronal injury 
(hippocampal volume, regional glucose metabolism, levels of CSF p-tau181) were not found 
to be equivalent [278,351].
8.1.1.3. Prediction of MCI to AD progression: Predictors of MCI progression to AD also 
reflect the biomarker changes occurring at that stage of disease progression. Combinations 
of regional volumetric, glucose metabolism, and cortical deposition measures predicted 
progression with accuracies of 72% [352] and 76% [353]. Neuropsychological measures 
alone (clock drawing + AVLT) [354], or in combination with hippocampal volume [355], 
reached similar accuracies. A point-based tool with a range of 0 to 9 which included scores 
from the Functional Activities Questionnaire (FAQ), ADAS-cog and Clock-drawing tests, 
middle temporal cortical thinning, and hippocampal atrophy also had good predictive 
accuracy: 91% of MCI subjects with 7 to 9 points converted to AD within 3 years [356]. The 
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primary drivers of prediction in the Disease State Index [357] were MRI features; additional 
neuropsychological and CSF markers improved accuracy only slightly [358]. A comparison 
of effect sizes of neuropsychological, MRI, FDG PET, and CSF measures for cognitive 
decline over 4 years in MCI nonconverters and converters (Fig. 37) [354] illustrates the 
relative importance of these measures, particularly atrophy in temporal regions, functional 
and memory impairment, and changes in glucose metabolism compared to CSF biomarkers 
in this transition.
8.1.1.4. The effect of APOE4 status on the prediction of progression: Inclusion of 
APOE4 status substantially improved the prediction of MCI progression. In APOE4+ 
subjects, a hippocampal volume classifier had an accuracy of 76% [349], and a classifier 
based on FDG PETand volumetric MRI measures had an accuracy of 86.8% [359]. In 
APOE4 subjects, the best predictor of progression was a CSF classifier including p-tau181 
that achieved 78% accuracy [349], suggesting that APOE4 plays a role in modulating 
disease trajectory, and may account for a portion of the observed disease heterogeneity.
8.1.1.5. Cognitive and clinical factors in prediction and diagnosis: Although 
multimodal classifiers currently predict future decline with the best overall accuracy, the use 
of cognitive or clinical factors that can be determined at a clinical visit can reduce cost, 
avoid invasive lumbar puncture procedures, and save time. A brief clinical index which 
included being female, several neuropsychiatric symptoms, and measures of cognition and 
functional dependence classified subjects into low (14% converted over 3 years), moderate 
(51% converted), and high-risk groups (91% converted) and had a Harrell’s c-statistic of 
0.71, a predictive power similar to other commonly used prediction indexes such as the 
Framingham cardiovascular risk indicator (Fig. 38) [360]. Specific cognitive tests may be 
effective predictors. Clock drawing and RAVLT trial 5 were equally predictive of MCI to 
AD progression (AUC 0.78) as other single cognitive, FDG PET, structural MRI, and CSF 
biomarkers [354]. Two items on the FAQ (paying attention and understanding TV program, 
paying bills/balancing checkbook) predicted greater hazard of progression from CN to MCI. 
Similarly, the Everyday Cognition scale item “keeping mail and papers organized” predicted 
CN to MCI progression with hazard ratio of 2.27 [361]. These studies support the idea that 
simple questions regarding function can predict progression to MCI in CN elderly.
8.1.1.6. MRI biomarkers in prediction and diagnosis: MRI, although more costly than 
cognitive tests, is noninvasive and accessible in most settings. Automatic MR imaging 
analysis may assist a clinician in making an initial diagnosis. An automatic medial temporal 
lobe atrophy measurement predicted progression from SMC to MCI, and from MCI to AD 
with sufficient accuracy for clinical utility (AUCs of 0.904 and 0.810, respectively) [362]. 
Two studies have investigated use of the established Visual Rating Scale which obviates the 
need for research-oriented volumetric segmentation methods such as FreeSurfer. The 
entorhinal cortex visual rating system outperformed other visual rating systems against 
FreeSurfer for the AD versus CN classification (AUCs of 0.87 and 0.86, for entorhinal 
cortex and Free-Surfer, respectively) and for the MCI versus CN classification (AUCs of 
0.73 and 0.75, for entorhinal cortex and FreeSurfer, respectively) [363]. Both visual rating 
systems and volumetric measures were good predictors of MCI to AD progression, with the 
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entorhinal cortex visual rating system outperforming both the hippocampal visual rating 
system and volumetric analysis of the entorhinal cortex [363]. The visual rating scale for 
medial temporal atrophy outperformed equivalent visual rating scales of global cortical 
atrophy and posterior atrophy, achieving AUCs of 0.838 and 0.624 for the classification of 
AD versus CN, and MCIc versus MCInc, respectively, when optimized cutoffs for specific 
age ranges were used [364]. Visual rating scales may also have clinical utility in detecting 
sources of disease heterogeneity. A visual rating scale, the frontal subscale of the global 
cortical atrophy scale, reliably detected frontal atrophy and reductions in cortical volume 
and thickness that characterize the executive subtype of AD [365].
Further gains in the predictive ability of MRI, particularly in CN subjects, have come from 
new approaches which can identify changes in subtle structural features that occur before 
hippocampal atrophy. For example, hippocampal texture in the absence of hippocampal 
volume loss accounted for cognitive impairment in MCI subjects [28]. A hippocampal 
grading score which detected subtle patterns of neurodegeneration predicted progression to 
AD with an accuracy of 72.5% 7 years in advance of this transition [366]. Other features 
with prognostic potential include changes in the hippocampal subfield and presubiculum 
volumes [367], shape changes and atrophy rate of the corpus callosum [368], greater WM 
signal intensity ratio [369], and signal and texture-related features [370]. Data-driven feature 
selection outperformed region of interest (ROI)-based approaches in the prediction of MCI 
progression [371], suggesting that the subtle relationships between different brain areas 
detected by methods such as recursive feature elimination are highly effective predictors 
(Table 9).
8.1.2. Novel CSF and blood biomarkers
8.1.2.1. Novel CSF biomarkers: Proteomic approaches have identified numerous 
potential novel AD biomarkers in both CSF and blood. Potential AD biomarkers can be 
identified using a multiplex panel of selected CSF analytes that reflect the brain proteome. 
The p-tau181/Aβ42 ratio, a strong predictor of progression from CN to MCI over a 3- to 4-
year period, was used as a continuous variable and endophenotype for AD to identify novel 
CSF analytes from a proteomic panel [168]. The most significantly associated analyte was 
heart fatty acid binding protein (FABP), which was comparable to p-tau181/Aβ42 in its 
ability to predict progression from CN to impaired cognition over 4 years. Other significant 
predictors were macrophage migration inhibitory factor and VEGF. A panel of 24 CSF 
analytes outperformed a combination of MRI and CSF measures in predicting MCI 
progression to AD (accuracy 94.1% vs. 76.5%) and included FABP, chromogranin A, matrix 
metalloproteinase 2, and pancreatic polypeptide as the strongest predictors [166]. The panel 
also discriminated between MCI and CN subjects with an accuracy of 91.5%, a sensitivity of 
87.7%, and a specificity of 94.3%. Markers of inflammation, complement 3 and factor H, 
were associated with increasing ADAS-cog scores and lateral ventricular volume over time, 
suggesting they may have prognostic, but not diagnostic, utility [167].
MS is an alternative proteomics technology to multiplex immunoassay panels that can 
increase the speed, sensitivity, and quantitative precision of biomolecule analysis limited to a 
subset of analytes. The Foundation for the National Institutes of Health Biomarkers 
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Consortium identified CSF-based AD biomarkers using a Multiple Reaction Monitoring MS 
panel of analytes selected for their relevance to AD and from previous multiplex 
immunoassay findings. The most significant peptides able to differentiate between MCIc 
and MCInc subjects were the blood proteins, hemoglobin A, hemoglobin B, and superoxide 
dismutase, consistent with the hypothesis that the blood brain barrier is leaky in AD. FABP 
was the top peptide for discriminating between MCI or AD and CN subjects, consistent with 
findings from immunoassay approaches. The top peptides predicting MCI to AD progression 
were putative markers of synaptic loss and neuronal injury/degeneration, neuronal pentraxin 
2, VEGF, and secretogranin-2 (AUC 0.79).
8.1.2.2. Blood-based biomarkers: Because a blood-based test for AD is less costly and 
less invasive than a CSF-based test, there has been considerable effort in identifying blood-
based diagnostic and prognostic AD biomarkers. Although CSF proteins are generally 
thought to reflect the brain proteome, the relationship between proteins in plasma and CSF is 
not clear. The cell bound fraction of Aβ42 was associated with left hippocampal and left 
entorhinal cortex volumes, suggesting that blood Aβ42 at least partially reflects Aβ 
production and/or clearance in the brain [421]. A blood biomarker–based signature 
comprising chemokine ligand 13, immunoglobulin M-1, interleukin 17, pancreatic 
polypeptide, and vascular cell adhesion protein-1 predicted neocortical Aβ burden with a 
sensitivity of 79% and a specificity of 76% [422]. These two studies suggest that Aβ 
accumulation in the blood is associated with neocortical Aβ burden and characteristic AD 
atrophy and that blood-based assessment of Aβ burden could have clinical utility.
Changes in plasma levels of bone morphogenetic protein 6, selectin, matrix 
metalloproteinase 10, and neuronal cell adhesion molecule were correlated with atrophy in 
temporal lobe structures, the posterior cingulate cortex, and thalamus, and diagnosed AD 
with a sensitivity of 93% and a specificity of 92% [423]. A panel of plasma proteins 
including interleukin 16, thyroxine-binding globulin, and peptide YY were predictive of 
MCI progression (accuracy 62.5%) [423]. Redox-reactive antiphospholipid autoantibodies 
may be increased early in disease due to neurodegenerative changes in cell membranes, and 
APOE4 may act by increasing redox-reactive Fe during disease progression [152]. Elevated 
levels of redox-reactive autoantibodies against phosphatidylserine, 
phosphatidylethanolamine, and phosphatidylcholine were elevated in MCI compared to CN 
subjects, and a panel of these autoantibodies discriminated between MCI and CN with a 
sensitivity of 80% and a specificity of 83.3% [424].
In conclusion, at the time of this review, no established validated blood test for AD exists. 
However, there is a pressing need for a test with relatively good sensitivity (even if lacking 
some specificity) to identify subjects at high risk for AD, who would then undergo further 
testing such as Aβ PET for diagnosis. There is a great deal of work going on in this field, 
and the availability of ADNI plasma samples hopefully will provide material for further 
investigation.
8.1.2.3. Combinations of CSF and blood biomarkers: A combination of both CSF and 
blood analytes may have even greater predictive power than either fluid alone. Lehallier et 
al. [425] examined multiple groups of variables—clinical, genetic, volumetric, cognitive, 
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and CSF and plasma analytes—to identify a biomarker signature that could predict the time 
to progression from MCI to AD 1 to 6 years before clinical diagnosis. Variables from 
different categories were differentially associated and appeared to carry complementary 
information about the disease (Fig. 39). For example, CSF and plasma “communicomes” 
containing proteins involved in intracellular communication were highly associated with 
each other but not with established CSF biomarkers, whereas genetic factors (APOE4, 
TOMM40) were predominantly associated with AD CSF biomarkers. Predictive models for 
each progression time point in 6- or 12-month intervals identified six variables as top 
predictors in most models: CDR-SB, CSF tumor necrosis factor–related apoptosis-inducing 
ligand receptor 3 (TRAIL-R3), plasma apolipoprotein A-II (ApoAII), and CSF fibroblast 
growth factor 4 (FGF-4). Most analytes had the highest accuracies in predicting progression 
within 2 to 3 years. A final model consisting of two plasma (ApoAII, cortisol), and four CSF 
(FGF-4, FABP-H, calcitonin, and TRAIL-R3) analytes predicted MCI progression within 3 
years with a sensitivity of 88% and a specificity of 70%. A comparison of this model with 
other groups of variables is shown in Fig. 40 and supports the idea that novel plasma and 
CSF biomarkers may outperform modalities traditionally used for prediction such as MRI 
volumes, cognitive scores, or AD CSF biomarkers and APOE status.
8.1.3. Arterial spin labeling—Hypoperfusion of brain tissue, detected by arterial spin 
labeling MRI, precedes atrophy and may therefore be a useful biomarker for early changes 
in the disease process. Cerebral blood flow was marginally outperformed by structural MRI 
(AUCs of 0.87 compared to 0.89) in the classification of AD versus CN subjects [426], but 
the technique may have more utility in classifications such as MCI versus CN or in 
predicting cognitive decline in subjects with normal cognition.
8.1.4. Network connectivity measures—The concept of AD as a disconnection 
syndrome posits that some of the earliest changes in disease progression are disruptions to 
network connectivity. Network connectivity measures, which have been shown to differ 
between patient groups [321–323,329,333], may therefore have prognostic and diagnostic 
utility.
8.1.4.1. Structural connectivity measures: A variety of structural connectivity measures 
have been tested for their diagnostic or prognostic abilities. These include connectivity 
measures of WM fiber pathways [427], the tensor–based Fiber Assignment by Continuous 
Tracking algorithm [428], a new tractographic feature, average tract length [429], and a 
novel flow-based measure of brain connectivity [430]. The results were variable with 
accuracies ranging from 71.25% [428] to 97% [429] for the AD versus CN challenge, and 
from 57.3% [428] to 59.2% [430] for the MCI versus CN challenge. One difficulty in using 
structural connectivity measures is the high dimensionality of WM tracts. Nir et al. [431] 
used a novel maximum density pathway algorithm to find the shortest path between 
probabilistic ROIs and made a compact representation of WM tracts from whole-brain 
tractography. They used their low-dimensionality representation for classification, achieving 
accuracies of 84.9% and 79% for the AD versus CN, and MCI versus CN challenges, 
respectively.
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8.1.4.2. Functional connectivity measures: Progressive deterioration of functional 
connectivity appears to be characteristic in AD and is reflected in changes to the network 
small-world properties and other measures. MCI subjects had lower clustering coefficients 
and longer characteristic path length than CN subjects in one study, and alterations in these 
properties in the DMN discriminated between EMCI and CN with an accuracy of 79.7% 
[432]. A topological metric, compression flow, derived from network centrality criteria, 
outperformed individual small-world metrics alone. It monotonically followed impairment 
progression in each patient group, and discriminated between all patient groups (CN, EMCI, 
LMCI, and AD) [433]. Other studies developed a novel multifractal feature [434] and 
created a compact representation of the brain network [395] for classification purposes. 
Machine learning techniques were used for dimensionality reduction and the selection of the 
most discriminative regions.
8.1.4.3. Cortical atrophy networks: Cortical atrophy networks which capture the spread 
of at rophy have been used for classification in several studies. Surface connectivity maps 
describing the center of each cortical region affected, the individual volume loss of these 
regions, and how they move apart were used to define functional regions of the brain [435]. 
This approach outperformed whole-brain or hippocampal volume in predicting the 
progression of MCI subjects and achieved AUCs of 0.88, 0.78, and 0.77 for AD versus CN, 
MCI versus CN, and MCI versus AD classifications, respectively. Instead of solely finding 
connectivity between areas of cortical atrophy, Friedman [436] developed a new approach, 
Directed Progression Networks (DPNets), based on the idea of a prionlike spread of the AD 
pathology along axonal tracts in a characteristic and systematic pattern. DPNets found the 
direction of connections between network hubs to capture the temporal progression of brain 
disease and outperformed undirected networks in the classification of AD versus CN 
subjects, achieving an AUC of 0.87. Interestingly, the network generated by this method did 
not have the small-world properties observed in almost all other brain networks probably 
because this network reflects the spread of disorder in the brain, and not computation.
8.1.4.4. Future directions: The use of connectivity measures in classification and 
prediction is still in its infancy. A study which combined metabolic and structural 
connectivity patterns by constructing networks from both FDG PET and structural MRI data 
was able to discriminate between AD and CN, MCI and CN, and MCI and AD subjects with 
AUCs of 0.96, 0.91, and 0.88, respectively [437]. The results for classifications involving 
MCI compare favorably with other state-of-the-art multimodal approaches, hinting at the 
potential power of multimodal network connectivity approaches. Methodological 
improvements will aid in the development of this exciting new area. Technical issues were 
found to influence interpretation of graph theory measures [438] and may be overcome by 
the standardization of connectomics methods. One study improved classification sensitivity 
and specificity by including a more modern group-wise DTI registration step [439] and 
likely represents just the initial phase of improvements in this area.
8.1.5. Single nucleotide polymorphisms—For the first time, ADNI studies 
demonstrated that diagnostic classification and the prediction of future clinical decline could 
be improved by the addition of selected SNPs to other modalities. One hundred eighty-nine 
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SNPs selected for their discriminative ability improved classification accuracy by 5% and 
3% for the MCI versus CN, and AD versus MCI classifications, respectively [254]. Top hits 
included CTNNA3 and PON2, but not APOE. SNPs did not improve the AD versus CN 
classification in combination with any other modality. The addition of 101 top SNPs from a 
GWAS to MRI features such as hippocampal volumetric and surface morphology data 
improved prediction of MCI to AD progression over 48 months, achieving an AUC of 0.95 
[255]. The SNP markers selected for prognosis differed from those associated with increased 
disease risk, suggesting that genes underlying the MCI to AD progression differ from those 
that increase disease risk. This is an exciting advance and holds much promise for the 
incorporation of similar data to improve stratification and subject selection.
8.2. Diagnosis and prediction methods
A plethora of novel machine learning approaches to diagnosis and prediction have been 
developed and tested using ADNI data in 2014 and 2015, leading to an overall improvement 
in classification and prediction accuracy. The use of standardized ADNI data sets has, in 
some cases, facilitated comparison of results. Deep learning algorithms that use multiple 
processing layers to model high-level data abstractions have proved exceptionally successful 
in selecting and combining optimal features from multiple modalities. In combination with 
some form of dimensionality reduction and a classifier such as a support vector machine or 
treebased algorithm, either as sequential steps or as an embedded wrapper algorithm, deep 
learning has improved the effectiveness of MRI as a single modality to the point where it 
rivals multimodal approaches for classification accuracy. Several studies reported MRI-
based methods that could discriminate between AD and CN subjects with accuracies 
between 92% and 97% [374,387,388,394] or predict MCI progression to AD with accuracies 
exceeding 80% [374]. Notably, Gorji et al. [394] used pseudo-Zernike moments, powerful 
shape descriptors used in image recognition, to characterize global and local pattern shapes 
and select discriminative features that were used by a supervised neural network for 
classification. Their results were comparable with other state-of-theart methods for the AD 
versus CN classification but substantially outperformed other methods, including 
multimodal approaches, for the more challenging problems of MCI versus CN (sensitivity 
95.9%, specificity 95.3%, and accuracy of 95.6%), and AD versus MCI (sensitivity 94.2%, 
specificity 95.6%, and accuracy 94.9%) classification. This publication illustrates the vast 
potential of neural networks in tackling these classification problems, and further rapid 
improvement in this area is likely concomitant with the burgeoning development of this area 
of machine learning.
However, the best classifiers generally still incorporated multimodal information; deep 
learning approaches improved feature selection, in part by preserving intermodal 
relationships. The best multimodal classifiers for the AD versus CN, and MCI versus CN 
challenges reached accuracies of >95% [405,408,410,411,416–418] and >82% 
[304,405,417,420], respectively. An approach which incorporated longitudinal multimodal 
data, and which notably included PICALM status, predicted progression of MCI subjects to 
AD with an accuracy of 91% [413]. It is beyond the purview of this review to detail all of 
these efforts; they are instead summarized in Table 10. Instead of binary classification, one 
study used machine learning of structural MR images of a normative population to define a 
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brain abnormality index [386], and others tackled multi-class classifications such as AD 
versus MCI versus CN (Table 11). Finally, a number of publications focused on addressing 
technical problems such as incomplete or imbalanced data in multimodal classification or 
problems with imperfect reference tests (Table 12).
8.3. Subject selection and outcome measures
With the transition of AD preventive and treatment clinical trials to preclinical and 
presymptomatic populations, the selection of subjects likely to decline in the near future, and 
the selection of clinical end points able to detect a treatment effect, are of paramount 
importance. Inclusion criteria include Aβ positivity, tau pathology, hippocampal atrophy, or 
combinations of these and genetic markers and are fundamentally guided by the need to 
decrease heterogeneity in the trial population. Both prognostic enrichment (selecting patients 
likely to progress) and predictive enrichment (selecting patients likely to respond to the 
therapy being trialed) need to be considered. Cognitive end points must be sensitive to early 
cognitive changes such as delayed recall, function, and attention, and imaging end points 
must also detect early changes. Once again, selection of inclusion criteria and outcome 
measures are informed by knowledge of disease progression. Understanding how covariates 
influence disease progression, even in an enriched MCI population, aids in selecting 
populations likely to progress.
A model predicting cognitive decline on the CDR-SB in MCI subjects found that the rate of 
disease progression was influenced by current CDR-SB score, baseline levels of CSF 
biomarkers, and baseline Delayed Logical Memory and Trails A scores [459]. Subjects 
selected for either low or high p-tau181/Aβ42 progressed at different rates, and the model 
identified a subpopulation with low likelihood of disease progression based on this ratio 
(Fig. 41). A different model found that baseline severity measured by CDR-SB, baseline 
hippocampal volume, and APOE4 predicted shorter times the clinical worsening [460] and 
estimated N80s of around 550 CN subjects using either low hippocampal volume or APOE4 
positivity as an enrichment strategy for a 2-year trial. However, baseline values of 
biomarkers may not be sufficiently informative to predict clinical decline. Longitudinal 
biomarker progressions predicted substantially more variability in cognitive decline than 
baseline measures; ventricular expansion explained 40% of variability compared to a mere 
8.7% of variability explained by baseline ventricular volume in MCI subjects [461]. 
Therefore, the use of longitudinal biomarker progressions for enrichment could improve the 
statistical power of clinical trials.
8.3.1. Enrichment biomarkers—Aβ positivity is currently used as an inclusion 
criterion for CN participants in the anti-Aβ A4 secondary prevention trial which aims to 
slow cognitive decline in CN elders using solanezumab [462]. Improvement of quantitative 
accuracy of amyloid PET scans by refinement of acquisition protocols and tracer 
administration, subject management, and image quality control and processing could reduce 
sample sizes for trials of intervention effects [463]. Prediction of Aβ positivity by florbetapir 
PETwas improved by the determination of a cutoff value of 1.24 based on three regions of 
interest (posterior cingulate cortex, precuneus, medial frontal cortex) which achieved an 
accuracy of 98.5% [464]. Visual inspection of florbetapir PET images was as effective as 
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SUVR in determining Aβ positivity [465]. Alternative automated methods such as Syngo-
PET Aβ Plaque [466], and a method based on a two-point correlation metric, wS2 [467], 
were comparable to SUVR and offered some advantages such as the ability to detect subtle 
changes in patterns of Aβ deposition [468].
Hippocampal volume is the first imaging biomarker to be qualified by the European 
Medicines Agency to select amnestic MCI subjects at risk of imminent rapid clinical 
deterioration for clinical trials [469]. As hippocampal volume is an established biomarker of 
AD, it can help to differentiate between the approximately two thirds of subjects who have 
MCI attributable to AD and the approximately one third of MCI subjects on a different 
disease pathways not necessarily attributable to Aβ pathology. Yu et al. [470] describes the 
systematic operationalization of hippocampal volume as an enrichment biomarker by 
defining specific cut points of hippocampal volume, comparing different commonly used 
algorithms for hippocampal volume quantification (FreeSurfer, HMAPS, LEAP, 
NeuroQuant), and considering three cognitive end points, MMSE, ADAS-cog, and CDR-SB. 
Hippocampal volume, calculated by any of the quantification methods, reduced sample sizes 
for all cognitive outcomes by 40% to 60%, with the greatest reduction in sample sizes at a 
cut point of 10% of normal volume. Trial costs were estimated to be reduced by 30% to 40% 
over a range of hippocampal volume cut points, although little effect on trial duration was 
predicted, regardless of cognitive end point (Fig. 42). Designed to guide clinical trial design, 
this analysis illustrates the trade-off between statistical and practical considerations.
Deep learning algorithms may also have great potential for selecting inclusion criteria that 
increase statistical power and reduce sample sizes in clinical trials. Ithapu et al. [471] 
described a new method of enrichment using inclusion criteria derived from FDG PET, 
florbetapir PET, and structural MRI features learned using their novel randomized denoising 
auto-encoder marker. Using CDR-SB scores as an outcome measure, this method reduced 
MCI sample sizes at least fivefold compared with no enrichment (N80s: 281 vs. 1586) and 
improved on enrichment with hippocampal volume alone (N80: 389) for a 2-year trial, 
suggesting that the learning algorithm can capture data from different modalities most 
representative of changes during disease progression.
8.3.2. Outcome measures—As clinical trials move to presymptomatic subjects, the 
development of outcome measures which can detect a subtle treatment effect is vital. Some 
investigations have focused on developing a clinical measure sensitive to very early 
cognitive changes; others have developed candidate biomarkers as potential surrogate 
outcome measures. A composite score developed from existing clinical end points and 
consisting of Word Recall, Delayed Word Recall, Orientation, 13-item CDR-SB, and FAQ 
had greater sensitivity to detect change in MCI subjects enriched with APOE4, hippocampal 
volume, and CSF Aβ42 than either CDR-SB alone or ADAS-cog [472]. The primary 
outcome measure in the A4 study is the Alzheimer’s Disease Cooperative Study Preclinical 
Alzheimer’s Cognitive Composite, comprising Total Recall, Delayed Recall, Digit Symbol 
Substitution, and MMSE [473]. Aβ+ CN participants had greater decline in this measure 
than Aβ− participants on this measure across different cohorts. With a cohort size of 500, it 
was predicted that the A4 study would be able to detect treatment benefit of about 0.5 units 
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of the measure at 80% power over 3 years [473], suggesting that the measure is sufficiently 
sensitive and specific to detect Aβ-related decline in this trial population.
The quest for a surrogate outcome measure with greater power to detect decline than 
cognitive measures has progressed with several systematic studies comparing the efficacy of 
various biomarkers. Imaging biomarkers, especially MRI, have been of particular interest as 
longitudinal changes in them can be precise and reproducible. Caroli et al. [474] compared 
the power and performance of MRI and FDG PET biomarkers, and ADAS-cog, and found 
that for a 2-year trial with yearly biomarker assessment, a measure of the longitudinal 
whole-brain atrophy, KN-BSI [475], had the greatest power, with N80s of 48 and 85 for 
MCI subjects selected for Aβ positivity, or hippocampal atrophy, respectively. In 
comparison, they calculated N80s of approximately 1000 using ADAS-cog as an outcome 
measure with either enrichment strategy. Longer trials, but not more frequent biomarker 
assessments, increased power. Although measures of atrophy such as KN-BSI are well 
established, they may be outperformed by machine learning algorithms that are optimized 
for power to detect brain change. Gutman et al. [476] extended a previous data-driven 
feature selection approach [477] to maps of whole-brain volume change derived from TBM 
measures and combined this with ventricular surface measures to generate one summary 
atrophy score. This outperformed either measure alone and statistically defined ROIs in 1- or 
2-year trials in both AD and MCI subjects, with calculated N80s of 31 for AD, and 56 for 
MCI subjects for a 2-year trial.
A systematic comparison of selection criteria and cognitive end points in CN elderly [478] 
found that a combination of the composite measure comprising the 11-point ADAS-cog, 
Delayed Recall on AVLT, and Trails B, and subject selection with three or four abnormal 
biomarkers (from APOE4, Aβ+, tau+, or hippocampal atrophy+) reached 79% power with N 
= 1500 participants per arm over a 3-year trial, assuming a 25% effect size of treatment (Fig. 
43). Trial durations of longer than 4 years were required to achieve greater than 80% power 
using this combination of enrichment criteria and cognitive outcome measure. Recruiting 
subjects with multiple pathologies increased the power to detect change by 15% to 20%, but 
this strategy would also increase costs and limit the pool of eligible participants. A structural 
MRI surrogate outcome measure may improve the feasibility of clinical trials in CN subjects 
by lowering costs and increasing the power to detect disease progression and may be 
especially suited to trials of therapies that aim to repair brain tissue rather than clear Aβ. 
Hua et al. [479] investigated the utility of longitudinal TBM biomarkers for tracking brain 
changes, comparing the power of single numerical summary of brain atrophy scores 
reflecting disease-related change in the temporal lobe (temporal-ROI) [480], statistically 
defined ROIs, or over the whole brain over different trial lengths, and with different subject 
groups, enrichment biomarkers, and scan intervals. The whole-brain measure and 
statistically defined ROI measure produced N80s of 127 and 241, respectively, for CN 
subjects, 141 and 314, respectively, for EMCI subjects, and 72 and 162, respectively for 
LMCI subjects for a 2-year trial using a 12-month scan interval. Both measures are 
trainingbased approaches which select regions with the most consistent and detectable 
change. Enrichment using APOE4 or Aβ further reduced sample sizes to around 100 
subjects regardless of diagnostic group (Fig. 44). Of 10 AD risk alleles tested as enrichment 
criteria, only APOE4 produced any gains in statistical power. Both statistically defined ROIs 
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and the whole-brain measure based on linear discriminant analysis are training approaches 
which differ in training sample size and region selected; statistically defined ROI requires a 
small training set and selects regions such as the temporal lobe which are likely to be 
affected in AD but has low statistical power, whereas the whole-brain approach requires a 
larger training set and may not select patterns of brain change germane to the treatment but 
has higher performance and statistical power. Trade-offs between end-point measures and 
selection biomarkers will ultimately represent a balance of cost and power and will reflect 
the drug mechanism.
8.4. Other improvements to clinical trials
The use of a placebo arm in addition to the treatment arm in clinical trials raises ethical 
issues. The Placebo Group Simulation Approach [481] models the placebo group based on 
baseline data of the treatment group and forecasts the distribution of quantified outcomes in 
MCI subjects. A comparison of empirically observed and simulated data suggested that the 
model approximated placebo data well. Of the baseline variables, cognitive performance 
predicted the trajectory of cognitive decline most accurately.
8.5. Conclusions
The overarching theme of publications focused on improving clinical trials from 2014 and 
2015 has been a shift to optimizing enrichment strategies and developing outcome measures 
suited to trials in CN cohorts. Knowledge of disease progression has guided this 
development; the effectiveness of established biomarkers at diagnostic and prognostic 
challenges reflects their position in the temporal ordering of biomarkers as described by the 
first model of the pathological cascade [482]. The prediction of imminent decline in CN 
participants may require adjustment of established cut points of CSF biomarkers, the use of 
subtle changes to MRI features instead of atrophy measures, or measures of cognitive 
domains first affected in the disease. Multimodal approaches remain the most effective at 
prediction and classification, and the addition of novel modalities such as selected SNPs or 
network connectivity measures may improve accuracy even further. Panels of CSF and/or 
blood biomarkers now rival established multimodal biomarkers for diagnostic and 
prognostic utility. A substantial number of machine learning approaches have been tested 
using ADNI data and illustrate the potential power of neural networks in selecting highly 
discriminative features in single modalities, and in detecting optimum intermodal 
relationships using multiple modalities. The greatest gains in accuracy have been made in 
the more difficult classification (MCI vs. CN, AD vs. MCI) and prediction (CN to MCI, 
MCI to AD) challenges. Systematic studies of enrichment biomarkers, outcome measures, 
and combinations of the two have provided critical guidance to inform clinical trial design. 
Enrichment strategies aim to reduce the heterogeneity of trial cohorts and select populations 
both at risk of imminent decline and likely to respond to the trial treatment. Some studies 
refined cognitive measures as outcome measures, whereas others developed surrogate 
outcome measures using MRI approaches. Combinations of subject selection using multiple 
inclusion criteria and MRI longitudinal measures as surrogate outcomes had the greatest 
power to detect treatment effect and the most feasible sample sizes for early intervention 
trials in CN subjects.
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9. Summary
Studies using ADNI data have produced an unprecedented body of research in 2014 and 
2015. What then are the fundamental conclusions from this work? If you have read this 
entire review, hearty congratulations on your perseverance; if not we offer the following 
summary. ADNI studies have been supported by the continued development and 
standardization of methodologies, sample collection and distribution, and curating and 
sharing of data by the various ADNI Cores. The longitudinal data extending now over a 
decade and the breadth of modalities represent a unique resource to the scientific community 
that has been used in a myriad of ways to expand and deepen our knowledge of AD 
progression and to inform AD clinical trial design.
Studies of subjects selected for Aβ positivity have largely confirmed the order in which 
biomarkers become abnormal during disease progression and have suggested that APOE 
modulates disease progression through Aβ clearance mechanisms. However, there appears to 
be variability in this relatively well-defined process. For example, Aβ+ subjects with 
predominantly cortical atrophy had impaired executive function, whereas those with 
predominantly hippocampal atrophy had impaired memory function. Cluster analysis studies 
of CN and MCI subjects also consistently identified an executive function-impaired subtype, 
in addition to the more typical memory–impaired amnestic subtype, and differences in 
underlying atrophy patterns may result in to diverse neuropsychiatric symptoms observed in 
AD. These subtypes may correspond to differing distributions of neurofibrillary tangles. 
Multiple lines of evidence suggest that deposition of abnormal Aβ alone does not result in 
memory impairments typical of AD. Instead, Aβ deposition may be a prequel for the 
development of neurofibrillary tangles which may be more strongly associated with 
cognition. The precise role of tau fibrillar Aβ is unknown, and the introduction of tau PET 
imaging in ADNI-3 is expected to shed light on the issue. Regional WM abnormalities, 
increased by vascular risk factors acting in conjunction with Aβ, may additionally augment 
the effects of tau abnormalities, accelerating the AD disease process.
Two diverse approaches attempted to integrate knowledge from disparate facets of AD 
research. The concept of AD as a disconnection syndrome was enabled by the inclusion of 
diffusion imaging and TF-fMRI in the ADNI-2 protocol to track perturbations to structural, 
functional, and metabolic, and cortical atrophy networks during AD progression. Network 
changes were observed in presymptom atic subjects and support the earliest pathological 
changes occurring in the posterior cingulate cortex, consistent with MRI studies of CN 
subjects in which initial atrophy was observed in areas outside the hippocampus, such as the 
precuneus. Models for the spread of pathology based on a prionlike misfolding of Aβ along 
WM tracts predicted patterns of cortical Aβ deposition, glucose hypometabolism, and 
atrophy. Likewise, a Systems Biology approach integrating genomics, transcriptomics, 
proteomics, and metabolomics has begun to capture the biological complexity of AD 
engendered in part by its polygenic nature. Biologically informed strategies have allowed 
insights into how genetic underpinnings of AD are associated with biochemical mechanisms. 
The search for the “missing heritability” of AD has identified novel risk alleles and 
highlighted the involvement of processes such as inflammation, synaptic function, cell 
migration, cholesterol metabolism, and calcium signaling.
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CN and MCI groups have proven to be highly heterogeneous; a sizeable portion of MCI 
subjects was virtually indistinguishable from CN subjects in all regards, and conversely, 
many CN subjects harbored pathology predictive of future clinical decline and were more 
aligned with the MCI group. This likely reflects the fact that MCI, even amnestic MCI, can 
be associated with a variety of pathologies, one of which is AD. It also implies that 
pathological events have already occurred in a portion of presymptomatic subjects. A group 
of MCI subjects with neurodegeneration in the absence of abnormal Aβ deposition appeared 
to be on a different pathway to dementia. The development of biomarkers of common 
comorbidities observed at autopsy such as Lewy bodies (α-SYN) and hippocampal sclerosis 
(TDP-43) will help future researchers to untangle the complex and seemingly intertwined 
trajectories to dementia.
Technological advances in machine learning such as the use of neural networks for feature 
selection have substantially improved the ability to discriminate between CN and MCI 
subjects, and MCI and AD subjects, and the ability to predict cognitive deterioration in CN 
and MCI subjects. Multimodal approaches to classification and prediction of future decline 
remain powerful, especially with the addition of new network connectivity measures or SNP 
data. However, the application of improved machine learning approaches to single 
modalities such as structural MRI has achieved accuracies rivaling state-of-the-art 
multimodal methods, and a cost-effective, widely available, and noninvasive approaches 
such as this may ultimately prove preferable for diagnosis.
Improvement of clinical trials of AD therapies, the overarching goal of the ADNI study, has 
been guided by a deeper understanding of AD progression and subject group heterogeneity. 
As AD therapies began to target presymptomatic patients, the choice of inclusion criteria 
that select subjects at risk of imminent decline, and outcome measures that are sufficiently 
sensitive to detect treatment effect within a feasible time frame is critical. Systematic studies 
have examined combinations of subject selection criteria such as APOE4 status, Aβ 
positivity, and hippocampal volume, together with cognitive and imaging outcome measures. 
Subject selection on the basis of a single pathology improves trial power; selection on the 
basis of multiple pathologies results in further gains in power. The sensitivity of cognitive 
end points to detect a subtle treatment effect in early phases of the disease has improved. 
However, surrogate outcome biomarkers such as longitudinal imaging have been predicted 
to significantly reduce sample sizes, trial duration, and trial cost and thus improve the 
feasibility of trials in presymptomatic subjects.
The remarkable advances described in ADNI papers over the course of 2 years have 
fundamentally altered our view of AD progression and offered significant guidance for 
clinical trial design. As the pace of discovery accelerates with the accumulation and sharing 
of an increasingly diverse longitudinal data set, ADNI will undoubtedly make even greater 
contributions to the field in the coming years.
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RESEARCH IN CONTEXT
1. Systematic review: The authors identified publications using data from the 
Alzheimer’s Disease Neuroimaging Initiative from their submission to the 
Data and Publications Committee, by traditional sources (PubMed and 
Google Scholar) and by personal communication with authors.
2. Interpretation: Substantial progress was made in 2014 and 2015 in improving 
biomarkers for clinical trials of Alzheimer’s disease (AD) therapies and the 
understanding of AD progression. Subtle structural and functional changes 
occur in presymptomatic subjects. Subjects positive for abnormal β-amyloid 
deposition progress according to the amyloid cascade hypothesis; other 
groups of mixed pathology may have different trajectories. Models of prion-
like spreading β-amyloid pathology along white-matter tracts predict aspects 
of disease progression and emphasize the importance of structural, functional, 
and metabolic connectivity in AD. A Systems Biology approach identified 
novel risk gene loci. Diagnostic and prognostic accuracies improved using 
deep learning strategies.
3. Future directions: This knowledge will inform and improve clinical trial 
design.
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Fig. 1. 
Applications for use of ADNI data, download activity, and the number of ADNI publications 
per year, 2006–2015. Abbreviation: ADNI, Alzheimer’s Disease Neuroimaging Initiative.
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Fig. 2. 
The correspondence among three measures of cognitive dysfunction in Alzheimer’s disease. 
Latent AD–related cognitive dysfunction was calculated using Item Response Theory 
methodologies estimated from ADAS-cog, MMSE, and CDR-SOB. Abbreviations: AD, 
Alzheimer’s disease; ADAS-cog, Alzheimer’s Disease Assessment Scale–cognitive 
subscale; CDR-SOB, Clinical Dementia Rating–Sum of Boxes; MMSE, Mini–Mental State 
Examination. Reproduced with permission from [21].
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Fig. 3. 
Steps followed to develop the European Alzheimer’s Disease Consortium–ADNI 
harmonized protocol for manual hippocampal segmentation (HarP). Reproduced with 
permission from [55].
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Fig. 4. 
Frequencies of different CSF and PET Aβ profiles in different diagnostic groups. Subjects 
were dichotomized by CSF Aβ42 or florbetapir PET and classified as concordant negative 
(CSF− PET−), discordant (CSF+ PET− and CSF− PET+), and concordant positive (CSF+ 
PET−). Abbreviations: AD, Alzheimer’s disease; CN, cognitively normal; CSF, 
cerebrospinal fluid; EMCI, early MCI; LMCI, late MCI; MCI, mild cognitive impairment; 
PET, positron emission tomography; SMC, subjective memory concern. Reproduced with 
permission from [141].
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Fig. 5. 
CSF ferritin independently predicts brain structural changes. (A–C) Longitudinal 
hippocampal volumetric changes based on tertiles of CSF: (A) ferritin, (B) ApoE, (C) tau/
Aβ42. (D–F) Longitudinal volumetric ventricular changes based on tertiles of CSF: (D) 
ferritin, (E) ApoE, (F) tau/Aβ42. Abbreviations: CN, cognitively normal; CSF, cerebrospinal 
fluid; H, highest tertile; M, middle tertile; MCI, mild cognitive impairment. Reproduced 
with permission from [152].
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Fig. 6. 
Word cloud of genes names reported in articles using ADNI genetic data. The color and size 
of the gene name corresponds to the number of abstracts mentioning the gene. Abbreviation: 
ADNI, Alzheimer’s Disease Neuroimaging Initiative. Reproduced with permission from 
[172].
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Fig. 7. 
Converging “multi-omics” in ADNI. This figure illustrates the landscape of multiple “-
omics” domains relevant to AD and how they contribute to an integrated Systems Biology 
approach to discovering the underlying genetic architecture of AD. *Data from ADNI-1. 
**Data from ADNI-GO/2. Abbreviations: AD, Alzheimer’s disease; ADNI, Alzheimer’s 
Disease Neuroimaging Initiative. Reproduced with permission from [171].
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Fig. 8. 
Sex-stratified FDG analyses. Analysis between APOE4 carriers and APOE4 noncarriers (P 
<.005 uncorrected) in (A) females and (B) males, covaried for age and years of education 
across the lateral and medial views of the cerebral cortex. As shown, female APOE4 carriers 
showed widespread clusters of decreased metabolism with respect to female APOE4 
noncarriers (A), whereas male APOE4 carriers only showed an isolated cluster of decreased 
metabolism (P <.005) in the precuneus with respect male noncarriers (B). Abbreviations: 
FDG, [18F]-fluorodeoxyglucose; APOE4, apolipoprotein E ε4 allele. Reproduced with 
permission from [179].
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Fig. 9. 
Significance maps displaying the associations between cortical Aβ binding (Pittsburgh 
compound B) and plasma ApoE protein. Plasma apoE levels were associated with Pittsburgh 
compound B SUVR in the pooled sample in all brain regions apart from the sensorimotor 
and entorhinal cortex (top panel). Plasma apoE levels were associated with Pittsburgh 
compound B SUVR in BIN1 rs 744373 minor allele carriers (second panel) and in CD2AP 
rs 9349407 and CR1 rs 38118361 minor allele noncarriers (third and fourth panel, 
respectively). Abbreviation: SUVR, standardized uptake value ratio. Reproduced with 
permission from [181].
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Fig. 10. 
Effect of interactions between CR1 or EPHA1 and cardiovascular disease risk factors on 
hippocampal volume. The estimated interaction effect on hippocampal volume for both risk 
genes is dominated by high cardiovascular disease risk. High genetic risk appears to reduce 
the interaction effect in the presence of high cardiovascular disease risk, suggesting that 
cardiovascular disease risk factors are more detrimental under low genetic risk. 
Abbreviations: CVD, cardiovascular risk; G, genetic risk. Reproduced with permission from 
[189].
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Fig. 11. 
The effects of APOE ε4 and rs509208 (BCHE) on cortical Aβ levels. The APOE ε4 allele 
and the minor allele (G) of rs509208 of BCHE exerted independent and additive effects on 
cortical Aβ burden. Bars represent mean cortical Aβ levels ± standard errors. Abbreviations: 
BCHE, butyrylcholinesterase; SUVR, standardized uptake value ratio. Reproduced with 
permission from [218].
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Fig. 12. 
Genome-wide CSF Aβ42 associations. GeneMANIA networks showing the interaction 
results of (A) associated genes and (B) highly associated genes. (C) Novel polymorphisms 
identified in study. Abbreviation: CSF, cerebrospinal fluid. Reproduced with permission 
from [219].
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Fig. 13. 
Association and the effect of ILRAP rs12053868-G on longitudinal change in cortical Aβ 
PET burden. The minor G allele of rs12053868 in ILRAP was associated with higher rates 
of amyloid accumulation compared to the major A allele. Mean annualized percent change 
and global cortical 18F-florbetapir SUVR ± standard error. Abbreviation: SUVR, 
standardized uptake value ratio. Reproduced with permission from [221].
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Fig. 14. 
Hypothetical signaling network integrating top genes identified through Rasch analysis. A 
Rasch model was applied to the genes of ADNI GWAS data and supports APOE as a major 
susceptibility gene for AD, and functionally links other top genes (AEN, ADANTS12, 
PSMA5, FXN, NTRN, LARP1, WDTC1, SEMA7A, VKORC1L1, COL5A3) to AD. A 
hypothetical signaling network was generated from a pathway analysis of these genes based 
on known proteinprotein, functional, and phenomenological interactions. Abbreviations: 
AD, Alzheimer’s disease; ADNI, Alzheimer’s Disease Neuroimaging Initiative; ARC, 
activity-regulated cytoskeleton-associated protein; EEF2K, eukaryotic elongation factor-2 
kinase, activated by GRM5 receptor, regulates global protein synthesis; HDAC3, histone 
deacetylase; MDM2, negative modulator of TP53 tumor suppression gene; PLXNC1, plexin 
C1 receptor for semaphorins; PTK2: FAK, kinase implicated in integrin signaling; FYN, src 
family tyrosine kinase, downstream target of GRM5 receptor; RPTOR, regulatory protein 
associated with MTORC1 complex. Reproduced with permission from [202].
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Fig. 15. 
Schematic outlining of the current understanding of the hypothetical timeline for the onset 
and progression of AD neurodegeneration and cognitive impairments. Age is indicated at the 
bottom, whereas the green, blue, and red bars indicate the time at which preventive, disease-
modifying, and symptomatic interventions, respectively, are likely to be most effective. 
Within the aqua bar, milestones are shown in the pathobiology of AD that culminate in death 
and autopsy confirmation of AD. The proposed ADNI model of the temporal ordering of 
biomarkers of AD pathology relative to stages in the clinical onset and progression of AD is 
shown in the insert at the upper right based on Jack et al. [258], whereas the insert at the left 
illustrates the defining plaque and tangle pathologies of AD and common comorbid 
pathologies including Lewy body pathology (SYN), TDP-43, and hippocampal sclerosis. In 
the insert on the right, clinical disease is on the horizontal axis and it is divided into three 
stages: CN, MCI, and dementia. The vertical axis indicates the range from normal to 
abnormal for each of the biomarkers and the measures of memory and functional 
impairments. Abbreviations: AD, Alzheimer’s disease; ADNI, Alzheimer’s Disease 
Neuroimaging Initiative; CN, cognitively normal; CSF, cerebrospinal fluid; FDG, [18F]-
fluorodeoxyglucose; MCI, mild cognitive impairment; MRI, magnetic resonance imaging; 
PET, positron emission tomography. Reproduced with permission from [129].
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Fig. 16. 
Model for Aβ status in disease progression. Illustrating the view of progression from 
presymptomatic Aβ negative to presymptomatic Aβ positive to MCI Aβ positive to AD Aβ 
positive as the primary pathway to AD, with the switch to Aβ positivity also occurring 
anywhere in the progression. A small percentage of clinically diagnosed AD patients lack 
Aβ pathology at autopsy. Abbreviations: AD, Alzheimer’s disease; MCI, mild cognitive 
impairment.
Weiner et al. Page 101
Alzheimers Dement. Author manuscript; available in PMC 2019 October 29.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 17. 
Differential trajectories of CSF biomarkers in Aβ+ and Aβ− subjects across disease 
progression. The means (±2 standard error of the mean) in ng/mL of (A) CSFAβ42; (B) CSF 
p-tau; (C) CSF p-tau181 are shown. In Aβ− groups, the levels of all three CSF biomarkers 
did not significantly increase across disease stage, whereas in Aβ+ subjects, CSF p-tau and 
t-tau, but not Aβ, increased across disease stages. Abbreviations: a-MCI, (advanced) mild 
cognitive impairment; Aβ+, subjects with abnormal brain Aβ; Aβ−, subjects without 
abnormal brain Aβ; CN, cognitively normal; CSF, cerebrospinal fluid; i-Dem, (incipient) 
dementia; iMCI, (incipient) mild cognitive impairment; m-Dem, (mild) dementia. 
Reproduced with permission from [261].
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Fig. 18. 
Hippocampal atrophy rate in Aβ+ and Aβ− CN and MCI subjects. The percentage of 
hippocampal atrophy rate attributable to Aβ status was calculated from the difference in 
hippocampal atrophy rate between Aβ+ and Aβ− subgroups. Aβ was measured using 
florbetapir PET. *P < .01, **P < .001, and ***P < .0001. Abbreviations: NC, normal 
cognition; MCI, mild cognitive impairment; PET, positron emission tomography. 
Reproduced with permission from [128].
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Fig. 19. 
Regions of Aβ-related atrophy ordered by acceleration and stabilization points. Regions, 
including the insula, posterior cingulate, amygdala, putamen, and precuneus, show early 
signs of atrophy before the hippocampus and entorhinal cortex. Parietal regions appear to 
have a shorter transition compared to temporal lobe regions with respect to Aβ. Red, yellow, 
and black dots represent significant (P <.05), marginally significant (.10 > P <.05), and 
nonsignificant (P >.10) acceleration or deceleration, respectively. Scale is pg/mL CSF Aβ42. 
Abbreviation: CSF, cerebrospinal fluid. Reproduced with permission from [266].
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Fig. 20. 
Hypometabolism originates earlier than atrophy in Aβ+ subjects. CN Aβ+ subjects 
displayed significant hypometabolism in medial parietal and bilateral parietal temporal 
regions compared to Aβ− subjects, whereas there was no difference in GM volume between 
these two groups, indicating that hypometabolism precedes atrophy in Aβ+ subjects (A) 
hypometabolism (red) and (B) atrophy (blue). Abbreviations: Aβ+, subjects with abnormal 
brain Aβ deposition; Aβ−, subjects without abnormal brain Aβ deposition; CN, cognitively 
normal; EMCI, early mild cognitive impairment; GM, gray matter; LMCI, late mild 
cognitive impairment. Reproduced with permission from [133].
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Fig. 21. 
Hippocampal volume and hypometabolism mediate the effect of Aβ on longitudinal change 
in Logical Memory Delayed Recall. Path analysis showing how hippocampal volume and 
angular FDG PET mediate the effect Aβ of on longitudinal change in Logical Memory 
delayed recall. (A) The direct effects of Aβ on memory; (B) hippocampal volume mediating 
the effects of Aβ on memory; (C) angular FDG PET mediating the effects of Aβ on 
memory; and (D) the combination of hippocampal volume and FDG PET mediating effects 
of Aβ on memory. The figure includes the following standardized regression coefficients: a, 
the effects of Aβ on hippocampal volume or FDG PET; b, the effects of hippocampal 
volume or FDG PET on the memory when adjusting for Aβ; c, the direct association 
Weiner et al. Page 106
Alzheimers Dement. Author manuscript; available in PMC 2019 October 29.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
between Aβ and memory (without adjusting for hippocampal volume or FDG PET); c′, the 
association between Aβ and memory when adjusting for hippocampal volume and/or FDG 
PET; and c-c′, the mediated effect on memory (with % mediation). *P < .05. Abbreviations: 
FDG, [18F]-fluorodeoxyglucose; PET, positron emission tomography. Reproduced with 
permission from [271].
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Fig. 22. 
Longitudinal changes in cognition in subtypes of Aβ+ cognitively normal subjects. 
Identified subtypes of cognitively normal subjects consisted of those with predominantly 
hippocampal atrophy, predominantly cortical atrophy, hippocampal and cortical atrophy 
combined, or neither type of atrophy. Baseline, 1-year, and 2-year follow-up data on (A) 
MMSE indicating global cognition, (B) ADNI-Mem indicating memory function, and (C) 
ADNI-EF indicating executive function are plotted, with means and standard errors. 
Abbreviations: ADNI, Alzheimer’s Disease Neuroimaging Initiative; BI, both impaired; BS, 
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both spared; CA, cortical atrophy only; EF, executive function; HA, hippocampal atrophy 
only; Mem, memory domain; MMSE, Mini–Mental State Examination. Reproduced with 
permission from [272].
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Fig. 23. 
Heterogeneity of the subjective memory concern cohort. Cluster analysis identified three 
distinct subgroups in both the normal cognition (NC) and subjective memory concern 
(SMC) groups. The first subgroup (1) had elevated brain amyloid, decreased CSF Aβ, and 
substantially reduced hippocampal volume; the second subgroup (2) was similar to group 1 
but with less hippocampal atrophy and was thought to correspond to the Jack sequence for 
early signs of AD, and the third group (3) was normal by all measures. Abbreviations: AD, 
Alzheimer’s disease; CSF, cerebrospinal fluid; ICV, intracranial volume; SUVR, 
standardized uptake value ratio. Reproduced with permission from [259].
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Fig. 24. 
Biomarker abnormality in A− N−, A+ N−, SNAP, and A+ N+ MCI patient groups, 
disaggregated by progressive cognitive deterioration. MCI subjects were grouped on the 
basis of absence or presence of abnormal levels of amyloid and neurodegeneration. SNAP 
subjects were neurodegeneration positive but amyloid negative. All four groups significantly 
differed in CSF Aβ42 concentrations, hypometabolism on FDG PET, and hippocampal 
volume. SNAP subjects were characterized by more severe hippocampal atrophy than other 
groups in the absence of abnormal amyloid. Triangles denote progressors, whereas circles 
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denote nonprogressors. Abbreviations: AD, Alzheimer’s disease; A− N−, amyloid negative 
neurodegeneration negative; A+ N−, amyloid positive neurodegeneration negative; A+ N+, 
amyloid positive neurodegeneration positive; CSF, cerebrospinal fluid; FDG, [18F]-
fluorodeoxyglucose; MCI, mild cognitive impairment; PET, positron emission tomography; 
SNAP, suspected non-Alzheimer’s pathology. Reproduced with permission from [291].
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Fig. 25. 
Effect of interaction of smoking history and APOE ε4 genotype on amyloid level and 
hypometabolism. ADNI participants were grouped on the basis of smoking history and 
APOE4 status. Smoking status interacted with APOE ε4 carrier status such that APOE4 
smokers had higher levels of amyloid and worse hypometabolism than other groups. (A) 
Florbetapir retention level across groups. Higher values indicate greater Aβ level. Levels 
above the horizontal line indicate Aβ positivity. Mean ± standard error of the mean. (B) 
Composite glucose uptake level across groups. Higher values indicate greater glucose 
metabolism. Mean ± standard error of the mean. Abbreviations: ADNI, Alzheimer’s Disease 
Neuroimaging Initiative; FDG, [18F]-fluorodeoxyglucose; SUVR, standardized uptake value 
ratio. Reproduced with permission from [302].
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Fig. 26. 
The effect of stroke risk on hippocampal volume and memory performance in Aβ-positive 
and Aβ-negative subjects. Stroke risk, assessed by the Framingham Stroke Risk Profile, was 
associated with decreased baseline hippocampal volume and decreased memory 
performance in both Aβ+ and Aβ− subjects. Worst performance on both measurements was 
observed in subjects with both abnormal amyloid and high stroke risk. Error bars represent 
95% confidence intervals. Abbreviations: ADNI-MEM, Alzheimer’s Disease Neuroimaging 
Initiative–memory domain; CSF, cerebrospinal fluid; ICV, intracranial volume. Reproduced 
with permission from [306].
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Fig. 27. 
Cumulative survival of individuals based on their high entorhinal cortex volume (ECV) and 
level of white-matter hyperintensities (WMHs). ADNI MCI subjects were dichotomized 
according to the median split of their ECV and levels of WMH. Individuals with high ECV 
and low WMH had low likelihood of rapid decline, whereas subjects with low ECV and low 
WMH or low ECV and high WMH appear to progress most rapidly. Solid line indicates high 
ECV, low WMH; dashed line indicates high ECV, high WMH; dotted line indicates low 
ECV, low WMH; dash-dotted line indicates low ECV, high WMH. Abbreviations: ADNI, 
Alzheimer’s Disease Neuroimaging Initiative; MCI, mild cognitive impairment. Reproduced 
with permission from [297].
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Fig. 28. 
The effect of hypertension and Aβ status on estimated trends of white-matter 
hyperintensities (WMHs) volume as a function of age. WMH volumes were predicted for 
the population average intracranial volume by age, exposure to elevated blood pressure, and 
CSF Aβ42 burden. High blood pressure increases WMH over time in both Aβ+ and Aβ− 
subjects, but the greatest effect in Aβ+ subjects. Abbreviation: CSF, cerebrospinal fluid. 
Reproduced with permission from [300].
Weiner et al. Page 116
Alzheimers Dement. Author manuscript; available in PMC 2019 October 29.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 29. 
Conceptual model linking white-matter hyperintensities to clinical progression of AD. 
Regional white-matter hyperintensities (WMHs) affect tau directly (a), affect regional 
atrophy and clinical progression directly (b), and modify the effect of tau on disease 
progression (c). The interaction between regional WMHs and Aβ has yet to be elucidated. 
Abbreviation: AD, Alzheimer’s disease. Reproduced with permission from [313].
Weiner et al. Page 117
Alzheimers Dement. Author manuscript; available in PMC 2019 October 29.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 30. 
Visualization of neuronal fibers touching limbic system ROIs in typical early MCI (left) and 
late MCI (right) patients. Abbreviation: MCI, mild cognitive impairment. Reproduced with 
permission from [326].
Weiner et al. Page 118
Alzheimers Dement. Author manuscript; available in PMC 2019 October 29.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 31. 
Average brain networks showing common connections at 90% of healthy controls (CN), 
MCI, and AD participants at k = 20 nodal degree threshold. Although individual connections 
(red edges) erode with disease progression, centrally positioned hubs (light blue nodes) are 
preserved in diagnostic groups. These hubs are in the superior frontal (SF), insula (I), 
posterior cingulate (PC), precuneus (P), and superior parietal cingulate regions (SP). 
Abbreviations: AD, Alzheimer’s disease; MCI, mild cognitive impairment. Reproduced with 
permission from [328].
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Fig. 32. 
Overview of intrinsic connectivity networks. The figure shows standardized maps of seven 
intrinsic conductivity networks projected on the cortical surface and a midsagittal section of 
the reference template. This map estimates the functional conductivity architecture of the 
human cerebral cortex based on resting state functional conductivity projected on the 
cortical surface and a midsagittal section of the reference template. Abbreviations: blue, 
limbic network; cyan, somatomotor network; green, dorsal attention network; pink, ventral 
attention network; purple, visual network; red, default mode network; yellow, frontoparietal-
control network. Reproduced with permission from [335].
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Fig. 33. 
Severity of AD-related imaging abnormalities within intrinsic connectivity networks. Plots 
depict means and 95% confidence intervals of averaged Z scores of Aβ deposition (top), 
hypometabolism (middle), and gray-matter atrophy (bottom) within the distinct intrinsic 
connectivity networks for each AD stage. The widespread distribution of amyloid deposition 
across the cerebral cortex appeared similar in all patient groups with highest amyloid load in 
the DMN and FPN. Hypometabolism was most pronounced in the AD group and occurred 
across most ICNs except the VIS and SMN. Likewise, atrophy was most pronounced in the 
AD group, which displayed a different relative pattern of atrophy severity across ICNs with 
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atrophy most pronounced in the LIN followed by the DMN and relative sparing of the FPN. 
Abbreviations: blue, limbic network (LIN); cyan, somatomotor network (SMN); green, 
dorsal attention network (DAN); pink, ventral attention network (VAN); purple, visual 
network (VIS); red, default mode network (DMN); yellow, frontal parietal control network 
(FTN); AD, Alzheimer’s disease; CN, cognitively normal; EMCI, early mild cognitive 
impairment; LMCI, late mild cognitive impairment. Reproduced with permission from 
[335].
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Fig. 34. 
Subsystems of the default mode network. Nodes within the default mode network segregate 
into distinct subsystems. Abbreviations: aMPFC, anterior or medial prefrontal cortex; blue: 
dorsal medial prefrontal cortex system; dMPFC, dorsal medial prefrontal cortex; green, 
medial temporal lobe memory system; yellow, midline core regions; PCC, posterior 
cingulate cortex; Rsp, retrosplenial cingulate. Reproduced with permission from [336].
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Fig. 35. 
Schematic of the proposed cascading network failure model of Alzheimer’s disease. Phase 
0: The posterior DMN (pDMN) serves as the central hub processing and integrating 
association cortices and is highly metabolically active. Independently, the medial temporal 
lobe (MTL) has accumulated age-related damage from neocortical processing of a different 
kind contributing to primary age-related tauopathy (PART) in these regions. Phase 1: 
Declining posterior DMN transfers information-processing duties to the neocortical regions 
including the ventral DMN and/or the anterior dorsal DMN. Aberrant betweenneocortical 
network synaptic activity leads to dysregulated amyloid precursor protein (APP) processing 
promoting Aβ plaque formation in neocortical layers. Phase 2: Given that the hippocampus 
is continually processing information from the same regions, noise in these cortical systems 
is propagated down to the hippocampus. This increased burden on the hippocampus 
accelerates the preexisting PART. Phase 3: Neurodegeneration expands to adjacent systems. 
This creates a detrimental positive feedback loop because degeneration lowers the noise-
handling capacity of the system leading to further degeneration. MCI phase: Posterior brain 
regions supporting memory succumb to the degenerative feedback loop as hippocampal 
regions increases processing. Later, the frontal brain regions begin to bear the high 
connectivity burden. Early Alzheimer’s disease phase: The high frontal connectivity firmly 
establishes the neurodegenerative feedback loop in these systems before declining as 
Alzheimer’s disease progresses. Abbreviations: DMN, default mode network; MCI, mild 
cognitive impairment. Reproduced with permission from [336].
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Fig. 36. 
Characteristic regional Aβ deposition patterns in healthy and pathological brains. An 
epidemic spreading model that predicts propagation/deposition of Aβ reproduces the 
characteristic Aβ deposition patterns in the ADNI cohort. (A) PET-based mean regional Aβ 
deposition probabilities in cognitively normal healthy controls (HC), early MCI (EMCI), 
late MCI (LMCI), and AD groups. Nodes correspond to 78 regions covering all the brains 
gray matter, with node sizes proportional to the associated Aβ burden. The progressive 
expansion of Aβ deposition starts mainly from the DMN regions and expands to the rest of 
the brain. (B) Correspondence between the estimated and PET-based mean regional Aβ 
deposition probabilities for the different clinical groups. Abbreviations: AD, Alzheimer’s 
disease; ADNI, Alzheimer’s Disease Neuroimaging Initiative; DMN, default mode network; 
MCI, mild cognitive impairment; PET, positron emission tomography. Reproduced with 
permission from [346].
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Fig. 37. 
Patterns of decline of the different classes of markers. The greatest effect sizes for MCI 
converters were for functional measures (Functional Activities Questionnaire [FAQ]) and for 
cognitive measures such as the ADAS-cog. Effect sizes for volumetric and CSF biomarker 
measures were much smaller. Panel 1: effect sizes for the difference in cognitive and 
functional measures between baseline and each one of the follow-ups from months 12–48: 
(A) MCI converters, (B) stable MCI. Panel 2: effect sizes in MRI morphometry, FDG PET 
HCI, and CSF biomarkers between baseline and months 12–36 follow-ups: (C) MCI 
converters, (D) stable MCI. Abbreviations: ADAS-cog, Alzheimer’s Disease Assessment 
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Scale–cognitive; CSF, cerebrospinal fluid; FDG, [18F]-fluorodeoxyglucose; HCI, hyperbolic 
convergence index; MCI, mild cognitive impairment; MRI, magnetic resonance imaging; 
PET, positron emission tomography. Reproduced with permission from [354].
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Fig. 38. 
Observed versus predicted progression from amnestic MCI to AD over 3 years by Brief 
Clinical Index point score. The solid line shows the proportion of subjects predicted to 
progress from amnestic MCI to AD over 3 years as a function of the Brief Clinical Index 
point score. The dotted line shows the actual proportions that progressed at each point score 
value based on 3-year Kaplan-Meier estimates. The vertical bars showed the number of 
individuals at each point score value (right vertical axis). Abbreviations: AD, Alzheimer’s 
disease; MCI, mild cognitive impairment. Reproduced with permission from [360].
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Fig. 39. 
Associations between 249 variables shown by a circular visualization of correlation plot. 
Data from 928 patients with mild cognitive impairment were used to produce a network 
visualization of the complex relationships between and within variables in ADNI. Lines 
represent the Spearman rank correlation coefficient |(r)| = .3 between two variables. 1—sex, 
2—years education, 3—age, 4—MMSE, 5—ADAS total score, 6—ADAS modified, 7—
CDR composite score, 8—CDR-SOB composite score, 9—FAQ, 10—GDS, 11—Hachinski 
Ischemic Scale score, 12—NIQ total score, 13—brain volume, 14—intracranial volume, 15
—ventricular volume, 16—hippocampal volume, 17—inferior lateral ventricular volume, 18
—middle temporal volume, 19—inferior temporal volume, 20—fusiform cortical volume, 
21—entorhinal cortex volume, 22—APOE4 carrier, 23—no. of APOE4 alleles, 24—
TOMM40 polyT allele one, 25—TOMM40 polyT allele 2, 26—8-Iso-PGF, 27—8,12-iso-
IPFa, 28—CSF white blood cell count, 29—CSF red blood cell count, 30—CSF total 
protein concentration, 31—CSF glucose level, 32—total plasma homocysteine level, 33—
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plasma Aβ40 level, 34—plasma Aβ42 level, 35—plasma Aβ40:AB42 ratio, 36—CSF Aβ42 
level, 37—CSF t-tau level, 39—CSF Aβ42:t-tau ratio, 40—CSF Aβ42-p-tau ratio, 41—CSF 
p-tau:t-tau ratio, 42 to 115—74 CSF analytes measured by multiplex assay, 116 to 249—
hundred and 34 plasma analytes measured by multiplex assay. Abbreviations: ADAS, 
Alzheimer’s Disease Assessment Scale; ADNI, Alzheimer’s Disease Neuroimaging 
Initiative; CDR-SOB, Clinical Dementia Rating–Sum of Boxes; CSF, cerebrospinal fluid; 
FAQ, Functional Activities Questionnaire; MMSE, Mini–Mental State Examination. 
Reproduced with permission from [425].
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Fig. 40. 
Prediction of progression from mild cognitive impairment to Alzheimer’s disease within 3 
years. Markers in plasma or CSF predicted progression with a relatively high sensitivity 
compared to standard AD CSF biomarkers, regional MRI volumes, or cognitive scores. 
Prediction includes seven models combining different subsets of variables. Correct 
classification rate of the top 20 variables was estimated on the test data set after 1000-fold 
resampling of the learning and test data sets. Sex and age were included in all models. 
APOE4 indicates apolipoprotein ε4. Abbreviations: AD, Alzheimer’s disease; CSF, 
cerebrospinal fluid; MRI, magnetic resonance imaging. Reproduced with permission from 
[425].
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Fig. 41. 
Nonlinear disease progression model capturing longitudinal Clinical Dementia Rating–Sum 
of Boxes (CDR-SB) scores. Visual predictive check simulations suggest that the model 
describes longitudinal progression of CDR-SB scores in both late MCI and mild AD 
subjects. Stratification using p-tau181/Aβ42 ratio reveals a lack of disease progression in 
biomarker negative subgroups. The upper, middle, and lower profiles indicated by the open 
circles represent the 95th, 50th, and 5th percentiles of the observed data, respectively. The 
upper, middle, and lower curves indicated by the lines are the median model–based 
predictions for the 95th, 50th, and 5th percentiles, respectively. The shaded areas are the 
90% confidence intervals of the corresponding percentiles of the simulations based on the 
model. Abbreviations: AD, Alzheimer’s disease; LMCI, late MCI; MCI, mild cognitive 
impairment. Reproduced with permission from [459].
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Fig. 42. 
Implications of hippocampal volume–based enrichment for clinical trials of amnestic MCI 
subjects. Estimates of trial costs and total duration for scenarios in which patients are 
enriched or not enriched with hippocampal volume are given for different outcome 
measures. (A–C) Trial cost and (D–F) trial execution time, as a function of cut point for (A 
and D) MMSE, (B and E) ADAS-cog, and (C and F) CDR-SB. Results are expressed as 
fractions of the unenriched scenario and are shown for four different hippocampal volume 
computational algorithms. Variance due to test-retest variability is shown as the shaded area 
for one of the four algorithms (LEAP). Abbreviations: ADAS-cog, Alzheimer’s Disease 
Assessment Scale–cognitive; CDR-SB, Clinical Dementia Rating–Sum of Boxes; MCI, mild 
cognitive impairment; MMSE, Mini–Mental State Examination. Reproduced with 
permission from [470].
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Fig. 43. 
Ability of cognitive end points to detect change in cognitively normal subjects selected for 
multiple pathologies. Composite cognitive tests were more able to capture decline in 
cognitively normal (CN) subjects over 7 years than any measure of a single cognitive 
domain or ADAS-cog alone. Enrichment with three or more pathologies optimally enhanced 
this effect. Groups with 0, 1, 2, or 3+ pathologies (APOE4, Aβ+, tau+, or hippocampal 
atrophy1) plotted for each standardized cognitive measure with 7 years of follow-up. 
Composite #1: ADAS-11, Trails B, and Logical Memory II. Composite #2: ADAS-11, Trails 
B, and dALVT. Abbreviations: ADAS, Alzheimer’s Disease Assessment Scale; ADAS-cog, 
Alzheimer’s Disease Assessment Scale–cognitive; dAVLT, delayed Rey Auditory Verbal 
Learning Test. Reproduced with permission from [478].
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Fig. 44. 
The effect of clinical trial enrichment using APOE4 status or brain Aβ load. After screening 
participants for APOE4 status or brain Aβ load, sample size requirements are around 100 
subjects for a 2-year trial. Sample size estimates (n80s) after trial enrichment using APOE4 
status (A), brain Aβ load at screening (B), or both combined (C). Abbreviations: AD, 
Alzheimer’s disease; CN, cognitively normal; EMCI, early mild cognitive impairment; 
LMCI, late mild cognitive impairment. Reproduced with permission from [479].
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 an
d 
a s
pe
ci
fic
ity
 o
f 9
0%
 
in
 th
e 
cl
as
sif
ic
at
io
n 
of
 A
D
 v
er
su
s 
N
C 
us
in
g 
hi
pp
oc
am
pa
l s
ha
pe
s.
[7
0]
Pr
es
en
t a
 m
et
ho
d 
us
in
g 
lin
ea
r r
eg
ist
ra
tio
n 
of
 b
ra
in
 im
ag
es
 to
 a
 st
an
da
rd
 te
m
pl
at
e,
 fe
at
ur
e 
ex
tr
ac
tio
n,
 a
nd
 v
o
x
el
 c
la
ss
ifi
ca
tio
n 
us
in
g 
a 
ra
nd
om
 F
o
re
st
 a
lg
or
ith
m
 to
 
de
te
rm
in
e 
w
he
th
er
 v
o
x
el
s b
el
on
g 
to
 th
e 
hi
pp
oc
am
pu
s o
r n
ot
. O
ut
pe
rfo
rm
ed
 F
re
eS
ur
fe
r.
[7
1]
Co
ns
tru
ct
ed
 a
 h
ig
h-
re
so
lu
tio
n 
at
la
s f
ro
m
 m
an
ua
lly
 se
gm
en
te
d 
hi
pp
oc
am
pa
l s
ub
str
uc
tu
re
s w
hi
ch
 in
cl
ud
ed
 m
an
ua
l a
nn
ot
at
io
ns
 fo
r n
ei
gh
bo
rin
g 
str
uc
tu
re
s. 
Th
e 
at
la
s, 
re
le
as
ed
 a
s p
ar
t o
f F
re
eS
ur
fe
r (
ve
rs
io
n 
6.
0),
 ou
tpe
rfo
rm
s t
he
 at
las
 an
d F
ree
Su
rfe
r v
er
sio
n 
5.
3.
[7
2]
Co
m
bi
ne
d 
th
at
 th
e 
us
e 
of
 F
re
eS
er
ve
r,
 
FI
R
ST
,
 
an
d 
SP
H
A
RM
 so
ftw
ar
e 
pa
ck
ag
es
 to
 c
re
at
e 
an
 a
tla
s b
y 
m
ap
pi
ng
 in
te
rp
ol
at
ed
 su
bf
ie
ld
s a
ut
om
at
io
n 
on
to
 th
e 
av
er
ag
e 
su
rfa
ce
. 
A
tla
s h
as
 g
oo
d 
re
pr
od
uc
ib
ili
ty
 u
sin
g 
A
D
N
I d
at
a.
[7
3]
 
A
ut
om
at
ed
 
hi
pp
oc
am
pa
l 
se
gm
en
ta
tio
n 
fo
r 
cl
in
ic
al
 u
se
U
se
s a
 fu
lly
 a
ut
om
at
ed
 m
ul
ti-
at
la
s s
eg
m
en
ta
tio
n.
 F
o
u
n
d 
a 
hi
gh
 D
ic
e 
Si
m
ila
rit
y 
Co
ef
fic
ie
nt
 w
ith
 m
an
ua
l s
eg
m
en
ta
tio
n.
 S
ug
ge
sts
 th
at
 N
eu
ro
Re
ad
er
 c
ou
ld
 h
av
e 
cl
in
ic
al
 a
pp
lic
at
io
ns
.
[7
4]
Pr
es
en
t a
 fu
lly
 a
ut
om
at
ed
 p
ip
el
in
e 
us
in
g 
an
 a
ffi
ne
 re
gi
str
at
io
n 
ste
p 
an
d 
cl
as
sif
ic
at
io
n 
of
 v
o
x
el
s u
sin
g 
a 
Ra
nd
om
 F
o
re
st
 c
la
ss
ifi
er
.
 
Cl
as
sif
ic
at
io
n 
w
as
 p
er
fo
rm
ed
 sl
ic
e 
by
 sl
ic
e 
al
on
g 
ea
ch
 o
f t
hr
ee
 o
rth
og
on
al
 d
ire
ct
io
ns
 a
nd
 a
ch
ie
v
ed
 c
om
pa
ra
bl
e 
re
su
lts
 to
 m
an
ua
l s
eg
m
en
ta
tio
n.
[7
5]
Pr
es
en
t a
 fu
lly
 a
ut
om
at
ed
 p
ip
el
in
e 
w
hi
ch
 is
 a
tla
s b
as
ed
 a
nd
 u
se
s S
ta
tis
tic
al
 P
ar
am
et
ric
 M
ap
pi
ng
 (S
PM
) s
oft
wa
re
. 
Th
e 
au
to
m
at
ed
 p
ip
el
in
e 
w
as
 c
o
m
pu
ta
tio
na
lly
 
in
ex
pe
ns
iv
e,
 a
cc
u
ra
te
, a
nd
 is
 fr
ee
ly
 av
ai
la
bl
e 
as
 a
n 
SP
M
8 
to
ol
bo
x.
[7
6]
 
D
ev
el
op
m
en
t o
f a
 
ro
bu
st
 h
ip
po
ca
m
pa
l 
at
ro
ph
y 
bi
om
ar
ke
r
D
es
cr
ib
e 
de
v
el
op
m
en
t o
f a
 lo
ng
itu
di
na
l h
ip
po
ca
m
pa
l a
tro
ph
y 
bi
om
ar
ke
r 
w
hi
ch
 is
 n
ot
 c
on
fo
un
de
d 
by
 fa
ct
or
s 
su
ch
 a
s a
cq
ui
sit
io
n 
no
ise
 o
r a
rti
fa
ct
s,
 a
nd
 p
hy
sio
lo
gi
ca
l 
v
ar
ia
tio
ns
. B
io
m
ar
ke
r 
de
te
ct
s h
ip
po
ca
m
pa
l a
tro
ph
y 
du
e 
to
 d
ise
as
e 
an
d 
no
t t
o 
ot
he
r f
ac
to
rs
 s
uc
h 
as
 lo
ng
-te
rm
 a
gi
ng
. I
n 
co
m
bi
na
tio
n 
w
ith
 b
as
el
in
e 
vo
lu
m
es
, t
he
 
m
et
ho
d 
w
as
 h
ig
hl
y 
ac
cu
ra
te
 in
 d
isc
rim
in
at
in
g 
pa
tie
nt
 g
ro
up
s.
[7
7]
 
Pa
tc
h 
la
be
l f
us
io
n
Pr
op
os
ed
 a
 n
ov
el
 p
at
ch
-b
as
ed
 la
be
ls 
fu
sio
n 
m
et
ho
d 
th
at
 c
om
bi
ne
s t
he
 tw
o
 a
pp
ro
ac
he
s v
ia
 m
at
rix
 c
om
pl
et
io
n.
 T
he
 m
et
ho
d 
re
su
lts
 in
 m
or
e 
ac
cu
ra
te
 se
gm
en
ta
tio
n 
th
an
 e
ith
er
 w
ith
 th
e 
re
co
ns
tru
ct
io
n-
ba
se
d 
or
 th
e 
cl
as
sif
ic
at
io
n-
ba
se
d 
ap
pr
oa
ch
es
.
[7
8]
Pr
es
en
t a
 n
ov
el
 p
at
ch
-b
as
ed
 la
be
l f
us
io
n 
fra
m
ew
o
rk
 th
at
 u
se
s a
n 
op
tim
iz
ed
 P
at
ch
M
at
ch
 L
ab
el
 F
us
io
n 
(O
PA
L)
 st
rat
eg
y.
 
O
PA
L 
pr
od
uc
ed
 a
 se
gm
en
ta
tio
n 
ac
cu
ra
cy
 
hi
gh
ly
 c
or
re
la
te
d 
w
ith
 m
an
ua
l s
eg
m
en
ta
tio
n.
[7
9]
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C
ha
lle
ng
e
A
pp
ro
a
ch
 a
nd
 re
su
lts
R
ef
er
en
ce
In
tro
du
ce
 th
re
e 
ne
w
 la
be
l f
us
io
n 
co
nt
rib
u
tio
ns
: (
1) 
the
 fe
atu
re 
rep
res
en
tat
ion
 fo
r e
ac
h i
ma
ge
 pa
tch
 en
co
de
s l
oc
al 
inf
orm
ati
on
; (
2) 
ea
ch
 at
las
 im
ag
e p
atc
h i
s f
urt
he
r 
pa
rti
tio
ne
d 
in
to
 p
ar
tia
l i
m
ag
e 
pa
tc
he
s; 
(3)
 la
be
l f
us
ion
 is
 im
pro
v
ed
 w
ith
 a
 h
ie
ra
rc
hi
ca
l a
pp
ro
ac
h.
 T
he
 im
pr
ov
em
en
ts
 p
ro
po
se
d 
re
su
lte
d 
in
 im
pr
ov
ed
 a
cc
ur
ac
y 
of
 
se
gm
en
ta
tio
n.
[8
0]
A
bb
re
v
ia
tio
ns
: A
D
, A
lz
he
im
er
’s
 d
ise
as
e;
 N
C,
 n
or
m
al
 c
og
ni
tio
n;
 A
D
N
I, 
A
lz
he
im
er
’s
 D
ise
as
e 
N
eu
ro
im
ag
in
g 
In
iti
at
iv
e.
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Ta
bl
e 
3
A
pp
ro
ac
he
s f
or
 th
e 
im
pr
ov
em
en
t o
f M
RI
 m
et
ho
do
lo
gy
C
ha
lle
ng
e
A
pp
ro
a
ch
 a
nd
 re
su
lts
R
ef
er
en
ce
Im
ag
e 
ac
qu
isi
tio
n
 
Ev
al
ua
te
 m
ea
su
re
m
en
t p
ro
pe
rti
es
 o
f t
he
 
B
ra
in
 A
tro
ph
y 
an
d 
Le
sio
n 
In
de
x
 (B
A
LI
) 
[1
18
] a
t 1
.5-
T 
an
d 3
-T
M
RI
.
Co
m
pa
re
d 
T1
- a
nd
 T
2-
w
ei
gh
te
d 
im
ag
in
g 
at
 d
iff
er
en
t f
ie
ld
 st
re
ng
th
s f
or
 th
ei
r a
bi
lit
y 
to
 c
or
re
ct
ly
 d
ia
gn
os
e 
pa
tie
nt
 g
ro
up
s. 
Fo
u
n
d 
th
at
 1
.5
-T
 
BA
LI
 sc
or
es
 w
er
e 
sim
ila
r t
o 
th
os
e 
ob
ta
in
ed
 u
sin
g 
3-
T 
im
ag
es
.
[8
1]
 
Co
m
pa
re
 1
.5
-T
 an
d 
3-
T 
M
RI
 fo
r 
au
to
m
at
ed
 h
ip
po
ca
m
pa
l s
eg
m
en
ta
tio
n
Co
m
pa
re
d 
th
e 
ab
ili
ty
 o
f b
as
el
in
e 
M
RI
 d
at
a 
of
 p
at
ie
nt
s s
ca
nn
ed
 a
t b
ot
h 
1.
5 
T 
an
d 
3 
T 
to
 m
ak
e 
a 
cl
in
ic
al
 d
ia
gn
os
is 
ba
se
d 
on
 h
ip
po
ca
m
pa
l r
ad
ia
l 
di
sta
nc
e.
 F
o
u
n
d 
th
at
 b
ot
h 
fie
ld
 st
re
ng
th
s y
ie
ld
ed
 c
om
pa
ra
bl
e 
hi
pp
oc
am
pa
l a
tro
ph
y 
pa
tte
rn
s b
u
t t
ha
t 3
 T
 h
ad
 a
 su
pe
rio
r s
ig
na
l-t
o-
no
ise
 ra
tio
 a
nd
 
ab
ili
ty
 to
 d
et
ec
t a
tro
ph
y.
[8
2]
 
Ef
fe
ct
 o
f 1
.5
-T
 v
er
su
s 
3-
T 
fie
ld
 
st
re
ng
th
s a
nd
 im
ag
e 
re
gi
str
at
io
n 
str
at
eg
y 
o
n
 V
BM
Te
st
ed
 d
iff
er
en
t d
iff
eo
m
or
ph
ic
 sp
at
ia
l r
eg
ist
ra
tio
n 
str
at
eg
ie
s o
v
er
 tw
o
 fi
el
d 
str
en
gt
hs
 fo
r t
he
ir 
ab
ili
ty
 to
 d
et
ec
t A
D
-re
la
te
d 
at
ro
ph
y.
 
R
eg
ist
ra
tio
n 
st
ra
te
gy
 a
ffe
ct
ed
 th
e 
es
tim
at
io
n 
of
 A
D
-re
la
te
d 
at
ro
ph
y,
 
w
he
re
as
 fi
el
d 
str
en
gt
hs
 a
ffe
ct
ed
 a
ss
es
sm
en
t o
f b
ra
in
 a
na
to
m
y 
in
 th
e 
ce
re
be
llu
m
, t
he
 
pr
ec
en
tra
l g
yr
us
, a
nd
 th
e 
th
al
am
us
 b
ila
te
ra
lly
.
[8
3]
 
Ch
an
ge
 in
 3
.0
-T
 M
RI
 im
ag
e 
ac
qu
isi
tio
n 
sc
he
m
e 
be
tw
ee
n 
A
D
N
I-1
 a
nd
 su
bs
eq
ue
nt
 
gr
an
ts
U
se
d 
vo
x
el
-b
as
ed
 m
or
ph
om
et
ry
 to
 c
om
pa
re
 3
.0
-T
 T
l-w
ei
gh
te
d 
vo
lu
m
es
 o
bt
ai
ne
d 
in
 A
D
N
I-1
 a
nd
 A
D
N
I-2
. T
he
 p
ro
to
co
l u
se
d 
in
 A
D
N
I-2
 
re
su
lte
d 
in
 in
cr
ea
se
d 
gr
ay
 m
at
te
r a
nd
 lo
ca
liz
ed
 d
ec
re
as
es
 in
 w
hi
te
 m
at
te
r c
om
pa
re
d 
to
 A
D
N
I-1
 im
ag
es
 a
nd
 th
e 
to
ta
l v
o
lu
m
es
 o
f g
ra
y 
m
at
te
r, 
w
hi
te
 m
at
te
r, 
an
d 
ce
re
br
os
pi
na
l f
lu
id
 a
lso
 d
iff
er
ed
. T
he
se
 re
su
lts
 sh
ou
ld
 b
e 
co
ns
id
er
ed
 w
he
n 
co
m
pa
rin
g 
im
ag
es
 o
bt
ai
ne
d 
du
rin
g 
th
es
e 
tw
o
 
pr
ot
oc
ol
s u
sin
g 
V
BM
.
[8
4]
 
A
na
ly
zi
ng
 th
e 
ef
fe
ct
 o
f g
eo
m
et
ric
 
di
sto
rti
on
s o
n 
di
ffe
re
nt
 sc
an
ne
r/p
ro
to
co
l 
co
m
bi
na
tio
ns
.
U
se
d 
th
e 
A
D
N
I p
ha
nt
om
 to
 m
ea
su
re
 M
RI
 im
ag
e 
di
sto
rti
on
. F
o
u
n
d 
th
at
 th
e 
siz
e 
of
 d
ist
or
tio
n 
fie
ld
 v
ar
ie
d 
be
tw
ee
n 
sc
an
ne
rs
 a
nd
 p
ro
to
co
ls 
bu
t 
th
at
 c
or
re
ct
io
ns
 a
pp
lie
d 
re
du
ce
d 
di
sto
rti
on
 to
 1
 m
m
 o
r l
es
s.
[8
5]
Pr
ep
ro
ce
ss
in
g
 
D
iff
er
en
t a
pp
ro
ac
he
s f
or
 th
e 
n
o
rm
al
iz
at
io
n 
of
 re
gi
on
al
 v
o
lu
m
es
 b
y 
in
tra
cr
an
ia
l v
o
lu
m
e 
(IC
V)
 m
ay
 in
flu
en
ce
 
th
e 
re
la
tio
ns
hi
p 
be
tw
ee
n 
hi
pp
oc
am
pu
s a
nd
 
co
gn
iti
on
.
Te
st
ed
 th
e 
ef
fe
ct
 o
f t
he
 th
re
e 
m
et
ho
ds
: r
aw
 v
o
lu
m
es
, v
o
lu
m
e 
to
 IC
V
 fr
ac
tio
ns
, o
r r
eg
io
na
l v
o
lu
m
es
, o
n 
th
e 
re
la
tio
ns
hi
p 
be
tw
ee
n 
hi
pp
oc
am
pa
l 
v
o
lu
m
e 
an
d 
co
gn
iti
on
. F
o
u
n
d 
th
at
 th
e 
th
re
e 
ap
pr
oa
ch
es
 d
id
 n
ot
 a
lte
r t
hi
s a
ss
oc
ia
tio
n 
bu
t h
ad
 sm
al
l e
ffe
ct
s o
n 
th
e 
pr
ed
ic
tio
n 
of
 d
ia
gn
os
tic
 
st
at
us
.
[8
6]
 
R
ob
u
st
 a
nd
 a
cc
ur
at
e 
au
to
m
at
ic
 b
ra
in
 
ex
tr
ac
tio
n 
ac
ro
ss
 d
iv
er
se
 s
u
bje
ct 
gro
up
s.
Pr
op
os
ed
 a
 m
et
ho
d 
co
m
bi
ni
ng
 a
n 
at
la
s-
ba
se
d 
ap
pr
oa
ch
 a
nd
 a
 d
ef
or
m
ab
le
 su
rfa
ce
-b
as
ed
 a
pp
ro
ac
h 
gu
id
ed
 b
y 
pr
io
r i
nf
or
m
at
io
n 
on
 lo
ca
l 
in
te
ns
iti
es
 a
nd
 sp
ec
ifi
c 
po
pu
la
tio
ns
. F
o
u
n
d 
th
at
 th
e 
m
et
ho
d 
w
as
 a
cc
u
ra
te
 a
cr
os
s 
al
l d
ise
as
e 
sta
te
s a
nd
 a
cr
os
s h
um
an
 li
fe
sp
an
 a
nd
 p
er
fo
rm
ed
 
fa
v
o
ra
bl
y 
co
m
pa
re
d 
to
 ex
ist
in
g 
pr
ot
oc
ol
s.
[8
7]
R
eg
ist
ra
tio
n 
an
d 
se
gm
en
ta
tio
n
 
Se
le
ct
io
n 
of
 th
e 
m
os
t d
isc
rim
in
at
iv
e 
fe
at
ur
es
 fo
r d
ef
or
m
ab
le
 im
ag
e 
re
gi
str
at
io
n.
Pr
op
os
ed
 a
n 
im
ag
e 
re
gi
str
at
io
n 
fra
m
ew
o
rk
 th
at
 u
se
s d
ee
p 
le
ar
ni
ng
 to
 d
isc
ov
er
 m
o
rp
ho
lo
gi
ca
l p
at
te
rn
s i
n 
im
ag
e 
pa
tc
he
s. 
A
ch
ie
v
ed
 m
or
e 
ac
cu
ra
te
 re
gi
str
at
io
n 
re
su
lts
 c
om
pa
re
d 
to
 st
at
e-
of
-th
e-
ar
t m
et
ho
ds
.
[8
8]
 
D
ev
el
op
m
en
t o
f a
 b
ra
in
 p
ar
ce
lla
tio
n 
to
ol
 b
as
ed
 o
n 
m
ul
ti-
at
la
s a
lg
or
ith
m
s t
ha
t i
s 
ro
bu
st
 fo
r m
an
y 
di
ffe
re
nt
 im
ag
in
g 
pr
ot
oc
ol
s
U
se
d 
a 
m
ul
tip
le
 a
tla
s, 
lik
el
ih
oo
d 
fu
sio
n 
al
go
rit
hm
 to
 te
st 
pa
rc
el
la
tio
n 
of
 th
e 
en
tir
e 
br
ai
n 
us
in
g 
six
 p
ro
to
co
ls 
ac
ro
ss
 d
iff
er
en
t m
an
uf
ac
tu
re
rs
 a
nd
 
fie
ld
 st
re
ng
th
s. 
Fo
u
n
d 
th
at
 th
er
e 
w
as
 li
ttl
e 
ef
fe
ct
 o
f d
iff
er
en
t p
ro
to
co
ls 
on
 th
e 
va
ria
bi
lit
y 
of
 b
ra
in
 v
o
lu
m
es
.
[8
9]
 
O
pt
im
al
 se
le
ct
io
n 
of
 th
e 
re
gu
la
riz
at
io
n 
pa
ra
m
et
er
Pr
es
en
ts
 a
 n
on
re
gr
es
sio
n 
ap
pr
oa
ch
 fo
r t
he
 se
le
ct
io
n 
of
 th
e 
re
gu
la
riz
at
io
n 
pa
ra
m
et
er
 b
as
ed
 o
n 
th
e 
Va
ria
tio
na
l-B
ay
es
ia
n 
cy
cl
e.
 F
o
u
n
d 
th
is 
is 
m
o
re
 c
o
m
pu
ta
tio
na
lly
 e
ffi
ci
en
t t
ha
n 
ot
he
r m
et
ho
ds
 o
f n
oi
se
 re
du
ct
io
n.
[9
0]
Pr
es
en
ts
 a
 n
ov
el
 m
et
ho
d 
ba
se
d 
on
 fu
ll 
Ba
ye
sia
n 
in
fe
re
nc
e 
on
 a
 p
ro
ba
bi
lis
tic
 re
gi
str
at
io
n 
m
od
el
, f
or
 in
fe
rri
ng
 sp
at
ia
lly
 v
ar
yi
ng
 re
gu
la
riz
at
io
n 
in
 
n
o
n
lin
ea
r r
eg
ist
ra
tio
n.
 T
he
 p
ro
po
se
d 
m
od
el
 is
 d
at
a 
dr
iv
en
 a
n
d 
its
 sp
at
ia
lly
 a
da
pt
iv
e 
pr
io
r p
ro
v
id
es
 b
et
te
r l
oc
al
iz
at
io
n 
of
 re
gi
on
al
 v
o
lu
m
e 
ch
an
ge
.
[9
1]
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C
ha
lle
ng
e
A
pp
ro
a
ch
 a
nd
 re
su
lts
R
ef
er
en
ce
 
Te
st
-r
et
es
t r
el
ia
bi
lit
y 
of
 a
ut
om
at
ed
 
se
gm
en
ta
tio
n 
m
et
ho
ds
U
se
d 
Fr
ee
Su
rfe
r t
o 
pr
oc
es
s i
nt
ra
se
ss
io
n 
an
d 
da
y-
to
-d
ay
 sc
an
s o
f s
ub
jec
ts.
 Fo
u
n
d 
th
at
 in
te
rs
es
sio
n 
va
ria
bi
lit
y 
ex
ce
ed
ed
 in
tra
se
ss
io
n 
va
ria
bi
lit
y 
fo
r s
om
e 
re
gi
on
s
[9
2]
 
Fa
st
er
 im
ag
e 
re
gi
str
at
io
n
U
se
d 
th
re
e 
ap
pr
oa
ch
es
 to
 a
cc
el
er
at
e 
th
e 
im
ag
e 
re
gi
str
at
io
n 
pa
ck
ag
e 
el
as
tix
: (
1) 
pa
ral
lel
iza
tio
n o
n t
he
 C
PU
; (
2) 
pa
ral
lel
iza
tio
n o
n t
he
 G
PU
; a
nd
 
(3)
 im
pro
v
em
en
ts
 o
f t
he
 B
-s
pl
in
e 
tra
ns
fo
rm
at
io
n 
m
od
el
. R
ep
or
te
d 
an
 a
cc
el
er
at
io
n 
fa
ct
or
 o
f 4
 to
 5
 fo
ld
 an
d 
th
at
 th
e a
cc
el
er
at
ed
 v
er
sio
n 
ha
d 
sim
ila
r c
la
ss
ifi
ca
tio
n 
ac
cu
ra
ci
es
 to
 th
e 
or
ig
in
al
 v
er
sio
n.
[9
3]
 
A
cc
ur
at
e 
pa
rti
al
 v
o
lu
m
e 
es
tim
at
io
n 
in
 
tis
su
e 
la
be
lin
g
Pr
op
os
ed
 a
 fa
st
 a
lg
or
ith
m
 b
as
ed
 o
n 
a 
Ba
ye
sia
n 
m
ax
im
um
 a
 p
os
te
rio
ri 
fo
rm
ul
at
io
n.
 A
lg
or
ith
m
 e
nh
an
ce
d 
di
ag
no
sti
c 
ac
cu
ra
cy
 in
 A
D
N
I 
st
an
da
rd
iz
ed
 d
at
a 
se
t.
[9
4]
 
A
ut
om
at
ed
 se
gm
en
ta
tio
n 
of
 o
th
er
 
re
gi
on
s
Pr
op
os
ed
 a
 n
ov
el
 a
ut
om
at
ed
 m
et
ho
d 
fo
r t
he
 se
gm
en
ta
tio
n 
of
 th
e 
hu
m
an
 b
ra
in
ste
m
 in
to
 m
id
br
ai
n 
an
d 
po
ns
 c
al
le
d 
La
nd
m
ar
k-
ba
se
d 
A
ut
om
at
ic
 
B
ra
in
ste
m
 S
eg
m
en
ta
tio
n 
(L
AB
S)
 w
hic
h u
ses
 a 
rev
ise
d 
la
nd
m
ar
k-
ba
se
d 
ap
pr
oa
ch
 in
te
gr
at
ed
 w
ith
 a
 th
re
sh
ol
di
ng
 m
et
ho
d.
 L
A
BS
 c
or
re
la
te
d 
hi
gh
ly
 w
ith
 m
an
ua
l s
eg
m
en
ta
tio
n.
[9
5]
Pr
es
en
t a
 n
ov
el
 se
gm
en
ta
tio
n 
al
go
rit
hm
 fo
r m
ea
su
rin
g 
ch
an
ge
 in
 M
TL
 v
o
lu
m
e.
 B
as
el
in
e 
M
TL
 v
o
lu
m
e 
is 
de
fin
ed
 a
s a
n 
at
la
s i
m
ag
e 
an
d 
m
ap
pe
d 
on
to
 th
e 
co
rre
sp
on
di
ng
 fo
llo
w
-u
p 
im
ag
e 
to
 m
ea
su
re
 v
o
lu
m
e 
ch
an
ge
. T
he
 a
ut
om
at
ed
 a
pp
ro
ac
h 
m
ea
su
re
d 
sig
ni
fic
an
t d
iff
er
en
ce
s 
be
tw
ee
n 
cl
in
ic
al
 g
ro
up
s, 
un
lik
e 
ex
ist
in
g 
Fr
ee
Su
rfe
r s
of
tw
ar
e.
[9
6]
Lo
ng
itu
di
na
l s
ca
ns
 
D
ev
el
op
 sc
or
in
g 
an
d 
tra
in
in
g 
m
et
ho
ds
 
fo
r B
A
LI
 fo
r t
he
 a
cc
ur
at
e 
qu
an
tit
at
iv
e 
an
d 
o
f w
ho
le
-b
ra
in
 st
ru
ct
ur
al
 c
ha
ng
es
Tr
ai
ne
d 
ra
te
rs
 u
sin
g 
a 
ste
p-
by
-s
te
p 
BA
LI
 p
ro
ce
ss
. N
ew
 r
at
er
s 
ac
hi
ev
ed
 >
90
%
 ac
cu
ra
cy
 fo
llo
w
in
g 
2 
w
ee
ks
 o
f t
ra
in
in
g 
an
d 
ac
hi
ev
ed
 b
ot
h 
hi
gh
 
in
te
rra
te
r a
nd
 in
tra
ra
te
r c
or
re
la
tio
n 
co
ef
fic
ie
nt
s. 
Su
gg
es
ts 
th
at
 B
A
LI
 is
 a
 ro
bu
st
 m
et
ho
d 
fo
r a
ss
es
sin
g 
th
e 
w
ho
le
-b
ra
in
 h
ea
lth
 in
 M
CI
 a
nd
 A
D
 
pa
tie
nt
s.
[9
7]
 
U
se
 o
f a
cc
el
er
at
ed
 v
er
su
s 
u
n
ac
ce
le
ra
te
d 
sc
an
s 
in
 se
ria
l M
RI
 to
 d
et
ec
t l
on
gi
tu
di
na
l 
ch
an
ge
U
se
d 
sy
m
m
et
ric
 d
iff
eo
m
or
ph
ic
 im
ag
e 
no
rm
al
iz
at
io
n 
(S
yN
) t
o n
orm
ali
ze
 se
ria
l s
ca
ns
 ob
tai
ne
d u
sin
g T
BM
. F
o
u
n
d 
th
at
 g
ro
up
w
ise
 
di
sc
rim
in
at
io
n 
an
d 
sa
m
pl
e 
siz
e 
es
tim
at
es
 w
er
e 
co
m
pa
ra
bl
e 
us
in
g 
ac
ce
le
ra
te
d 
an
d 
un
ac
ce
le
ra
te
d 
sc
an
s b
u
t t
ha
t t
he
 tw
o
 p
ro
to
co
ls 
re
su
lte
d 
in
 
di
ffe
re
nc
es
 in
 T
BM
-S
yn
.
[9
8]
Co
m
pa
re
d 
th
e 
im
pa
ct
 o
f n
on
ac
ce
le
ra
te
d 
ve
rs
u
s 
ac
ce
le
ra
te
d 
sc
an
s o
n 
br
ai
n 
at
ro
ph
y 
us
in
g 
th
e 
m
ea
ns
 n
or
m
al
iz
ed
 b
ou
nd
ar
y 
sh
ift
 in
te
rv
al
 (K
N-
B
SI
) a
nd
 de
for
ma
tio
n-b
ase
d m
orp
ho
me
try
.
 
Fo
u
n
d 
di
ffe
re
nc
es
 in
 m
ea
su
re
d 
at
ro
ph
y 
ra
te
s u
sin
g 
sc
an
ne
rs
 fr
om
 d
iff
er
en
t v
en
do
rs
 b
u
t l
itt
le
 
di
ffe
re
nc
e 
be
tw
ee
n 
no
na
cc
el
er
at
ed
 a
nd
 a
cc
el
er
at
ed
 b
as
el
in
e 
sc
an
s a
nd
 fo
llo
w
-u
p 
sc
an
s.
[9
9]
U
se
d 
m
or
ph
om
et
ry
 to
 c
om
pa
re
 n
um
er
ic
al
 su
m
m
ar
ie
s o
f a
cc
el
er
at
ed
 v
er
su
s 
n
o
n
ac
ce
le
ra
te
d 
sc
an
s a
cr
os
s p
at
ie
nt
 g
ro
up
s o
v
er
 6
- a
nd
 1
2-
m
on
th
 
sc
an
n
ed
 in
te
rv
al
s. 
Sc
an
 a
cc
el
er
at
io
n 
ha
d 
m
in
im
al
 e
ffe
ct
s o
n 
th
e 
TB
M
-d
er
iv
ed
 a
tro
ph
y 
m
ea
su
re
s.
[1
00
]
 
Pr
ed
ic
tio
n 
of
 a
 b
ra
in
 im
ag
e 
at
 a
 
pa
rti
cu
la
r t
im
e 
po
in
t g
iv
en
 m
in
im
al
 
lo
ng
itu
di
na
l d
at
a
Pr
es
en
te
d 
an
 a
lg
or
ith
m
 fo
r t
he
 si
m
ul
ta
ne
ou
s r
eg
ist
ra
tio
n 
of
 N
 
lo
ng
itu
di
na
l i
m
ag
e 
pa
irs
. I
nf
or
m
at
io
n 
fro
m
 e
ac
h 
pi
er
 is
 u
se
d 
to
 c
on
str
ai
n 
th
e 
re
gi
str
at
io
n 
of
 e
ac
h 
ot
he
r p
ai
r. 
Th
e 
us
e 
of
 a
 g
ro
up
w
ise
 c
on
sis
te
nc
y 
pr
io
r c
an
 p
re
di
ct
 a
n 
im
ag
e 
ac
t a
nd
 th
ird
 ti
m
e 
po
in
t n
ot
 in
cl
ud
ed
 in
 th
e 
re
gi
str
at
io
n 
ste
p.
[1
01
]
Pr
es
en
te
d 
an
 a
lg
or
ith
m
 to
 in
co
rp
or
at
e 
in
fo
rm
at
io
n 
fro
m
 th
e 
en
tir
e 
pa
tie
nt
 g
ro
up
 to
 p
re
di
ct
 lo
ng
itu
di
na
l c
ha
ng
e,
 a
s t
he
y 
sh
ar
e 
sim
ila
r s
pa
tia
l 
di
str
ib
u
tio
ns
 o
f v
o
lu
m
e 
ch
an
ge
. U
se
 lo
ng
itu
di
na
l r
eg
ist
ra
tio
n 
w
as
 a
 g
ro
up
w
ise
 c
ou
pl
in
g 
pr
io
r a
nd
 fo
un
d 
it 
ab
le
 to
 e
sti
m
at
e 
ch
an
ge
 ro
bu
st
ly
.
[1
02
]
Pr
op
os
ed
 a
 m
et
ho
d 
fo
r s
up
pl
em
en
tin
g 
th
e 
la
ck
 o
f l
on
gi
tu
di
na
l i
nf
or
m
at
io
n 
fo
r a
n 
in
di
v
id
ua
l p
at
ie
nt
 w
ith
 c
ro
ss
-s
ec
tio
na
l d
at
a 
fro
m
 th
e 
po
pu
la
tio
n.
 U
se
d 
a 
pr
ob
ab
ili
sti
c 
m
od
el
 b
as
ed
 o
n 
Ja
m
es
 S
te
in
 e
sti
m
at
or
s t
o 
im
pr
ov
e 
ge
od
es
ic
 e
sti
m
at
io
n.
 M
et
ho
d 
al
lo
w
ed
 p
re
di
ct
io
n 
of
 b
ra
in
 
ch
an
ge
s o
f i
m
ag
es
 o
v
er
 ti
m
e.
[1
03
]
 
A
cc
ou
nt
in
g 
fo
r s
pa
tia
lly
 
in
ho
m
og
en
eo
us
 lo
ng
itu
di
na
l d
at
a
Pr
op
os
ed
 a
 m
et
ho
d 
ba
se
d 
on
 th
e 
Sa
nd
w
ic
h 
Es
tim
at
or
 to
 a
cc
ou
nt
 fo
r w
ith
in
-s
ub
jec
t c
orr
ela
tio
n i
n l
on
git
ud
ina
l d
ata
. F
o
u
n
d 
th
at
 th
e 
m
et
ho
d 
w
as
 
fle
x
ib
le
 a
nd
 fi
t w
ith
in
-a
nd
 b
et
w
ee
n-
su
bje
ct 
eff
ec
ts 
on
 th
e 
sin
gl
e 
m
od
el
 in
 a
n 
un
ba
la
nc
ed
 lo
ng
itu
di
na
l d
at
a 
se
t.
[1
04
]
 
M
ea
su
rin
g 
lo
ng
itu
di
na
l g
ra
y-
m
at
te
r 
v
o
lu
m
e 
ch
an
ge
 in
 th
e 
de
fa
u
lt 
m
od
e 
n
et
w
o
rk
Pr
op
os
ed
 u
se
 o
f a
 v
o
lu
m
e 
sta
nd
ar
di
ze
d 
w
ith
 g
lo
ba
l g
ra
y-
m
at
te
r v
o
lu
m
e.
 M
et
ho
d 
de
te
ct
ed
 si
gn
ifi
ca
nt
 d
iff
er
en
ce
s i
n 
lo
ng
itu
di
na
l g
ra
y 
m
at
te
r i
n 
th
e 
de
fa
u
lt 
m
od
e 
ne
tw
o
rk
 a
cr
os
s p
at
ie
nt
 g
ro
up
s.
[1
05
]
 
D
ai
ly
 c
ha
ng
es
 in
 b
ra
in
 v
o
lu
m
e 
re
su
lti
ng
 
fro
m
 p
hy
sio
lo
gi
ca
l f
lu
ct
ua
tio
ns
 m
ay
 
im
pa
ct
 a
bi
lit
y 
of
 im
ag
in
g 
to
 d
et
ec
t 
lo
ng
itu
di
na
l c
ha
ng
es
 in
 b
ra
in
 v
o
lu
m
e.
U
se
d 
sta
tis
tic
al
 m
od
el
in
g 
of
 M
RI
 im
ag
es
, m
ea
su
rin
g 
th
e 
br
ai
n 
pa
re
nc
hy
m
al
 fr
ac
tio
n 
to
 a
cc
ou
nt
 fo
r v
ar
ia
tio
ns
 in
 h
ea
d 
siz
e.
 F
o
u
n
d 
a 
st
at
ist
ic
al
ly
 si
gn
ifi
ca
nt
 ti
m
e 
of
 d
ay
 e
ffe
ct
 o
n 
br
ai
n 
pa
re
nc
hy
m
al
 fr
ac
tio
n.
 S
ug
ge
sts
 th
at
 a
n 
ac
qu
isi
tio
n 
tim
e 
bi
as
 sh
ou
ld
 b
e 
ac
co
un
te
d 
fo
r i
n 
br
ai
n 
vo
lu
m
et
ric
 st
ud
ie
s.
[1
06
]
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C
ha
lle
ng
e
A
pp
ro
a
ch
 a
nd
 re
su
lts
R
ef
er
en
ce
 
Im
pr
ov
em
en
t o
f t
he
 b
ou
nd
ar
y 
sh
ift
 
in
te
rv
al
 fo
r m
ea
su
rin
g 
lo
ng
itu
di
na
l c
ha
ng
e 
in
 b
ra
in
 v
o
lu
m
e
Pr
op
os
ed
 a
n 
ex
te
ns
io
n 
to
 th
e 
bo
un
da
ry
 sh
ift
 in
te
rv
al
 w
hi
ch
 u
se
s p
ro
ba
bi
lis
tic
 se
gm
en
ta
tio
ns
 a
nd
 th
en
 e
sti
m
at
es
 a
 n
on
bi
na
ry
 ex
cl
us
iv
e 
o
r 
a 
re
gi
on
 o
f i
nt
er
es
t t
o 
be
tte
r c
ap
tu
re
 p
at
te
rn
s o
f b
ra
in
 a
tro
ph
y.
[1
07
]
Co
rti
ca
l t
hi
ck
ne
ss
 e
sti
m
at
io
n
 
Co
rti
ca
l t
hi
ck
ne
ss
 e
sti
m
at
io
n
Pr
es
en
te
d 
an
 a
lg
or
ith
m
 d
riv
en
 b
y 
th
e 
gr
ap
h 
sp
ec
tru
m
 a
nd
 h
ea
t k
er
n
el
 th
eo
ry
 to
 e
sti
m
at
e 
co
rti
ca
l t
hi
ck
ne
ss
. S
uc
ce
ss
fu
lly
 d
et
ec
te
d 
sta
tis
tic
al
 
di
ffe
re
nc
es
 b
et
w
ee
n 
pa
tie
nt
 c
la
ss
es
.
[1
08
]
Te
st
ed
 th
e 
ab
ili
ty
 o
f v
o
x
el
-b
as
ed
 m
or
ph
om
et
ry
 (V
BM
) t
o m
ea
su
re 
co
rti
ca
l th
ick
ne
ss.
 Fo
u
n
d 
th
at
 th
e 
V
BM
 w
as
 le
ss
 se
ns
iti
v
e 
to
 c
or
tic
al
 
at
ro
ph
y 
as
 it
 w
as
 b
ia
se
d 
to
 m
ed
ia
l t
em
po
ra
l l
ob
e 
at
ro
ph
y 
an
d 
th
at
 F
re
eS
ur
fe
r w
as
 m
o
re
 s
en
sit
iv
e 
to
 c
or
tic
al
 th
in
ni
ng
.
[1
09
]
M
or
ph
om
et
ry
 
Co
rti
ca
l p
at
te
rn
 a
na
ly
sis
Pr
op
os
ed
 a
 m
ul
ti-
re
so
lu
tio
n 
ap
pr
oa
ch
 w
hi
ch
 p
re
sc
rib
es
 sh
ap
e 
de
sc
rip
to
rs
 th
at
 c
ha
ra
ct
er
iz
e 
th
e 
sig
na
l a
t e
ac
h 
m
es
h 
ve
rt
ex
. 
M
et
ho
d 
sh
ow
ed
 
in
cr
ea
se
d 
se
ns
iti
v
ity
 a
nd
 st
at
ist
ic
al
 p
ow
er
 to
 d
et
ec
t g
ro
up
-le
v
el
 d
iff
er
en
ce
s.
[1
10
]
 
Ve
n
tr
ic
ul
ar
 m
or
ph
ol
og
y 
an
al
ys
is
Pr
es
en
te
d 
a 
no
v
el
 sy
ste
m
 fo
r v
en
tr
ic
ul
ar
 m
or
ph
om
et
ry
 b
as
ed
 o
n 
th
e 
hy
pe
rb
ol
ic
 R
ic
ci
 fl
ow
 m
et
ho
d 
an
d 
te
ns
or
 m
or
ph
om
et
ry
 st
at
ist
ic
s. 
Th
e 
TB
M
 st
at
ist
ic
s e
nh
an
ce
d 
su
rfa
ce
 s
ha
pe
 a
na
ly
sis
 a
nd
 th
e 
m
et
ho
d 
re
v
ea
le
d 
sh
ap
e 
di
ffe
re
nc
es
 c
lo
se
 to
 th
e 
te
m
po
ra
l l
ob
e 
an
d 
po
ste
rio
r c
in
gu
la
te
. 
Co
rre
la
tio
ns
 w
er
e 
de
te
ct
ed
 b
et
w
ee
n 
ve
n
tr
ic
ul
ar
 m
or
ph
om
et
ry
,
 
n
eu
ro
ps
yc
ho
lo
gi
ca
l m
ea
su
re
s, 
an
d 
m
et
ab
ol
ism
.
[1
11
]
 
R
ep
re
se
nt
at
io
n 
of
 o
v
er
al
l b
ra
in
 
m
o
rp
ho
lo
gy
Pr
op
os
ed
 a
 n
ov
el
 a
pp
ro
ac
h 
to
 d
ef
or
m
at
io
n-
ba
se
d 
m
or
ph
om
et
ry
,
 
re
gi
on
al
 fl
ux
 a
na
ly
sis
, b
as
ed
 o
n 
th
e 
sc
he
m
e 
ha
lts
 d
ec
om
po
sit
io
n 
of
 
de
fo
rm
at
io
ns
 p
ar
am
et
er
iz
ed
 b
y 
sta
tio
na
ry
 v
el
oc
ity
 fi
el
ds
. T
he
 fr
am
ew
o
rk
 u
ni
fie
s v
o
x
el
-b
as
ed
 a
nd
 re
gi
on
al
 a
pp
ro
ac
he
s a
nd
 h
ad
 g
oo
d 
po
w
er
 to
 
di
sc
ov
er
 s
ha
pe
s d
ef
or
m
at
io
ns
 b
ot
h 
cr
os
s-
se
ct
io
na
lly
 a
nd
 lo
ng
itu
di
na
lly
.
[1
12
]
In
tro
du
ce
d 
Br
ai
nP
rin
t, 
a 
fu
lly
 a
ut
om
at
ed
 fr
am
ew
o
rk
 w
hi
ch
 g
en
er
at
es
 a
 c
om
pa
ct
 re
pr
es
en
ta
tio
n 
of
 b
ra
in
 m
or
ph
ol
og
y 
by
 c
ap
tu
rin
g 
sh
ap
e 
in
fo
rm
at
io
n 
fro
m
 b
ot
h 
co
rti
ca
l a
nd
 su
bc
or
tic
al
 st
ru
ct
ur
es
. M
et
ho
d 
w
as
 e
ffi
ci
en
t a
nd
 d
isc
rim
in
at
iv
e.
[1
13
]
Pr
es
en
te
d 
a 
m
as
s u
ni
v
ar
ia
te
 fr
am
ew
o
rk
 th
at
 u
se
s l
on
gi
tu
di
na
l V
BM
 d
at
a 
an
d 
Ba
ye
sia
n 
in
fe
re
nc
e 
to
 a
na
ly
ze
 w
ho
le
-b
ra
in
 st
ru
ct
ur
al
 c
ha
ng
es
 
o
v
er
 ti
m
e.
 T
he
 p
ro
ba
bi
lis
tic
 m
od
el
 d
et
ec
ts 
in
di
v
id
ua
l a
nd
 g
ro
up
 tr
aje
cto
rie
s o
f d
ise
ase
 pr
og
res
sio
n.
[1
14
]
 
M
ea
su
rin
g 
pa
tte
rn
s o
f b
ra
in
 
m
o
rp
ho
lo
gi
ca
l c
ha
ng
es
 in
 p
op
ul
at
io
ns
.
Pr
op
os
ed
 a
 d
at
a-
dr
iv
en
 p
ro
ba
bi
lis
tic
 u
ns
up
er
vi
se
d 
fra
m
ew
o
rk
 th
at
 a
ut
om
at
ic
al
ly
 se
gm
en
ts 
he
te
ro
ge
ne
ou
s s
et
 o
f i
m
ag
es
 u
sin
g 
an
 a
tla
s-
ba
se
d 
m
et
ho
d 
an
d 
cl
us
te
rs
 im
ag
es
 in
to
 h
om
og
en
eo
us
 su
bg
ro
up
s. 
It 
co
ns
tru
ct
s s
ep
ar
at
e 
pr
ob
ab
ili
sti
c 
at
la
se
s f
or
 e
ac
h 
cl
us
te
r. 
Fo
u
n
d 
th
at
 c
om
bi
ni
ng
 
se
gm
en
ta
tio
n 
an
d 
at
la
s c
on
str
uc
tio
n 
le
d 
to
 im
pr
ov
ed
 se
gm
en
ta
tio
n 
ac
cu
ra
cy
 a
nd
 c
lu
ste
rs
 g
en
er
at
ed
 c
oi
nc
id
ed
 w
ith
 c
lin
ic
al
 su
bg
ro
up
s.
[1
15
]
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 fa
ct
or
s
R
ed
uc
ed
 h
ip
po
ca
m
pa
l v
o
lu
m
e
In
cr
ea
se
 o
f n
eu
ro
de
ge
ne
ra
tio
n 
in
 p
re
se
nc
e 
of
 C
V
D
[1
89
]
GR
IN
2B
D
ise
as
e 
sta
tu
s
G
lu
ta
m
at
e 
sig
na
lin
g
[2
01
]
H
M
GC
R
rs
38
46
66
2G
 al
le
le
D
el
ay
ed
 a
ge
 o
f A
D
 o
ns
et
, r
ed
uc
ed
 ri
sk
 o
f A
D
[1
93
]
M
M
P1
M
in
or
 a
lle
le
Cl
in
ic
al
 st
at
us
[2
04
]
NA
PR
T1
M
in
or
 a
lle
le
Cl
in
ic
al
 st
at
us
[2
04
]
SO
RL
1
rs
20
70
04
5G
 al
le
le
In
cr
ea
se
d 
CS
F 
ta
u,
 h
ip
po
ca
m
pa
l a
tro
ph
y
M
ay
 in
cr
ea
se
 n
eu
ro
de
ge
ne
ra
tio
n
[1
86
]
TO
M
M
40
M
in
or
 a
lle
le
Cl
in
ic
al
 st
at
us
[2
04
]
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G
en
e
SN
P
Ph
en
ot
yp
e
Pr
o
po
se
d 
bi
ol
og
ic
al
 fu
nc
tio
n
R
ef
er
en
ce
TO
M
M
40
To
p 
SN
Ps
CS
F 
A
β4
2
Sy
na
pt
ic
 tr
an
sm
iss
io
n,
 tr
an
sm
iss
io
n 
of
 n
er
ve
 im
pu
lse
s, 
an
d 
tra
it 
cl
as
s
[2
19
]
TR
EM
2
M
in
or
 a
lle
le
Cl
in
ic
al
 st
at
us
[2
04
]
TR
EM
L2
p.
R4
7H
In
cr
ea
se
d 
ris
k 
of
 A
D
[1
84
]
CL
U-
M
S4
A4
E*
G
en
e 
in
te
ra
ct
io
n 
de
cr
ea
se
d 
A
D
 in
ci
de
nc
e
[1
88
]
RY
R3
-C
AC
NA
1C
M
in
or
 a
lle
le
s
In
cr
ea
se
d 
co
rti
ca
l A
β l
oa
d
R
eg
ul
at
io
n 
of
 in
tra
ce
llu
la
r c
al
ci
um
 h
om
oe
os
ta
sis
[1
97
]
GS
K3
β-A
PP
rs
33
45
43
 m
in
or
 
al
le
le
-3
SN
Ps
In
cr
ea
se
d 
co
rti
ca
l A
β l
oa
d
Ta
u
 k
in
as
es
 in
te
ra
ct
 w
ith
 A
PP
 to
 in
cr
ea
se
 d
ep
os
iti
on
[1
99
]
C9
-IE
R6
In
cr
ea
se
d 
co
rti
ca
l A
β l
oa
d
N
eu
ro
in
fia
m
m
at
io
n 
m
ay
 e
nh
an
ce
 A
β d
ep
os
iti
on
[1
98
]
U
N
C5
C
H
ip
po
ca
m
pa
l a
nd
 p
re
cu
ne
al
 a
tro
ph
y
U
nc
-5
 N
et
rin
 R
ec
ep
to
r C
—
tri
gg
er
s a
po
pt
os
is
[1
82
]
N
M
E8
rs
27
18
05
8G
 al
le
le
H
ig
he
r C
D
R-
SB
 sc
or
es
, l
ow
er
 a
tr
op
hy
 h
ig
he
r m
et
ab
ol
ism
M
ay
 in
hi
bi
t n
eu
ro
de
ge
ne
ra
tio
n
[1
85
]
O
PR
D
1
rs
67
88
49
R
eg
io
na
l b
ra
in
 v
o
lu
m
e 
di
ffe
re
nc
es
, C
SF
 b
io
m
ar
ke
rs
D
el
ta
 o
pi
oi
d 
re
ce
pt
or
 m
ay
 p
ro
m
ot
e 
th
e 
pr
oc
es
sin
g 
of
 A
PP
[2
31
]
N
AV
2
Ep
iso
di
c 
m
em
or
y 
sc
or
es
N
eu
ro
n 
na
v
ig
at
or
 2
, n
eu
rit
e 
ou
tg
ro
w
th
, a
nd
 c
el
l m
ig
ra
tio
n
[1
91
]
TP
53
IN
P1
D
ise
as
e 
sta
tu
s
Pr
oa
po
pt
ot
ic
 tu
m
or
 su
pp
re
ss
or
[2
00
]
IG
H
V1
D
ise
as
e 
sta
tu
s
U
nk
no
w
n
ZN
F8
27
*
CS
F 
A
β4
2
Tr
an
sc
rip
tio
n 
fa
ct
or
[2
03
]
ZN
F6
28
*
M
in
or
 a
lle
le
D
ise
as
e 
sta
tu
s
Tr
an
sc
rip
tio
n 
fa
ct
or
[2
04
]
KD
M
2B
*
p-
ta
u 1
81
[2
03
]
N
AN
P*
R
eg
io
na
l a
tro
ph
y
O
X
PH
O
S 
(ox
ida
tiv
e 
ph
os
ph
or
yl
at
io
n 
ge
ne
s)
D
ise
as
e 
sta
tu
s, 
CN
 to
 M
CI
 p
ro
gr
es
sio
n,
 h
ip
po
ca
m
pa
l 
v
o
lu
m
e,
 e
nt
or
hi
na
l c
or
te
x
 v
o
lu
m
e
O
ve
rla
p 
of
 A
D
 a
nd
 st
ro
ke
 g
en
es
 in
flu
en
ce
 d
ise
as
e 
tr
aje
cto
ry
[1
96
]
AE
N
D
ise
as
e 
sta
tu
s
Si
gn
al
in
g 
ne
tw
o
rk
 in
v
o
lv
ed
 c
ho
le
ste
ro
l m
et
ab
ol
ism
[2
02
]
AD
AM
TS
12
PS
M
A5
FX
N
N
TM
LA
RP
1
W
D
TC
1
SE
M
A7
A 
VK
0R
C1
L1
 
CO
L5
A3
H
0M
ER
2
D
ise
as
e 
sta
tu
s, 
rig
ht
 th
al
am
us
 v
o
lu
m
e
Tr
an
sc
rip
tio
n 
fa
ct
or
 li
nk
ed
 to
 A
PP
[2
12
]
PM
L
H
ip
po
ca
m
pa
l s
ha
pe
, i
ns
ul
ar
 c
or
tic
es
[2
14
]
Alzheimers Dement. Author manuscript; available in PMC 2019 October 29.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Weiner et al. Page 148
G
en
e
SN
P
Ph
en
ot
yp
e
Pr
o
po
se
d 
bi
ol
og
ic
al
 fu
nc
tio
n
R
ef
er
en
ce
ST
O
M
L1
H
ip
po
ca
m
pa
l s
ha
pe
, i
ns
ul
ar
 c
or
tic
es
SY
N
J2
-P
I4
KA
In
fe
rio
r l
at
er
al
 v
en
tr
ic
le
 a
tro
ph
y
In
os
ito
l p
at
hw
ay
[2
16
]
RE
ST
*
rs
37
96
52
9 
m
in
or
 T
 
al
le
le
Le
ss
 h
ip
po
ca
m
pa
l a
tro
ph
y,
 
gr
ea
te
r m
ed
ia
l t
em
po
ra
l l
ob
e 
m
et
ab
ol
ism
N
eg
at
iv
e 
tr
an
sc
rip
tio
na
l r
eg
ul
at
or
 o
f h
ip
po
ca
m
pa
l 
n
eu
ro
ge
ne
sis
CT
XN
Pl
as
m
a 
A
β4
2 
an
d 
A
β4
0
Co
rte
x
in
 m
od
ul
at
es
 A
β4
2 
se
cr
et
io
n
[2
20
]
IL
RA
P*
rs
12
05
38
68
 m
in
or
 G
 
al
le
le
Lo
ng
itu
di
na
l A
β a
cc
u
m
u
la
tio
n
Pr
oi
nf
la
m
m
at
or
y 
cy
to
ki
ne
, a
ct
iv
at
io
n 
of
 m
ic
ro
gl
ia
[2
21
]
SU
LG
2*
CS
F 
A
β4
2,
 c
og
ni
tiv
e 
de
cl
in
e
FR
A1
0A
C1
*
Fr
ag
ile
 si
te
CS
F 
A
β4
2,
 c
og
ni
tiv
e 
de
cl
in
e
[2
22
]
PO
T1
rs
47
28
02
9
CS
F 
p-
ta
u 1
81
,
 
v
en
tr
ic
ul
ar
 ex
pa
ns
io
n
N
eu
ro
in
fla
m
m
at
or
y 
m
ec
ha
ni
sm
 re
la
te
d 
to
 in
te
rle
uk
in
 6
 
re
ce
pt
or
[2
24
]
G
en
es
 m
ed
ia
te
d 
by
 
m
iR
-3
3
CS
F 
p-
ta
u 1
81
D
isr
up
tio
n 
of
 c
el
lu
la
r c
ho
le
ste
ro
l h
om
oe
os
ta
sis
SP
O
N
1
M
in
or
 a
lle
le
s
M
or
e 
ra
pi
d 
de
cl
in
e 
on
 A
DA
S-
co
g
Sp
on
di
n 
1 
in
hi
bi
ts 
cl
ea
v
ag
e 
of
 A
PP
 b
y 
BA
CE
[2
26
]
EX
O
C4
, G
AB
RG
3,
 V
AT
1L
M
or
e 
ra
pi
d 
de
cl
in
e 
on
 A
DA
S-
co
g
N
eu
ro
na
l m
ai
nt
en
an
ce
, n
eu
ro
tra
ns
m
iss
io
n,
 c
al
ci
um
 
sig
na
lin
g
CA
M
K4
, C
YC
S,
 N
CS
1,
 C
AC
NA
1G
M
or
e 
ra
pi
d 
de
cl
in
e 
on
 A
DA
S-
co
g
H
om
oe
os
ta
sis
RN
AS
E1
3 
(+
PT
K
2B
, P
IC
AL
M
, 
M
S4
A2
, a
nd
 A
PP
 fr
om
 p
ath
wa
y 
an
al
ys
is)
Co
gn
iti
v
e 
re
sil
ie
nc
e
N
eu
ro
n 
lo
ss
, p
re
sy
na
pt
ic
 m
em
br
an
e,
 a
nd
 p
os
tsy
na
pt
ic
 
de
ns
ity
[2
27
]
A
bb
re
v
ia
tio
ns
: A
D
N
I, 
A
lz
he
im
er
’s
 D
ise
as
e 
N
eu
ro
im
ag
in
g 
In
iti
at
iv
e;
 S
N
P,
 
sm
al
l n
uc
le
ot
id
e 
po
ly
m
or
ph
ism
; B
CH
E,
 b
u
ty
ry
lc
ho
lin
es
te
ra
se
; C
SF
,
 
ce
re
br
os
pi
na
l f
lu
id
; A
D
, A
lz
he
im
er
’s
 d
ise
as
e;
 W
M
, w
hi
te
 
m
at
te
r;
 C
V
D
, c
ar
di
ov
as
cu
la
r d
ise
as
e;
 A
PP
,
 
A
β p
re
cu
rs
or
 p
ro
te
in
; C
D
R-
SB
, C
lin
ic
al
 D
em
en
tia
 R
at
in
g–
Su
m
 o
f B
ox
es
; C
N
, c
og
ni
tiv
el
y 
no
rm
al
; M
CI
, m
ild
 c
og
ni
tiv
e 
im
pa
irm
en
t; 
A
DA
S-
co
g,
 A
lz
he
im
er
’s
 
D
ise
as
e 
A
ss
es
sm
en
t S
ca
le
–c
og
ni
tiv
e 
su
bs
ca
le
; B
A
CE
, b
et
a-
se
cr
et
as
e.
*
In
de
pe
nd
en
t o
f A
PO
E 
st
at
us
. N
ov
el
 lo
ci
 a
re
 in
 b
ol
d,
 a
nd
 b
lu
e 
sh
ad
ed
 b
ox
es
 r
ep
re
se
nt
 p
ro
te
ct
iv
e 
al
le
le
s.
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Ta
bl
e 
7
A
pp
ro
ac
he
s f
or
 th
e 
im
pr
ov
em
en
t o
f g
en
et
ic
 st
ud
ie
s
C
ha
lle
ng
e
A
pp
ro
a
ch
 a
nd
 re
su
lts
R
ef
er
en
ce
Av
o
id
in
g 
bi
as
ed
 
in
te
rfe
re
nc
e 
w
he
n 
us
in
g 
se
co
n
da
ry
 p
he
no
ty
pe
s
Te
st
ed
 w
he
th
er
 a
 st
an
da
rd
 a
na
ly
sis
 o
f s
ec
on
da
ry
 p
he
no
ty
pe
s e
nc
ou
nt
er
ed
 p
ro
bl
em
s s
uc
h 
as
 ty
pe
-I 
er
ro
rs
 a
nd
 re
du
ce
d 
po
w
er
 fo
r a
ss
oc
ia
tio
n 
te
sti
ng
. A
lth
ou
gh
 
th
e 
an
al
ys
is 
w
as
 g
en
er
al
ly
 v
al
id
, a
ut
ho
rs
 re
co
m
m
en
d 
ca
ut
io
n 
w
he
n 
an
al
yz
in
g 
th
es
e 
ty
pe
s o
f d
at
a.
[2
37
]
Im
pr
ov
in
g 
co
m
pu
ta
tio
na
l e
ffi
ci
en
cy
 
o
f m
as
s u
ni
v
ar
ia
te
 
an
al
ys
es
Pr
es
en
te
d 
a 
fu
nc
tio
na
l m
ix
ed
-e
ffe
ct
s m
od
el
in
g 
fra
m
ew
o
rk
 to
 jo
int
ly 
an
aly
ze 
hig
h-d
im
en
sio
na
l im
ag
ing
 da
ta 
wi
th 
ge
ne
tic
 m
ark
er
s 
an
d 
cl
in
ic
al
 c
ov
ar
ia
nt
s. 
Te
st
ed
 a
ss
oc
ia
tio
ns
 o
f c
an
di
da
te
 g
en
es
 (C
R1
, C
D2
AP
, 
PI
CA
LM
) w
ith
 M
RI
 b
ra
in
 re
gi
on
s. 
D
et
ec
te
d 
re
gi
on
al
 c
lu
ste
rs
 o
f v
o
x
el
s a
ss
oc
ia
te
d 
w
ith
 c
an
di
da
te
 g
en
es
 
an
d 
di
ffe
re
nt
 p
at
ie
nt
 g
ro
up
s. 
M
et
ho
d 
w
as
 c
o
m
pu
ta
tio
na
lly
 e
ffi
ci
en
t.
[2
39
]
Pr
es
en
te
d 
a 
fa
st
 v
o
x
el
w
ise
 g
en
om
e-
w
id
e 
as
so
ci
at
io
n 
an
al
ys
is 
fra
m
ew
o
rk
 a
bl
e 
to
 se
ar
ch
 fo
r s
pa
rs
e 
sig
na
ls 
w
hi
le
 c
on
tro
lli
ng
 fo
r f
am
ily
-w
ise
 e
rro
r r
at
e.
 W
he
n 
te
st
ed
 o
n 
A
D
N
I d
at
a 
w
ith
 7
08
 su
bje
cts
, 1
93
,27
5 v
o
x
el
s, 
an
d 
50
1,
58
4 
SN
Ps
, t
he
 to
ta
l p
ro
ce
ss
in
g 
tim
e w
as
 2
03
,6
45
 se
co
nd
s f
or
 a 
sin
gl
e C
PU
, a
 su
bs
ta
nt
ia
l 
im
pr
ov
em
en
t o
v
er
 tr
ad
iti
on
al
 m
et
ho
ds
.
[2
40
]
Pr
es
en
te
d 
m
od
ifi
ca
tio
ns
 to
 m
as
s u
ni
v
ar
ia
te
 a
na
ly
se
s b
y 
us
in
g 
di
m
en
sio
na
lit
y 
re
du
ct
io
n 
te
ch
ni
qu
es
 o
n 
bo
th
 M
RI
 im
ag
in
g 
da
ta
 a
nd
 g
en
om
ic
s d
at
a,
 a
nd
 a
 n
ew
 
m
u
lti
pl
e 
te
sti
ng
 a
dju
stm
en
t m
eth
od
. E
xp
eri
me
nts
 su
gg
est
 pr
oc
ed
ure
 ha
s m
ore
 po
w
er
 to
 d
et
ec
t a
ss
oc
ia
tio
ns
.
[2
41
]
Pr
es
en
te
d 
a 
m
et
ho
d 
ba
se
d 
on
 a
 g
en
er
al
iz
at
io
n 
of
 th
e 
pa
rti
al
 le
as
t s
qu
ar
es
 c
or
re
sp
on
de
nc
e 
an
al
ys
is 
w
hi
ch
 c
an
 si
m
ul
ta
ne
ou
sly
 a
na
ly
ze
 b
eh
av
io
ra
l a
nd
 g
en
et
ic
 
da
ta
.
[2
42
]
Se
le
ct
in
g 
m
os
t 
in
fo
rm
at
iv
e 
SN
Ps
 o
r 
qu
an
tit
at
iv
e 
fe
at
ur
es
Pr
es
en
te
d 
m
et
ho
d 
th
at
 u
se
s t
re
e-
gu
id
ed
 sp
ar
se
 le
ar
ni
ng
 to
 le
ar
n 
th
e 
m
os
t i
nf
or
m
at
iv
e 
SN
Ps
 a
nd
 M
RI
 m
ea
su
re
s a
nd
 th
at
 m
od
el
s t
he
 a
 p
rio
ri 
hi
er
ar
ch
ic
al
 
gr
ou
pi
ng
 st
ru
ct
ur
e 
am
on
g 
SN
Ps
. E
xp
er
im
en
ts 
su
gg
es
t m
et
ho
d 
ca
n 
id
en
tif
y 
in
fo
rm
at
iv
e 
SN
Ps
.
[2
43
]
A
do
pt
ed
 a
 g
en
er
al
iz
ed
 e
sti
m
at
io
n 
eq
ua
tio
ns
 m
et
ho
do
lo
gy
 to
 te
st 
th
e 
as
so
ci
at
io
n 
be
tw
ee
n 
sin
gl
e 
SN
Ps
 a
nd
 m
ul
tip
le
 q
ua
nt
ita
te
d 
tra
its
. F
o
u
n
d 
th
e 
m
et
ho
d 
w
as
 
ge
ne
ra
l a
nd
 fl
ex
ib
le
 w
he
n 
te
ste
d 
on
 A
D
N
I d
at
a 
us
in
g 
se
v
en
 M
R
I-
de
riv
ed
 m
ul
tiv
ar
ia
te
 tr
ai
ts.
 O
ut
pe
rfo
rm
ed
 p
rin
ci
pa
l c
om
po
ne
nt
 a
na
ly
sis
 o
r c
an
on
ic
al
 
co
rr
el
at
io
n 
an
al
ys
is 
fo
r d
im
en
sio
na
lit
y 
re
du
ct
io
n.
[2
44
]
Pr
es
en
te
d 
a 
sp
ar
se
 p
ro
jec
tio
n r
eg
re
ss
io
n 
m
od
el
in
g 
fra
m
ew
o
rk
. I
nc
or
po
ra
te
s t
w
o
 n
o
v
el
 h
er
ita
bi
lit
y 
ra
tio
s t
o 
sim
ul
ta
ne
ou
sly
 p
er
fo
rm
 d
im
en
sio
na
lit
y 
re
du
ct
io
n,
 
re
sp
on
se
 se
le
ct
io
n,
 e
sti
m
at
io
n,
 a
nd
 te
sti
ng
.
[2
45
]
Ev
al
ua
te
d 
se
v
er
al
 sp
ar
se
 c
an
on
ic
al
 c
or
re
la
tio
n 
an
al
ys
is 
m
et
ho
ds
 th
at
 c
an
 re
v
ea
l c
om
pl
ex
 m
u
lti
-S
N
P,
 
m
u
lti
qu
an
tit
at
iv
e 
tr
ai
t a
ss
oc
ia
tio
ns
. S
ug
ge
st 
th
at
 th
e 
es
tim
at
io
n 
of
 c
ov
ar
ia
te
 st
ru
ct
ur
e 
is 
lim
ite
d 
in
 th
es
e 
m
et
ho
ds
.
[2
46
]
Te
st
ed
 th
re
e 
Ba
ye
sia
n 
ne
tw
o
rk
 su
pe
rv
ise
d 
le
ar
ni
ng
 m
et
ho
ds
 o
n 
a 
w
ho
le
-g
en
om
e 
se
qu
en
ci
ng
 d
at
a 
to
 id
en
tif
y 
ca
us
al
 A
D
 S
N
Ps
 a
nd
 th
e 
ge
ne
-S
N
P 
in
te
ra
ct
io
ns
. 
R
ep
or
te
d 
th
at
 M
ar
ko
ff 
bl
an
ke
t-
ba
se
d 
m
et
ho
ds
 o
ut
pe
rfo
rm
ed
 b
ot
h 
na
ïv
e 
B
ay
es
 a
nd
 tr
ee
-a
ug
m
en
te
d 
na
ïv
e 
B
ay
es
 m
et
ho
ds
 in
 se
le
ct
in
g 
SN
Ps
 st
ro
ng
ly
 a
ss
oc
ia
te
d 
w
ith
 A
D
 fr
om
 to
p-
ra
nk
ed
 su
sc
ep
tib
ili
ty
 g
en
es
.
[2
47
]
D
ev
el
op
in
g 
a 
su
m
m
ar
y 
m
ea
su
re
 o
f a
ss
oc
ia
tio
ns
 
be
tw
ee
n 
m
ul
tip
le
 S
N
Ps
 
an
d 
tra
its
 o
f i
nt
er
es
t
A
da
pt
ed
 th
e 
Ra
sc
h 
m
od
el
 to
 c
om
pu
te
 a
 m
ul
tim
ar
ke
r 
ge
ne
tic
 su
m
m
ar
y 
sc
or
e 
w
hi
ch
 a
cc
ou
nt
s f
or
 st
at
ist
ic
al
 is
su
es
 su
ch
 a
s i
nf
la
te
d 
fa
lse
-p
os
iti
v
e 
ra
te
s,
 li
nk
ag
e 
di
se
qu
ili
br
iu
m
. G
en
et
ic
 su
m
m
ar
y 
sc
or
e 
ca
n 
th
en
 b
e 
us
ed
 fo
r a
ss
oc
ia
tio
n 
an
al
ys
is.
[2
02
]
D
ev
el
op
ed
 a
 su
m
m
ar
y 
sc
or
e 
ba
se
d 
on
 a
n 
as
ym
pt
ot
ic
al
ly
 n
or
m
al
 a
nd
 c
on
sis
te
nt
 e
sti
m
at
e 
of
 th
e 
pa
ra
m
et
er
 v
ec
to
r t
o 
be
 te
ste
d 
an
d 
its
 c
ov
ar
ia
nc
e 
m
at
rix
. T
he
 
de
riv
ed
 sc
or
e 
ve
ct
or
 e
x
te
nd
ed
 se
v
er
al
 sc
or
e-
ba
se
d 
te
sts
 to
 m
ix
ed
-e
ffe
ct
s m
od
el
s.
[2
48
]
A
cc
ur
at
el
y 
ca
lli
ng
 
m
u
lti
sa
m
pl
e 
va
ria
nt
s f
or
 
w
ho
le
-g
en
om
e 
se
qu
en
ci
ng
Co
m
pa
re
d 
tw
o
 m
u
lti
sa
m
pl
e 
va
ria
nt
-c
al
lin
g 
m
et
ho
ds
 fo
r t
he
 d
et
ec
tio
n 
of
 sm
al
l n
uc
le
ot
id
e 
va
ria
nt
s a
nd
 sh
or
t o
n 
so
lu
tio
ns
 a
nd
 d
el
et
io
ns
 u
sin
g 
a 
w
ho
le
-g
en
om
e 
se
qu
en
ci
ng
 d
at
a 
fro
m
 A
D
N
I s
ub
jec
ts.
 Fo
u
n
d 
th
at
 th
e 
JO
IN
T 
m
et
ho
d,
 w
hi
ch
 fi
rs
t c
al
ls 
va
ria
nt
s i
nd
iv
id
ua
lly
 a
nd
 th
en
 g
en
ot
yp
es
 th
e 
va
ria
nt
 fi
le
s f
or
 a
ll 
sa
m
pl
es
, 
o
u
tp
er
fo
rm
ed
 th
e 
se
co
nd
 m
et
ho
d,
 R
ED
U
CE
.
[2
49
]
Id
en
tif
yi
ng
 in
te
ra
ct
io
n 
ef
fe
ct
s
Co
m
bi
ne
d 
ke
rn
el
 m
ac
hi
ne
 re
gr
es
sio
n 
an
d 
ke
rn
el
 d
ist
an
ce
 c
ov
ar
ia
nc
e 
to
 id
en
tif
y 
as
so
ci
at
ed
 g
en
et
ic
 m
ar
ke
rs
 w
ith
 m
ul
tid
im
en
sio
na
l p
he
no
ty
pe
s. 
Id
en
tif
ie
d 
SN
Ps
 
in
 F
LJ
16
12
4 
th
at
 ex
hi
bi
t p
ai
rw
ise
 in
te
ra
ct
io
n 
ef
fe
ct
s c
or
re
la
te
d 
w
ith
 v
o
lu
m
et
ric
 c
ha
ng
es
.
[2
50
]
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C
ha
lle
ng
e
A
pp
ro
a
ch
 a
nd
 re
su
lts
R
ef
er
en
ce
Pr
op
os
ed
 a
 g
en
er
al
 k
er
n
el
 m
ac
hi
ne
-b
as
ed
 m
et
ho
d 
to
 jo
int
ly 
de
tec
tin
g g
en
eti
c a
nd
 no
ng
en
eti
c v
ar
ia
bl
es
 a
nd
 th
ei
r i
nt
er
ac
tio
ns
. F
ra
m
ew
o
rk
 c
on
sis
ts 
of
 a
 g
en
et
ic
 
ke
rn
el
 to
 c
ap
tu
re
 e
pi
sta
sis
, a
nd
 a
 n
on
ge
ne
tic
 k
er
n
el
 w
hi
ch
 c
an
 m
od
el
 th
e 
joi
nt 
eff
ec
ts 
of
 m
ul
tip
le
 v
ar
ia
bl
es
.
[1
89
]
Pr
op
os
ed
 a
 n
ew
 B
ay
es
ia
n 
ge
ne
ra
liz
ed
 lo
w
-r
an
k 
re
gr
es
sio
n 
m
od
el
 to
 c
ha
ra
ct
er
iz
e 
th
e 
as
so
ci
at
io
n 
be
tw
ee
n 
ge
ne
tic
 v
ar
ia
nt
s a
nd
 b
ra
in
 im
ag
in
g 
ph
en
ot
yp
es
, w
hi
le
 
ac
co
u
n
tin
g 
th
e 
im
pa
ct
 o
f o
th
er
 c
ov
ar
ia
nc
e.
 T
es
te
d 
us
in
g 
20
 m
os
t s
ig
ni
fic
an
t S
N
Ps
 fr
om
 A
D
N
I a
nd
 id
en
tif
ie
d 
lo
ci
 a
ss
oc
ia
te
d 
w
ith
 b
ra
in
 re
gi
on
s. 
M
et
ho
d 
w
as
 
m
o
re
 c
o
m
pu
ta
tio
na
lly
 e
ffi
ci
en
t a
nd
 le
ss
 n
oi
sy
 b
ec
au
se
 it
 re
du
ce
d 
th
e 
nu
m
be
r o
f p
ar
am
et
er
s t
o 
be
 sa
m
pl
ed
 a
nd
 te
ste
d.
[2
51
]
Pr
es
en
te
d 
a 
m
et
ho
d 
to
 c
on
sid
er
 jo
int
 ef
fe
ct
s f
or
 p
ol
ym
or
ph
ism
s i
n 
a 
bi
ol
og
ic
al
ly
 d
ef
in
ed
 p
at
hw
ay
.
 
D
et
er
m
in
es
 S
N
P-
SN
P 
in
te
ra
ct
io
ns
 u
sin
g 
a 
qu
an
tit
at
ed
 
m
u
lti
fa
ct
or
 d
im
en
sio
na
lit
y 
re
du
ct
io
n 
te
ch
ni
qu
e,
 in
fe
rs
 fu
nc
tio
na
l r
el
at
io
ns
hi
ps
 b
et
w
ee
n 
se
le
ct
ed
 g
en
es
, a
nd
 u
se
s g
en
e-
se
t e
nr
ic
hm
en
t a
na
ly
sis
 to
 d
et
er
m
in
e 
w
he
th
er
 g
en
es
 a
nd
 fu
nc
tio
na
l n
et
w
o
rk
 o
cc
ur
 m
or
e 
fre
qu
en
tly
 th
an
 ex
pe
ct
ed
 b
y 
ch
an
ce
 a
nd
 b
io
lo
gi
ca
l p
at
hw
ay
s d
ef
in
ed
 b
y 
ge
ne
 o
nt
ol
og
y.
[2
05
] [
25
2]
Pr
op
os
ed
 a
 v
er
sa
til
e 
lik
el
ih
oo
d 
ra
tio
 te
st 
to
 d
et
ec
t m
ea
n 
an
d 
va
ria
nc
e 
he
te
ro
ge
ne
ity
 p
re
se
nt
 in
 lo
ci
 d
ue
 to
 b
io
lo
gi
ca
l d
isr
up
tio
n,
 g
en
e 
by
 g
en
e 
or
 g
en
e 
by
 
en
v
iro
nm
en
t i
nt
er
ac
tio
ns
 o
r l
in
ka
ge
 d
ise
qu
ili
br
iu
m
.
Vi
su
al
iz
in
g 
ge
ne
tic
 
in
te
ra
ct
io
n 
ne
tw
o
rk
s
U
se
d 
3D
 p
rin
tin
g 
to
 v
isu
al
iz
e 
a 
sta
tis
tic
al
 e
pi
sta
sis
 n
et
w
o
rk
 o
f 3
4 
sig
ni
fic
an
t S
N
Ps
. S
ug
ge
st 
th
at
 a
 3
D
 p
hy
sic
al
 m
od
el
 m
ay
 m
ak
e 
in
te
rp
re
ta
tio
n 
of
 d
at
a 
ea
sie
r 
th
an
 fr
om
 a
 d
ig
ita
l r
ep
re
se
nt
at
io
n.
[2
53
]
Im
pu
tin
g 
co
m
m
on
 
A
PO
E 
SN
Ps
 m
iss
in
g 
fro
m
 g
en
om
e-
w
id
e 
ge
no
ty
pi
ng
 a
rra
ys
.
Co
m
pa
re
d 
di
re
ct
ly
 g
en
ot
yp
ed
 S
N
Ps
 v
er
su
s 
SN
Ps
 im
pu
te
d 
vi
a 
re
fe
re
nc
e 
pa
ne
l c
om
pi
le
d 
by
 th
e 
Th
ou
sa
nd
s G
en
om
e 
Pr
oje
ct.
 R
ep
ort
ed
 th
at 
the
 im
pu
tat
ion
 
m
et
ho
d 
is 
hi
gh
ly
 a
cc
ur
at
e.
[2
38
]
Le
ar
ni
ng
 p
re
di
ct
iv
e 
m
o
de
ls 
or
 p
ro
gr
es
sio
n 
pr
of
ile
s
A
pp
lie
d 
th
re
e 
fe
at
ur
e 
se
le
ct
io
n 
m
et
ho
ds
 (m
ult
ipl
e k
er
n
el
 le
ar
ni
ng
, h
ig
h-
or
de
r g
ra
ph
 m
at
ch
in
g-
ba
se
d 
fe
at
ur
e 
se
le
ct
io
n,
 sp
ar
se
 m
ul
tim
od
al
 le
ar
ni
ng
) t
o 
cl
as
sif
ic
at
io
n 
ch
al
le
ng
es
 u
sin
g 
m
ul
tid
im
en
sio
na
l i
m
ag
in
g 
ge
no
m
ic
s d
at
a 
an
d 
bi
oc
he
m
ic
al
 m
ar
ke
rs
. 
Fo
u
n
d 
th
at
 h
ig
he
r o
rd
er
 g
ra
ph
 m
at
ch
in
g-
ba
se
d 
fe
at
ur
e 
se
le
ct
io
n 
ga
v
e 
be
st 
re
su
lts
.
[2
54
]
U
se
d 
th
e 
pr
in
ci
pa
l c
om
po
ne
nt
 a
na
ly
sis
 to
 se
le
ct
 m
os
t i
m
po
rta
nt
 S
N
Ps
 a
ss
oc
ia
te
d 
w
ith
 c
lin
ic
al
 d
ia
gn
os
is 
an
d 
us
ed
 th
es
e 
da
ta
 a
lo
ng
 w
ith
 h
ip
po
ca
m
pa
l s
ur
fa
ce
 
in
fo
rm
at
io
n 
to
 p
re
di
ct
 M
CI
 to
 A
D
 p
ro
gr
es
sio
n.
[2
55
]
A
bb
re
v
ia
tio
ns
: M
RI
, m
ag
ne
tic
 re
so
na
nc
e 
im
ag
in
g;
 A
D
N
I, 
A
lz
he
im
er
’s
 D
ise
as
e 
N
eu
ro
im
ag
in
g 
In
iti
at
iv
e;
 S
N
P,
 
sm
al
l n
uc
le
ot
id
e 
po
ly
m
or
ph
ism
; A
D
, A
lz
he
im
er
’s
 d
ise
as
e;
 M
CI
, m
ild
 c
og
ni
tiv
e 
im
pa
irm
en
t.
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Ta
bl
e 
8
Cl
us
te
r-d
er
iv
ed
 M
CI
 su
bt
yp
es
 fr
om
 A
D
N
I s
tu
di
es
C
lu
st
er
-
de
ri
v
ed
 M
C
I s
ub
ty
pe
s (
%
 of
 M
CI
 gr
o
u
p)
Ed
m
on
ds
 e
t a
l. 
[2
82
]
Ed
m
on
ds
 e
t a
l. 
[2
81
]
 
Pe
te
r 
et
 a
l. 
[2
83
]
Bo
nd
i e
t a
l. 
[2
80
], 
Ac
tu
ar
ial
†
Bo
nd
i e
t a
l. 
[2
80
], 
AD
NI
 cr
ite
ria
A
m
ne
sti
c 
(ty
pic
al 
AD
)
25
.7
34
.9
32
.0
58
.6
56
D
ys
ex
ec
u
tiv
e/
m
ix
ed
33
.0
*
12
.4
-
12
.9
19
.7
N
or
m
al
41
.3
34
.2
-
-
31
.3
La
ng
ua
ge
/n
am
in
g 
im
pa
ire
d
-
18
.5
17
21
-
Vi
su
os
pa
tia
l i
m
pa
ire
d
-
-
42
-
-
Fo
ca
l i
nt
ru
sio
ns
-
-
9
-
-
A
bb
re
v
ia
tio
ns
: M
CI
, m
ild
 c
og
ni
tiv
e 
im
pa
irm
en
t; 
A
D
N
I, 
A
lz
he
im
er
’s
 D
ise
as
e 
N
eu
ro
im
ag
in
g 
In
iti
at
iv
e;
 A
D
, A
lz
he
im
er
’s
 d
ise
as
e.
*
In
cl
ud
ed
 im
pa
irm
en
ts 
in
 n
am
in
g.
† C
la
ss
ifi
ed
 4
01
 su
bje
cts
 as
 M
CI
 (c
om
pa
red
 to
 84
6 u
sin
g c
on
v
en
tio
na
l A
D
N
I c
rit
er
ia
).
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Ta
bl
e 
9
Su
m
m
ar
y 
of
 c
la
ss
ifi
ca
tio
n 
an
d 
pr
ed
ic
tio
n 
m
et
ho
ds
C
la
ss
ifi
ca
tio
n 
ch
al
le
ng
e
M
od
al
ity
Fe
a
tu
re
 s
el
ec
tio
n/
di
m
en
sio
na
lit
y 
re
du
ct
io
n
C
la
ss
ifi
er
N
A
D
 v
er
su
s 
C
N
M
C
I v
er
su
s 
C
N
M
C
I v
er
su
s 
A
D
M
C
Ic
 
v
er
su
s 
M
C
In
c
O
th
er
U
ni
qu
e a
pp
ro
a
ch
R
ef
er
en
ce
M
R
I
M
ul
ti-
at
la
s
SV
M
45
9
A
CC
91
.6
A
CC
72
.4
Su
bje
cts
 re
gi
ste
re
d 
to
 
m
u
lti
pl
e 
at
la
se
s, 
fe
at
ur
es
 
se
le
ct
ed
 fr
om
 e
ac
h 
at
la
s, 
th
en
 jo
int
ly 
sel
ect
ed
[3
72
]
SE
N
88
.6
SE
N
72
.1
SP
E
93
.9
SP
E
72
.6
AU
C
0.
87
AU
C
0.
67
M
R
I
M
ul
ti-
at
la
s
SV
M
45
9
A
CC
90
.7
A
CC
73
.7
Jo
in
t l
ea
rn
in
g 
of
 o
pt
im
um
 
re
pr
es
en
ta
tio
n 
of
 fe
at
ur
es
 
fro
m
 m
ul
tip
le
 a
tla
se
s a
nd
 
cl
as
sif
ie
r u
sin
g 
m
ax
im
um
 
m
ar
gi
n 
ap
pr
oa
ch
[3
73
]
SE
N
87
.6
SE
N
76
.4
SP
E
93
.0
SP
E
70
.8
M
R
I
M
ul
tit
em
pl
at
e
SV
M
45
9
A
CC
93
.3
A
CC
80
.9
In
he
re
nt
 st
ru
ct
ur
e-
ba
se
d 
m
u
lti
v
ie
w
 le
ar
ni
ng
 (I
SM
L)
 
cl
us
te
rs
 su
bje
cts
 w
ith
in 
a 
sp
ec
ifi
c 
cl
as
s i
nt
o 
su
bc
la
ss
es
 
ba
se
d 
on
 fe
at
ur
es
 le
ar
ne
d 
u
sin
g 
m
ul
tip
le
 te
m
pl
at
es
[3
74
]
SE
N
92
.8
SE
N
86
.0
SP
E
95
.7
SP
E
78
.4
M
R
I
In
de
pe
nd
en
t 
co
m
po
ne
nt
 
an
al
ys
is
SV
M
81
8
A
CC
86
.4
A
CC
70
.2
A
CC
69
.8
U
se
s n
ov
el
 IC
A
-b
as
ed
 
fe
at
ur
e 
ex
tr
ac
tio
n 
m
et
ho
d 
an
d 
lin
ea
r S
V
M
 fo
r 
cl
as
sif
ic
at
io
n
[3
75
]
SE
N
88
.3
SE
N
72
.9
SE
N
73
.4
SP
E
84
.0
SP
E
67
.5
SP
E
66
.2
M
R
I
Sp
at
ia
lly
 w
ei
gh
te
d 
pr
in
ci
pa
l 
co
m
po
ne
nt
 
an
al
ys
is
SV
M
39
0
Av
er
ag
e 
m
isc
la
ss
ifi
ca
tio
n 
%
: 0
.2
16
In
co
rp
or
at
es
 sp
at
ia
l 
st
ru
ct
ur
e 
by
 u
sin
g 
bo
th
 
gl
ob
al
 a
nd
 lo
ca
l s
pa
tia
l 
w
ei
gh
ts 
fo
r f
ea
tu
re
 se
le
ct
io
n 
to
 im
pr
ov
e 
o
n
 P
CA
 a
lo
ne
[3
76
]
M
R
I
Ci
rc
ul
ar
 h
ar
m
on
ic
 
fu
nc
tio
n 
+ 
pr
in
ci
pa
l 
co
m
po
ne
nt
 
an
al
ys
is
SV
M
N
A
A
CC
83
.8
A
CC
69
.5
A
CC
62
.1
U
se
s c
irc
ul
ar
 h
ar
m
on
ic
 
fu
nc
tio
ns
 to
 ex
tr
ac
t l
oc
al
 
fe
at
ur
es
 fr
om
 th
e 
hi
pp
oc
am
pu
s a
nd
 p
os
te
rio
r 
ci
ng
ul
at
e 
co
rte
x
 a
n
d 
PC
A
 
fo
r d
im
en
sio
na
lit
y 
re
du
ct
io
n
[3
77
]
SE
N
88
.2
SE
N
74
.8
SE
N
75
.1
SP
E
79
.1
SP
E
62
.5
SP
E
49
.0
M
R
I
G
au
ss
ia
n 
pr
oc
es
s 
m
o
de
ls
41
5
AU
C
0.
94
AU
C
0.
91
G
en
er
at
es
 q
ua
nt
ita
tiv
e 
m
ap
s 
o
f z
-s
co
re
s f
or
 W
M
, G
M
, 
an
d 
CS
F 
ab
no
rm
al
iti
es
 fo
r 
cl
in
ic
al
 d
ec
isi
on
 su
pp
or
t
[3
78
]
M
CI
c 
ve
rs
u
s 
CN
M
R
I
M
an
ifo
ld
 le
ar
ni
ng
: 
re
le
v
an
t v
ar
ia
bl
e 
se
le
ct
io
n 
(le
arn
ed
 
RO
Is
)
M
R
1 
di
se
as
e 
st
at
e 
sc
or
e
36
3
A
CC
61
N
ov
el
 M
RI
 d
ise
as
e 
sta
te
 
sc
o
re
 (M
RI
 D
SS
). A
lso
 us
ed
 
to
 p
re
di
ct
 M
M
SE
 sc
or
es
 a
nd
 
ac
hi
ev
ed
 se
pa
ra
tio
n 
be
tw
ee
n 
[3
79
]
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C
la
ss
ifi
ca
tio
n 
ch
al
le
ng
e
M
od
al
ity
Fe
a
tu
re
 s
el
ec
tio
n/
di
m
en
sio
na
lit
y 
re
du
ct
io
n
C
la
ss
ifi
er
N
A
D
 v
er
su
s 
C
N
M
C
I v
er
su
s 
C
N
M
C
I v
er
su
s 
A
D
M
C
Ic
 
v
er
su
s 
M
C
In
c
O
th
er
U
ni
qu
e a
pp
ro
a
ch
R
ef
er
en
ce
A
D
N
I-
G
O
SE
N
50
CN
, E
M
CI
, M
CI
nc
, M
CI
c,
 
an
d 
A
D
 g
ro
up
s
SP
E
72
EM
CI
 v
er
su
s 
CN
SV
M
51
1
A
CC
86
A
CC
71
A
CC
82
A
D
N
I
SE
N
86
SE
N
75
SE
N
81
SP
E
85
SP
E
67
SP
E
83
M
CI
c 
ve
rs
u
s 
CN
M
R
I
M
an
ifo
ld
 le
ar
ni
ng
: 
se
lf-
or
ga
n
iz
in
g 
m
ap
SV
M
81
8
A
CC
90
A
CC
84
U
se
s s
el
f-o
rg
an
iz
in
g 
m
ap
 to
 
se
le
ct
 m
ax
im
al
ly
 
di
sc
rim
in
at
iv
e 
RO
Is
 a
nd
 
co
m
pu
te
s r
el
at
iv
e 
im
po
rta
nc
e 
m
ea
su
re
 fo
r 
ea
ch
 R
O
I
[3
80
]
SE
N
87
SE
N
82
SP
E
92
SP
E
87
AU
C
0.
92
AU
C
0.
84
M
R
I
M
an
ifo
ld
 le
ar
ni
ng
: 
lo
ca
l b
in
ar
y 
m
ap
 +
 
cu
st
om
 m
as
ks
SV
M
36
3
A
CC
82
.8
A
CC
61
.5
U
se
s l
oc
al
 b
in
ar
y 
m
ap
s t
o 
di
re
ct
ly
 se
le
ct
 d
ise
as
e-
sp
ec
ifi
c 
pa
tte
rn
s o
n 
a 
v
o
x
el
w
ise
 b
as
is 
w
ith
ou
t 
n
o
n
rig
id
 re
gi
str
at
io
n.
 A
lso
 
u
se
s 
se
v
en
 k
no
w
le
dg
e-
ba
se
d 
RO
Is
[3
81
]
SE
N
80
.4
SE
N
61
.5
SP
E
82
.7
SP
E
63
.5
AU
C
0.
87
AU
C
0.
64
M
R
I
M
ul
tiv
ar
ia
te
 
re
gr
es
sio
n:
 e
la
sti
c 
n
et
Lo
w
 d
en
sit
y 
se
pa
ra
tio
n
83
4
AU
C
0.
73
U
se
d 
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ra
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 m
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at
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at
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 m
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re
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at
io
n 
fu
nc
tio
n 
in
to
 
sin
gl
e 
le
ar
ni
ng
 a
lg
or
ith
m
 fo
r 
[4
15
]
FD
G
 P
ET
SE
N
85
.3
CS
F
SP
E
73
.3
AU
C
0.
85
Alzheimers Dement. Author manuscript; available in PMC 2019 October 29.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Weiner et al. Page 158
C
la
ss
ifi
ca
tio
n 
ch
al
le
ng
e
M
od
al
ity
Fe
a
tu
re
 s
el
ec
tio
n/
di
m
en
sio
na
lit
y 
re
du
ct
io
n
C
la
ss
ifi
er
N
A
D
 v
er
su
s 
C
N
M
C
I v
er
su
s 
C
N
M
C
I v
er
su
s 
A
D
M
C
Ic
 
v
er
su
s 
M
C
In
c
O
th
er
U
ni
qu
e a
pp
ro
a
ch
R
ef
er
en
ce
bo
th
 fe
at
ur
e 
se
le
ct
io
n 
an
d 
cl
as
sif
ic
at
io
n
M
R
I
M
ul
tim
od
al
 c
an
on
ic
al
 c
or
re
la
tio
n 
an
al
ys
is
10
3
A
CC
95
.1
U
se
d 
ca
no
ni
ca
l c
or
re
la
tio
n 
an
al
ys
is 
to
 fu
se
 d
at
a 
in
 
m
u
lti
m
od
al
 c
la
ss
ifi
ca
tio
n 
as
 
it 
pr
es
er
ve
s 
in
te
rm
od
al
 
re
la
tio
ns
hi
ps
.
[4
16
]
FD
G
 P
ET
CS
F
M
R
I
D
ee
p 
ar
ch
ite
ct
ur
e 
+
 m
ul
tit
as
k 
le
ar
ni
ng
SV
M
20
2
A
CC
95
.1
A
CC
80
.1
93
.9
A
CC
74
.1
U
se
s n
ov
el
 d
ee
p 
le
ar
ni
ng
 
ar
ch
ite
ct
ur
e 
th
at
 d
isc
ar
ds
 
u
n
in
fo
rm
at
iv
e 
fe
at
ur
es
 in
 a
 
hi
er
ar
ch
ic
al
 m
an
ne
r d
ur
in
g 
m
u
lti
ta
sk
 le
ar
ni
ng
[4
17
]
PE
T
SE
N
92
SE
N
53
.7
SE
N
50
.5
CS
F
SP
E
98
.3
SP
E
SP
E
92
.7
M
R
I/P
ET
/C
SF
M
R
I/P
ET
M
R
I/P
ET
M
R
I
D
ee
p 
le
ar
ni
ng
 
w
ith
 D
ee
p 
B
ol
tz
m
an
 
M
ac
hi
ne
H
ie
ra
rc
hi
ca
l 
SV
M
39
8
A
CC
95
.4
A
CC
85
.7
A
CC
75
.9
U
se
s d
ee
p 
le
ar
ni
ng
 w
ith
 a
 
B
ol
tz
m
an
 M
ac
hi
ne
 to
 fi
nd
 
hi
er
ar
ch
ic
al
 fe
at
ur
e 
re
pr
es
en
ta
tio
n 
fro
m
 M
RI
 
fe
at
ur
es
 a
nd
 th
en
 fu
se
s t
he
se
 
w
ith
 c
om
pl
em
en
ta
ry
 
in
fo
rm
at
io
n 
fro
m
 P
ET
[4
18
]
PE
T
SE
N
94
.7
SE
N
95
.4
SE
N
48
SP
E
95
.2
SP
E
65
.9
SP
E
95
.2
AU
C
0.
99
AU
C
0.
88
AU
C
0.
75
M
R
I
PC
A
/L
A
SS
O
 +
 
m
u
lti
ta
sk
 d
ee
p 
le
ar
ni
ng
 w
ith
 
dr
op
ou
t t
ec
hn
iq
ue
SV
M
20
2
A
CC
91
.4
A
CC
77
.4
A
CC
57
.4
U
se
s d
ro
po
ut
 te
ch
ni
qu
e 
as
 
m
et
ho
d 
of
 re
gu
la
riz
at
io
n 
fo
r 
de
ep
 le
ar
ni
ng
 w
ith
 sm
al
l 
da
ta
[4
19
]
PE
T
CS
F
D
em
og
ra
ph
ic
s
M
R
I
In
de
pe
nd
en
t 
co
m
po
ne
nt
 
an
al
ys
is
D
isc
rim
in
an
t 
cl
as
sif
ic
at
io
n 
an
al
ys
is
32
0
A
CC
94
.3
A
CC
83
.3
A
CC
84
.1
A
CC
80
.0
D
er
iv
ed
 G
M
 c
ov
ar
ia
te
s 
pa
tte
rn
s u
sin
g 
in
de
pe
nd
en
t 
co
m
po
ne
nt
 a
na
ly
sis
 a
nd
 
u
se
d 
fo
r d
ia
gn
os
tic
 
cl
as
sif
ic
at
io
n 
in
 
co
m
bi
na
tio
n 
w
ith
 c
og
ni
tiv
e 
pe
rfo
rm
an
ce
[3
04
]
D
em
og
ra
ph
ic
s
SE
N
94
.9
SE
N
76
.7
SE
N
86
.1
SE
N
78
.3
SP
E
94
.0
SP
E
89
.1
SP
E
73
.0
SP
E
81
.5
M
R
I
St
ac
ke
d 
au
to
-
en
co
de
r +
 
m
u
lti
ta
sk
 d
ee
p 
le
ar
ni
ng
 w
ith
 z
er
o-
m
as
k 
str
at
eg
y
So
ftm
ax
 
lo
gi
sti
c 
re
gr
es
sio
n
33
1
A
CC
91
.4
A
CC
82
.1
U
se
s s
ta
ck
ed
 a
ut
oe
nc
od
er
s 
to
 e
x
tr
ac
t h
ig
h-
le
v
el
 fe
at
ur
es
 
an
d 
a 
ze
ro
-m
as
ki
ng
 st
ra
te
gy
 
to
 e
x
tr
ac
t s
yn
er
gy
 b
et
w
ee
n 
m
o
da
lit
ie
s
[4
20
]
PE
T
SE
N
92
.3
SE
N
60
.0
SP
E
90
.4
SP
E
92
.3
A
bb
re
v
ia
tio
ns
: A
D
, A
lz
he
im
er
’s
 d
ise
as
e;
 C
N
, c
og
ni
tiv
el
y 
no
rm
al
; M
CI
, m
ild
 c
og
ni
tiv
e 
im
pa
irm
en
t; 
M
CI
c,
 m
ild
 c
og
ni
tiv
e 
im
pa
irm
en
t c
on
v
er
te
rs
 (p
rog
res
siv
e 
M
CI
); 
M
CI
nc
, m
ild
 co
gn
itiv
e 
im
pa
irm
en
t n
on
-
co
nv
er
te
rs
 (s
tab
le 
M
CI
); 
M
RI
, m
ag
ne
tic
 re
so
na
nc
e i
ma
gin
g; 
SV
M
, s
up
po
rt 
ve
ct
or
 m
ac
hi
ne
; A
CC
, a
cc
ur
ac
y;
 S
EN
, s
en
sit
iv
ity
; S
PE
, s
pe
ci
fic
ity
; A
U
C,
 a
re
a 
un
de
r t
he
 re
ce
iv
er
 o
pe
ra
tin
g 
cu
rv
e;
 IC
A
, 
in
de
pe
nd
en
t c
om
po
ne
nt
 a
na
ly
sis
; P
CA
, p
rin
ci
pa
l c
om
po
ne
nt
 a
na
ly
sis
; W
M
, w
hi
te
 m
at
te
r; 
G
M
, g
ra
y 
m
at
te
r; 
CS
F,
 
ce
re
br
os
pi
na
l f
lu
id
; A
D
N
I, 
A
lz
he
im
er
’s
 D
ise
as
e 
N
eu
ro
im
ag
in
g 
In
iti
at
iv
e;
 E
M
CI
, e
ar
ly
 m
ild
 
co
gn
iti
v
e 
im
pa
irm
en
t; 
RO
I, 
re
gi
on
s o
f i
nt
er
es
t; 
V
BM
, v
o
x
el
-b
as
ed
 m
or
ph
om
et
ry
; f
M
RI
, f
un
ct
io
na
l m
ag
ne
tic
 re
so
na
nc
e 
im
ag
in
g;
 S
M
C,
 su
bje
cti
v
e 
m
em
o
ry
 c
on
ce
rn
; F
D
G
 P
ET
,
 
18
F-
flu
ro
de
ox
yg
lu
co
se
 
Alzheimers Dement. Author manuscript; available in PMC 2019 October 29.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Weiner et al. Page 159
po
sit
ro
n 
em
iss
io
n 
to
m
og
ra
ph
y;
 M
A
P,
 
m
ea
n
 a
v
er
ag
e 
pr
ec
isi
on
; A
PO
E4
,
 
ap
ol
ip
op
ro
te
in
 ε4
 a
lle
le
; P
ET
,
 
po
sit
ro
n 
em
iss
io
n 
to
m
og
ra
ph
y;
 H
C,
 h
ip
po
ca
m
pu
s; 
LA
SS
O
, l
ea
st 
ab
so
lu
te
 sh
rin
ka
ge
 a
nd
 se
le
ct
io
n 
o
pe
ra
to
r; 
LD
D
M
M
, l
ar
ge
 d
ef
or
m
at
io
ns
 v
ia
 d
iff
eo
m
or
ph
ism
s.
Alzheimers Dement. Author manuscript; available in PMC 2019 October 29.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Weiner et al. Page 160
Ta
bl
e 
10
Pr
ed
ic
tio
n 
of
 c
on
tin
uo
us
 v
ar
ia
bl
es
C
la
ss
ifi
ca
tio
n 
ch
al
le
ng
e
M
od
al
ity
Fe
a
tu
re
 s
el
ec
tio
n/
di
m
en
sio
na
lit
y 
re
du
ct
io
n
C
la
ss
ifi
er
N
A
DA
S-
co
g
M
M
SE
R
A
LV
T
U
ni
qu
e a
pp
ro
a
ch
R
ef
er
en
ce
M
R
I 
Co
rti
ca
l 
su
rfa
ce
M
ul
tiv
ar
ia
te
 re
gr
es
sio
n:
 l 
2,
1 
n
o
rm
SV
M
71
8
R
M
SE
0.
76
63
 
±
 0
.0
37
5
0.
83
25
 
±
 0
.0
39
9
0.
91
67
 
±
 0
.0
47
1
Pr
op
os
e 
sp
ar
se
 m
ul
tit
as
k 
le
ar
ni
ng
 m
od
el
 G
ro
up
-S
pa
rs
e 
M
ul
ti-
ta
sk
 R
eg
re
ss
io
n 
an
d 
Fe
at
ur
e 
Se
le
ct
io
n 
(G
-
SM
uR
FS
) t
o s
ele
ct 
co
rti
ca
l s
urf
ac
e 
m
ar
ke
rs
[4
40
]
CC
0.
64
38
 
±
 0
.0
25
8
0.
52
77
 
±
 0
.0
53
9
0.
39
85
 
±
 0
.0
53
3
M
R
I
M
ul
tit
as
k 
le
ar
ni
ng
: r
el
at
io
na
l 
fu
nc
tio
n 
+ 
l 2
,1
 
re
gr
es
sio
n
SV
M
20
2
CC
(A
D 
vs
. 
M
CI
)
0.
68
0
0.
68
2
In
tro
du
ce
s a
 fu
nc
tio
n 
to
 c
on
se
rv
e 
in
fo
rm
at
io
n 
ab
ou
t 
fe
at
ur
e-
fe
at
ur
e 
re
la
tio
ns
, r
es
po
ns
e-
re
sp
on
se
 re
la
tio
ns
, a
nd
 
sa
m
pl
e-
sa
m
pl
e 
re
la
tio
ns
 w
hi
le
 jo
int
ly 
sol
vin
g b
oth
 
cl
as
sif
ic
at
io
n 
an
d 
pr
ed
ic
tio
n 
of
 c
on
tin
uo
us
 v
ar
ia
bl
es
[4
10
]
PE
T
CC
 (M
CI
 
v
s.
 C
N
)
0.
52
0
0.
50
8
CC
 (M
CI
c 
v
s.
 
M
CI
nc
)
0.
59
1
0.
62
2
M
R
I
Ca
no
ni
ca
l c
or
re
la
tio
n 
an
al
ys
is 
+
 n
ov
el
 sp
ar
se
 m
ul
tit
as
k 
le
ar
ni
ng
SV
M
20
2
CC
0.
74
0 
±
0.
18
0.
67
5 
±
 0
.2
3
U
se
s c
an
on
ic
al
 c
or
re
la
tio
n 
an
al
ys
is 
to
 d
et
er
m
in
e 
co
rr
el
at
io
ns
 b
et
w
ee
n 
fe
at
ur
es
 o
f d
iff
er
en
t m
od
al
iti
es
[4
41
]
FD
G
 P
ET
N
ot
e:
 fo
r A
D
 v
s. 
M
CI
 v
s. 
CN
M
R
I
Ca
no
ni
ca
l c
or
re
la
tio
n 
an
al
ys
is 
+
 n
ov
el
 sp
ar
se
 m
ul
tit
as
k 
le
ar
ni
ng
SV
M
20
2
R
M
SE
4.
20
1 
±
 0
.8
2
2.
11
0 
±
 0
.4
1
Si
m
ila
r t
o 
[4
41
]
[4
42
]
FD
G
 P
ET
CC
0.
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 c
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 c
or
re
la
te
d 
fe
at
ur
es
 
th
at
 c
an
 jo
int
ly 
pre
dic
t c
las
s l
ab
el 
an
d c
lin
ica
l s
co
res
.
[4
12
]
FD
G
 P
ET
LA
SS
O
 g
ro
up
 p
en
al
ty
CS
F
M
R
I
M
ul
tiv
ar
ia
te
 re
gr
es
sio
n:
 
sp
ar
se
 m
od
el
Sp
ar
se
 
B
ay
es
ia
n
39
3
CC
0.
76
7
0.
75
8
M
od
el
s c
og
ni
tiv
e 
sc
o
re
s 
as
 n
o
n
lin
ea
r f
un
ct
io
ns
 o
f 
n
eu
ro
im
ag
in
g 
va
ria
bl
es
; m
od
el
s c
or
re
la
tio
ns
 b
et
w
ee
n 
re
gr
es
sio
n 
co
ef
fic
ie
nt
s. 
D
er
iv
es
 s
pa
rs
e 
Ba
ye
sia
n 
le
ar
ni
ng
 
al
go
rit
hm
 fo
r l
ea
rn
in
g.
[4
43
]
M
R
I (
TB
M
)
M
ul
tiv
ar
ia
te
 T
BM
 +
 
Co
nv
ex
 F
us
ed
 S
pa
rs
e 
G
ro
up
 L
A
SS
O
Pr
ed
ic
tio
n 
of
 
co
n
tin
uo
us
 
v
ar
ia
bl
es
: A
DA
S-
co
g
61
6
Pr
ed
ic
tio
n 
of
 A
DA
S-
co
g 
sc
or
es
 
(R
M
SE
)
U
se
s C
on
v
ex
 F
us
ed
 S
pa
rs
e 
G
ro
up
 L
A
SS
O
 
fo
r m
ul
tit
as
k 
le
ar
ni
ng
 u
sin
g 
m
ul
tiv
ar
ia
te
 
TB
M
 d
at
a 
to
 p
re
di
ct
 A
DA
S-
co
g 
sc
or
es
 a
t 6
, 
12
, 2
4,
 3
6,
 an
d 
48
 m
on
th
s.
[4
44
]
H
C 
sh
ap
e,
 
Cl
in
ic
al
, 
A
PO
E4
,
 
ba
se
lin
e 
M
M
SE
M
on
th
s
6
12
24
36
48
w
/o
 
m
TB
M
5.
25
9 
±
 0
.8
7
5.
65
3 
±
 1
.1
4.
 7
5.
53
2 
±
 1
.0
3
4.
77
7 
±
 0
.8
3
4.
36
7 
±
 1
.1
8
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W
ith
 
m
TB
M
4.
53
4 
±
 0
.8
8
4.
98
9 
±
 1
.1
3
4.
88
5 
±
 1
.0
9
4.
05
5 
±
 1
.0
2
3.
16
4 
±
 1
.0
9
A
bb
re
v
ia
tio
ns
: A
DA
S-
co
g,
 A
lz
he
im
er
’s
 D
ise
as
e 
A
ss
es
sm
en
t S
ca
le
–c
og
ni
tiv
e 
su
bs
ca
le
; M
M
SE
, M
in
i–
M
en
ta
l S
ta
te
 E
xa
m
in
at
io
n;
 R
AV
LT
,
 
R
ey
’s
 A
ud
ito
ry
 V
er
ba
l L
ea
rn
in
g 
Te
st
; M
R
I, 
m
ag
ne
tic
 re
so
na
nc
e 
im
ag
in
g;
 S
V
M
, s
up
po
rt 
ve
ct
or
 m
ac
hi
ne
; R
M
SE
, r
oo
t m
ea
n 
sq
ua
re
 e
rro
r; 
CC
, c
or
re
la
tio
n 
co
ef
fic
ie
nt
; P
ET
,
 
po
sit
ro
n 
em
iss
io
n 
to
m
og
ra
ph
y 
(F
DG
 an
d A
β);
 A
D,
 A
lzh
eim
er’
s d
ise
ase
; M
CI
c, 
mi
ld 
co
gn
itiv
e 
im
pa
irm
en
t c
on
v
er
te
rs
 (p
rog
res
siv
e 
M
CI
); 
M
CI
nc
, m
ild
 co
gn
itiv
e 
im
pa
irm
en
t n
on
co
nv
er
te
rs
 (s
tab
le 
M
CI
); 
FD
G 
PE
T, 
18
F-
flu
ro
de
ox
yg
lu
co
se
 p
os
itr
on
 e
m
iss
io
n 
to
m
og
ra
ph
y;
 M
CI
, m
ild
 c
og
ni
tiv
e 
im
pa
irm
en
t; 
CS
F,
 
ce
re
br
os
pi
na
l f
lu
id
; C
N
, c
og
ni
tiv
el
y 
no
rm
al
; T
BM
, t
en
so
r-b
as
ed
 m
or
ph
om
et
ry
; H
C,
 h
ip
po
ca
m
pu
s; 
A
PO
E4
,
 
ap
ol
ip
op
ro
te
in
 ε4
 a
lle
le
; m
TB
M
, m
ul
tiv
ar
ia
te
 te
ns
or
-
ba
se
d 
m
or
ph
om
et
ry
; 
LA
SS
O
, l
ea
st 
ab
so
lu
te
 sh
rin
ka
ge
 a
nd
 se
le
ct
io
n 
op
er
at
or
.
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Ta
bl
e 
11
M
ul
tic
la
ss
 c
la
ss
ifi
ca
tio
n
M
od
al
ity
Fe
a
tu
re
 s
el
ec
tio
n/
di
m
en
sio
na
lit
y 
re
du
ct
io
n
C
la
ss
ifi
er
N
C
ro
ss
-
v
a
lid
at
ed
C
la
ss
ifi
ca
tio
n 
ch
al
le
ng
e
U
ni
qu
e a
pp
ro
a
ch
R
ef
er
en
ce
M
R
I
Ca
no
ni
ca
l c
or
re
la
tio
n 
an
al
ys
is 
+ 
n
o
v
el
 sp
ar
se
 m
ul
tit
as
k 
le
ar
ni
ng
SV
M
20
2
Y
M
ul
tic
la
ss
 c
la
ss
ifi
ca
tio
n
U
se
s c
an
on
ic
al
 c
or
re
la
tio
n 
an
al
ys
is 
to
 d
et
er
m
in
e 
co
rr
el
at
io
ns
 b
et
w
ee
n 
fe
at
ur
es
 o
f d
iff
er
en
t m
od
al
iti
es
. 
A
pp
lie
s t
o 
m
ul
tic
la
ss
 c
la
ss
ifi
ca
tio
n 
pr
ob
le
m
.
[4
41
]
PE
T
A
D
 v
er
su
s 
M
CI
 
v
er
su
s 
CN
A
D
 v
er
su
s 
M
CI
c 
v
er
su
s 
M
CI
nc
 v
er
su
s 
N
C
A
CC
71
.9
A
CC
61
.9
M
R
I
Ca
no
ni
ca
l c
or
re
la
tio
n 
an
al
ys
is 
+ 
n
o
v
el
 sp
ar
se
 m
ul
tit
as
k 
le
ar
ni
ng
SV
M
20
2
Y
A
CC
68
.6
A
CC
56
.2
Si
m
ila
r t
o 
[4
41
].
[4
42
]
PE
T
M
R
I
Li
ne
ar
 d
isc
rim
in
an
t a
na
ly
sis
 +
 
lo
ca
lit
y 
pr
es
er
vi
ng
 p
ro
jec
tio
n
SV
M
20
2
Y
A
CC
76
.4
A
CC
61
.1
Co
m
bi
ne
s t
w
o
 s
u
bs
pa
ce
 le
ar
ni
ng
 te
ch
ni
qu
es
, l
in
ea
r 
di
sc
rim
in
an
t a
na
ly
sis
 a
nd
 lo
ca
lit
y 
pr
es
er
vi
ng
 
pr
oje
cti
on
 fo
r f
eat
ure
 se
lec
tio
n a
nd
 ap
pli
ed
 to
 
m
u
lti
cl
as
s a
nd
 b
in
ar
y 
cl
as
sif
ic
at
io
n 
pr
ob
le
m
s.
[4
45
]
PE
T
M
R
I
D
ee
p 
ar
ch
ite
ct
ur
e 
+ 
m
ul
tit
as
k 
le
ar
ni
ng
SV
M
20
2
Y
A
CC
62
.5
A
CC
52
.5
U
se
s n
ov
el
 d
ee
p 
le
ar
ni
ng
 a
rc
hi
te
ct
ur
e 
th
at
 d
isc
ar
ds
 
u
n
in
fo
rm
at
iv
e 
fe
at
ur
es
 in
 a
 h
ie
ra
rc
hi
ca
l m
an
ne
r 
du
rin
g 
m
ul
tit
as
k 
le
ar
ni
ng
.
[4
17
]
FD
G
 P
ET
CS
F
A
bb
re
v
ia
tio
ns
: M
RI
, m
ag
ne
tic
 re
so
na
nc
e 
im
ag
in
g;
 P
ET
,
 
po
sit
ro
n 
em
iss
io
n 
to
m
og
ra
ph
y;
 S
V
M
, s
up
po
rt 
ve
ct
or
 m
ac
hi
ne
; A
D
, A
lz
he
im
er
’s
 d
ise
as
e;
 M
CI
, m
ild
 c
og
ni
tiv
e 
im
pa
irm
en
t; 
CN
, c
og
ni
tiv
el
y 
no
rm
al
; 
M
CI
c,
 m
ild
 c
og
ni
tiv
e 
im
pa
irm
en
t c
on
v
er
te
rs
 (p
rog
res
siv
e 
M
CI
); 
M
CI
nc
, m
ild
 co
gn
itiv
e 
im
pa
irm
en
t n
on
co
nv
er
te
rs
 (s
tab
le 
M
CI
); 
NC
, n
orm
al 
co
gn
itio
n; 
AC
C,
 a
cc
ur
ac
y;
 C
SF
,
 
ce
re
br
os
pi
na
l f
lu
id
; F
D
G
 P
ET
,
 
18
F-
flu
ro
de
ox
yg
lu
co
se
 p
os
itr
on
 e
m
iss
io
n 
to
m
og
ra
ph
y.
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Ta
bl
e 
12
M
et
ho
ds
 th
at
 a
dd
re
ss
 te
ch
ni
ca
l p
ro
bl
em
s i
n 
cl
as
sif
ic
at
io
n 
an
d 
pr
ed
ic
tio
n
Pr
o
bl
em
A
pp
ro
a
ch
R
es
ul
ts
 a
nd
 c
on
cl
us
io
ns
R
ef
er
en
ce
Va
ria
nc
e 
in
 v
al
id
at
io
n 
str
at
eg
ie
s c
an
 m
ak
e 
co
m
pa
ris
on
 o
f t
he
 p
er
fo
rm
an
ce
 o
f 
su
pe
rv
ise
d 
cl
as
sif
ic
at
io
n 
al
go
rit
hm
s 
di
ffi
cu
lt.
U
se
 o
f a
n 
em
pi
ric
al
 e
sti
m
at
or
 th
at
 p
er
fo
rm
s v
al
id
at
io
n 
on
 tw
o
 d
isj
oin
t 
se
ts
 a
nd
 c
om
pa
ris
on
 w
ith
 d
iff
er
en
t v
ar
ia
nc
e 
es
tim
at
or
s i
n 
an
 A
D
 v
er
su
s 
CN
 c
la
ss
ifi
ca
tio
n 
ex
pe
rim
en
t.
Pr
op
os
ed
 e
sti
m
at
or
 is
 c
on
sta
nt
 w
ith
 sa
m
pl
e 
siz
e 
an
d 
is 
un
bi
as
ed
 
w
ith
 re
ga
rd
 to
 tr
ai
ni
ng
 se
t s
iz
e.
 R
ec
om
m
en
d 
ag
ai
ns
t t
he
 u
se
 o
f 
le
av
e 
o
n
e 
o
u
t c
ro
ss
-v
al
id
at
io
n 
be
ca
us
e 
of
 it
s h
ig
h 
va
ria
nc
e.
[4
46
]
Es
tim
at
io
n 
of
 th
e 
se
ns
iti
v
ity
 o
f a
 
bi
om
ar
ke
r 
to
 th
e 
ea
rly
 d
ise
as
ed
 st
ag
e 
ba
se
d 
on
 it
s p
er
fo
rm
an
ce
 o
n 
th
e 
fu
lly
 
di
se
as
ed
 st
ag
e.
U
se
 o
f e
m
pi
ric
al
 li
ke
lih
oo
d-
ba
se
d 
(E
LB
) c
on
fid
en
ce
 in
te
rv
al
s.
EL
B
 m
et
ho
d 
is 
m
or
e 
ro
bu
st
 th
an
 p
ar
am
et
ric
 m
et
ho
ds
 a
nd
 m
or
e 
ac
cu
ra
te
 th
an
 n
on
pa
ra
m
et
ric
 m
et
ho
ds
 o
f c
on
fid
en
ce
 in
te
rv
al
 
es
tim
at
io
n.
[4
47
]
La
ck
 o
f a
 m
et
ho
d 
fo
r s
el
ec
tin
g 
di
ag
no
sti
c 
cu
t p
oi
nt
s i
n 
a 
m
ul
tis
ta
ge
 d
ise
as
e 
th
at
 is
 
n
o
t d
ep
en
de
nt
 o
n 
co
rre
ct
 c
la
ss
ifi
ca
tio
n 
ra
te
s.
D
ev
el
op
ed
 n
ew
 m
ea
su
re
, 
m
ax
im
um
 a
bs
ol
ut
e 
de
te
rm
in
an
t f
or
 d
ise
as
es
 
w
ith
 k
 st
ag
es
, w
hi
ch
 se
le
ct
s c
ut
 p
oi
nt
s u
sin
g 
al
l a
v
ai
la
bl
e 
cl
as
sif
ic
at
io
n 
da
ta
.
W
he
n 
ap
pl
ie
d 
to
 A
D
N
I b
io
m
ar
ke
r 
da
ta
, t
he
 p
ro
po
se
d 
m
et
ho
d 
m
o
re
 a
cc
u
ra
te
ly
 se
le
ct
ed
 c
ut
 p
oi
nt
s f
or
 th
e 
ea
rly
 d
ise
as
ed
 st
ag
e 
th
an
 ex
ist
in
g 
m
et
ho
ds
.
[4
48
]
Pa
tte
rn
s 
of
 a
tro
ph
y 
in
 n
or
m
al
 a
gi
ng
 c
an
 
co
n
fo
un
d 
m
ul
tiv
ar
ia
te
 m
od
el
s o
f a
tro
ph
y 
in
 A
D
.
Co
m
pa
re
d 
tw
o
 a
ge
 c
or
re
ct
io
n 
ap
pr
oa
ch
es
 o
n 
A
D
 v
er
su
s 
CN
 
cl
as
sif
ic
at
io
n 
an
d 
pr
ed
ic
tio
n 
of
 M
CI
 to
 A
D
 p
ro
gr
es
sio
n:
 (1
) u
sin
g a
ge
 as
 
a 
co
v
ar
ia
te
 in
 M
RI
-d
er
iv
ed
 m
ea
su
re
s; 
(2)
 lin
ea
r d
etr
en
din
g o
f a
ge
-re
lat
ed
 
ch
an
ge
s b
as
ed
 o
n 
CN
 m
ea
su
re
s.
B
ot
h 
m
od
el
s i
m
pr
ov
ed
 c
la
ss
ifi
ca
tio
n 
an
d 
pr
ed
ic
tio
n 
ac
cu
ra
cy
.
 
A
na
ly
sis
 o
f i
nc
or
re
ct
ly
 c
la
ss
ifi
ed
 su
bje
cts
 su
gg
est
ed
 th
at 
the
 
in
flu
en
ce
 o
f c
og
ni
tiv
e 
im
pa
irm
en
t, 
A
PO
E 
ge
no
ty
pe
, a
nd
 g
en
de
r i
s 
pa
rti
al
ly
 m
as
ke
d 
by
 a
ge
 e
ffe
ct
s.
[4
49
]
Er
ro
rs
 in
 re
fe
re
nc
e 
te
st 
fo
r A
D
 
bi
om
ar
ke
rs
 (c
lin
ica
l d
iag
no
sis
 or
 A
β P
ET
 
in
 th
e 
ab
se
nc
e 
of
 a
 g
ol
d 
sta
nd
ar
d) 
ca
us
e 
bi
as
 in
 th
ei
r d
ia
gn
os
tic
 a
cc
ur
ac
y.
U
se
s B
ay
es
ia
n 
m
et
ho
d 
to
 d
et
er
m
in
e 
di
ag
no
sti
c 
ac
cu
ra
cy
 o
f A
D
 
bi
om
ar
ke
rs
 ta
ki
ng
 im
pe
rfe
ct
ne
ss
 o
f r
ef
er
en
ce
 te
st 
in
to
 a
cc
ou
nt
.
Pr
op
os
ed
 m
et
ho
do
lo
gy
 im
pr
ov
ed
 e
sti
m
at
es
 o
f e
x
ac
t d
ia
gn
os
tic
 
v
al
ue
s o
f t
hr
ee
 C
SF
 b
io
m
ar
ke
rs
 in
 th
e 
A
D
 v
er
su
s 
CN
 
cl
as
sif
ic
at
io
n.
[4
50
]
Im
pe
rfe
ct
 re
fe
re
nc
e 
te
st 
ca
n 
le
ad
 to
 b
ia
s 
in
 a
cc
ur
ac
y 
of
 a
 c
om
bi
na
tio
n 
of
 
di
ag
no
sti
c 
bi
om
ar
ke
rs
.
U
se
s B
ay
es
ia
n 
m
et
ho
d 
to
 se
le
ct
 c
om
bi
na
tio
n 
of
 b
io
m
ar
ke
rs
 th
at
 
m
ax
im
iz
es
 th
e 
AU
C 
w
hi
le
 ta
ki
ng
 im
pe
rfe
ct
ne
ss
 o
f r
ef
er
en
ce
 te
st 
in
to
 
ac
co
u
n
t.
Pr
op
os
ed
 m
et
ho
do
lo
gy
 im
pr
ov
ed
 e
sti
m
at
es
 o
f A
U
Cs
 o
f A
D
 
bi
om
ar
ke
rs
 o
v
er
 tr
ad
iti
on
al
 lo
gi
sti
c 
re
gr
es
sio
n 
m
od
el
.
[4
51
]
In
co
m
pl
et
e/
im
ba
la
nc
ed
 d
at
a 
bi
as
es
 
es
tim
at
io
n 
of
 d
ia
gn
os
tic
 a
cc
ur
ac
y 
of
 A
D
 
bi
om
ar
ke
rs
.
N
ov
el
 a
pp
ro
ac
h 
us
es
 a
ug
m
en
te
d 
w
ei
gh
te
d 
es
tim
at
or
 fo
r c
ov
ar
ia
te
-
sp
ec
ifi
c 
tim
e-
de
pe
nd
en
t r
ec
ei
v
er
 o
pe
ra
to
r c
ur
ve
s 
u
sin
g 
in
fo
rm
at
io
n 
fro
m
 
su
bje
cts
 w
ith
 in
co
mp
let
e d
ata
.
Pr
op
os
ed
 e
sti
m
at
or
 c
or
re
ct
ed
 b
ia
s a
nd
 im
pr
ov
ed
 e
ffi
ci
en
cy
 o
f 
cl
as
sif
ic
at
io
n 
in
 in
co
m
pl
et
e 
da
ta
 se
ts 
ov
er
 o
th
er
 e
sti
m
at
or
s.
[4
52
]
In
co
m
pl
et
e/
im
ba
la
nc
ed
 d
at
a 
in
 
m
u
lti
m
od
al
 c
la
ss
ifi
ca
tio
n.
Ex
te
ns
iv
e 
an
d 
sy
ste
m
at
ic
 a
na
ly
sis
 o
f e
ffe
ct
iv
en
es
s 
o
f c
om
bi
na
tio
ns
 o
f 
sa
m
pl
in
g 
te
ch
ni
qu
es
 (u
nd
ers
am
pli
ng
, o
v
er
sa
m
pl
in
g,
 a
nd
 a
 c
om
bi
na
tio
n),
 
six
 c
om
m
on
 fe
at
ur
e 
se
le
ct
io
n 
al
go
rit
hm
s, 
an
d 
Ra
nd
om
 F
o
re
st
 a
nd
 S
V
M
 
cl
as
sif
ie
rs
 o
n 
A
D
/M
CI
c 
ve
rs
u
s 
A
D
 a
nd
 M
CI
 v
er
su
s 
CN
 c
la
ss
ifi
ca
tio
n 
pr
ob
le
m
s.
K
-M
ed
oi
ds
 u
nd
er
sa
m
pl
in
g 
te
ch
ni
qu
e 
ga
v
e 
be
st 
re
su
lts
 o
n 
im
ba
la
nc
ed
 d
at
a 
se
ts.
 S
pa
rs
e 
lo
gi
sti
c 
re
gr
es
sio
n 
w
ith
 st
ab
ili
ty
 
se
le
ct
io
n 
w
as
 b
es
t f
ea
tu
re
 se
le
ct
io
n 
te
ch
ni
qu
e.
[4
53
]
N
ov
el
 a
pp
ro
ac
h 
ba
se
d 
on
 c
ol
le
ct
io
n 
of
 fe
at
ur
e 
va
lu
es
 in
to
 a
 la
rg
e 
in
co
m
pl
et
e 
m
at
rix
, a
nd
 su
bs
eq
ue
nt
 m
at
rix
 sh
rin
ka
ge
 a
nd
 c
om
pl
et
io
n 
u
sin
g 
a 
m
ul
tit
as
k 
le
ar
ni
ng
 a
lg
or
ith
m
.
Im
pr
ov
ed
 c
la
ss
ifi
ca
tio
n 
ac
cu
ra
cy
 o
v
er
 tw
o
 r
ec
en
t m
et
ho
ds
 fo
r 
ac
co
u
n
tin
g 
fo
r m
iss
in
g 
da
ta
 (i
nc
lud
ing
 In
co
mp
let
e M
ult
i-S
ou
rce
 
Fe
at
ur
e 
Le
ar
ni
ng
 [4
54
]).
[4
55
]
N
ov
el
 a
pp
ro
ac
h,
 M
ul
ti-
Ta
sk
 L
in
ea
r P
ro
gr
am
m
in
g 
D
isc
rim
in
an
t a
na
ly
sis
 
w
hi
ch
 d
ec
om
po
se
s t
he
 c
la
ss
ifi
ca
tio
n 
pr
ob
le
m
 in
to
 d
iff
er
en
t c
la
ss
ifi
ca
tio
n 
ta
sk
s, 
ad
ap
tiv
el
y 
ch
oo
se
s d
iff
er
en
t f
ea
tu
re
 su
bs
et
s f
or
 e
ac
h 
ta
sk
, t
he
n 
so
lv
es
 th
em
 jo
int
ly.
Im
pr
ov
ed
 c
la
ss
ifi
ca
tio
n 
ac
cu
ra
cy
 o
f M
CI
c 
ve
rs
u
s 
M
CI
nc
 
cl
as
sif
ic
at
io
n 
ov
er
 In
co
m
pl
et
e 
M
ul
ti-
So
ur
ce
 F
ea
tu
re
 L
ea
rn
in
g 
[4
54
].
[4
56
]
N
ov
el
 a
pp
ro
ac
h 
(3D
-C
NN
) b
ase
d o
n a
 co
nv
o
lu
tio
na
l n
eu
ra
l n
et
w
o
rk
 th
at
 
ca
n
 e
st
im
at
e 
m
iss
in
g 
da
ta
 in
 a
n 
ou
tp
ut
 m
od
al
ity
 (P
ET
 im
ag
es)
 us
ing
 da
ta 
fro
m
 a
n 
in
pu
t m
od
al
ity
 (M
R 
im
ag
es)
.
3D
-C
N
N
 a
pp
ro
ac
h 
us
ed
 o
n 
in
co
m
pl
et
e 
da
ta
 se
ts 
ac
hi
ev
ed
 si
m
ila
r 
cl
as
sif
ic
at
io
n 
ac
cu
ra
ci
es
 to
 u
sin
g 
co
m
pl
et
e 
da
ta
 se
ts 
in
 A
D
 v
er
su
s 
CN
, M
CI
 v
er
su
s 
CN
, a
nd
 M
CI
c 
ve
rs
u
s 
M
CI
nc
 ta
sk
s a
nd
 
[4
57
]
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Pr
o
bl
em
A
pp
ro
a
ch
R
es
ul
ts
 a
nd
 c
on
cl
us
io
ns
R
ef
er
en
ce
o
u
tp
er
fo
rm
ed
 tw
o
 c
o
m
m
o
n
ly
 u
se
d 
m
iss
in
g 
da
ta
 e
sti
m
at
io
n 
m
et
ho
ds
.
Co
nv
en
tio
na
l f
al
se
 d
isc
ov
er
y 
ra
te
 
pr
oc
ed
ur
es
 fo
r v
o
x
el
 le
v
el
 m
ul
tip
le
 
te
st
in
g 
ig
no
re
 c
or
re
la
tio
ns
 b
et
w
ee
n 
n
ei
gh
bo
rin
g 
vo
x
el
s.
N
ov
el
 a
pp
ro
ac
h 
ex
te
nd
s t
he
 lo
ca
l s
ig
ni
fic
an
ce
 in
de
x
 p
ro
ce
du
re
 w
ith
 a
 
M
ar
ko
v
 r
an
do
m
 fi
el
d 
m
od
el
 to
 c
on
sid
er
 sp
at
ia
l c
or
re
la
tio
ns
 a
lo
ng
 
n
ei
gh
bo
rin
g 
vo
x
el
s.
W
he
n 
m
et
ho
d 
w
as
 a
pp
lie
d 
to
 A
D
N
I F
D
G
 P
ET
 d
at
a,
 it
 
o
u
tp
er
fo
rm
ed
 o
th
er
 fa
lse
 d
isc
ov
er
y 
ra
te
 p
ro
ce
du
re
s.
[4
58
]
A
bb
re
v
ia
tio
ns
: A
D
, A
lz
he
im
er
’s
 d
ise
as
e;
 C
N
, c
og
ni
tiv
el
y 
no
rm
al
; A
D
N
I, 
A
lz
he
im
er
’s
 D
ise
as
e 
N
eu
ro
im
ag
in
g 
In
iti
at
iv
e;
 M
CI
, m
ild
 c
og
ni
tiv
e 
im
pa
irm
en
t; 
M
RI
, m
ag
ne
tic
 re
so
na
nc
e 
im
ag
in
g;
 C
SF
,
 
ce
re
br
os
pi
na
l f
lu
id
; A
U
C,
 a
re
a 
un
de
r t
he
 re
ce
iv
er
 o
pe
ra
tin
g 
ch
ar
ac
te
ris
tic
; S
V
M
, s
up
po
rt 
ve
ct
or
 m
ac
hi
ne
; M
CI
c,
 m
ild
 c
og
ni
tiv
e 
im
pa
irm
en
t c
on
v
er
te
rs
 (p
rog
res
siv
e 
M
CI
); 
M
CI
nc
, m
ild
 co
gn
itiv
e 
im
pa
irm
en
t 
n
o
n
co
nv
er
te
rs
 (s
tab
le 
M
CI
); 
M
R,
 m
ag
ne
tic
 re
so
na
nc
e; 
PE
T, 
po
sit
ro
n 
em
iss
io
n 
to
m
og
ra
ph
y.
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